Clinical trial NCT04206332
Conditions: Malaria
Keywords: Prevention and Control Mosquito Malaria Challenge Parasitemia Passive Immunization Controlled Human Malaria Infection (CHMI)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Start date: 2020-01-07; Completion date: 2022-02-28
Enrollment: 71 participants; Allocation: NON_RANDOMIZED; Intervention model: SEQUENTIAL

Brief summary:
Background:

People get malaria when they are bitten by an infected mosquito. Malaria can be serious and sometimes deadly. Although there are medicines to treat malaria, there is no vaccine that fully prevents infection. Researchers want to test if an experimental drug can help.

Objective:

To test the safety and effectiveness of a drug called CIS43LS that could prevent malaria infection.

Eligibility:

Healthy people ages 18-50 who have never been infected with malaria

Design:

Participants were enrolled on the basis of eligibility criteria, evaluated by clinical laboratory tests, self-reported medical history, and physical examination.

Participants received CIS43LS either infused into a vein in their arm or injected into the fat under the skin. They were monitored for side effects for up to 4 hours after they received the drug. Participants received a thermometer and recorded their temperature and symptoms every day on/with/via a diary card for 7 days after administration. The administration site was checked for redness, swelling, itching or bruising.

Participants had up to 12 follow-up visits. At follow-up visits, participants had blood drawn and were checked for health changes or problems.

Most participants who received CIS43LS took part in a Controlled Human Malaria Infection Challenge (CHMI) along with control participants who did not receive CIS43LS. During the CHMI, mosquitoes carrying the malaria parasite bit participants in a controlled setting. The participants had clinic visits every day for up to 12 days starting 7 days after the CHMI. Participants were treated right away with antimalarial medication if they tested positive for malaria. Approximately 21 days after the CHMI, participants were treated with antimalarial medication for 3 days.

The study lasted 2-6 months depending on the participant's study group.

Detailed description:
This was a multicenter, three-part, first-in-human, Phase 1, open-label, dose escalation study to evaluate the dose, safety, tolerability and protective efficacy of an anti-malaria human monoclonal antibody, VRC-MALMAB0100-00-AB (CIS43LS). The primary objective was to evaluate the safety and tolerability of CIS43LS when administered by either intravenous (IV) or subcutaneous (SC) routes. The secondary objectives were to evaluate the pharmacokinetics of CIS43LS at each dose level, determine if IV or SC administration will confer protection following a controlled human malaria infection (CHMI), and estimate the lowest protective dose of CIS43LS.

Part A: Part A evaluated the doses and routes in an open-label, dose escalation design.

Part B: Part B evaluated CIS43LS doses and routes prior to CHMI in participants previously enrolled in Part A and new Part B enrollees. A subgroup of participants from Part A continued to Part B, and some received a second CIS43LS dose intravenously. Additional participants were enrolled in Part B and received CIS43LS intravenously.

Part C: Part C evaluated CIS43LS doses and routes needed to reach a threshold of protection by assessing serum concentration prior to CHMI in a dose down design.

Study Product:

CIS43LS is a human immunoglobulin gamma-1 (IgG1) monoclonal antibody that was developed and manufactured by the National Institutes of Health (NIH) Vaccine Research Center (VRC). A recombinant Chinese hamster ovary DG44 clonal cell line14 developed by the Vaccine Production Program was transferred to the VRC pilot plant for clinical material manufacture. The study product was manufactured according to Good Manufacturing Practice at the VRC pilot plant operated by the Vaccine Clinical Materials Program, Leidos Biomedical Research (Frederick, MD, USA).

VRC-MALMAB0100-00-AB (CIS43LS) is a monoclonal antibody that recognizes a unique and conserved region of the Plasmodium falciparum (P. falciparum) circumsporozoite protein and incorporates an LS mutation to increase product half-life in plasma.

Participants:

A total of 71 participants enrolled in the study as follows:

Part A: 29 participants enrolled in Groups 1-5

Part B: 21\* participants enrolled in Groups 6-10

\*Out of the 21 Part B participants, 11 were newly enrolled and 10 were Part A participants who re-enrolled.

Of the 10 Part A participants who re-enrolled in Part B, 3 were back up participants who did not receive additional CIS43LS or CHMI and were terminated early because they were not needed.

Therefore, only 18 participants were actively enrolled in Part B: 11 newly enrolled and 7 Part A participants who re-enrolled.

Part C: 31 participants enrolled in Groups 11-16

Of the 71 participants enrolled, 47 participants received at least one dose of CIS43LS and 43 participants completed the CHMI.

Of the 47 participants who received CIS43LS, 4 participants who received a dose in Part A were also enrolled in Part B and received a second dose as follows:

* one participant received a 5 mg/kg IV dose in Part A and 20 mg/kg IV dose in Part B,
* one participant received a 5 mg/kg SC dose in Part A and 20 mg/kg IV dose in Part B, and
* two participants received a 20 mg/kg IV dose in Part A and Part B.

Therefore, a total of 51 doses of CIS43LS were administered to 47 participants as follows:

* 7 doses of 1 mg/kg IV
* 8 doses of 5 mg/kg SC
* 8 doses of 5 mg/kg IV
* 3 doses of 10 mg/kg IV
* 4 doses of 10 mg/kg SC
* 9 doses of 20 mg/kg IV and
* 12 doses of 40 mg/kg IV

Study Duration:

Participants who received CIS43LS were followed for up to 24 weeks after product administration. Control participants were followed through 7 weeks after CHMI.

Arms: arm 1: CIS43LS (5 mg/kg) administered by intravenous (IV) infusion (Day 0) arm 2: CIS43LS (5 mg/kg) administered by subcutaneous (SC) injection (Day 0) arm 3: CIS43LS (20 mg/kg) administered by IV infusion (Day 0) arm 4: CIS43LS (40 mg/kg) administered by IV infusion (Day 0) arm 5: CIS43LS (40 mg/kg) administered by IV infusion (Day 0) arm 6: Control participants who did not receive CIS43LS and were enrolled to complete the controlled human malaria infection (CHMI); however, Group 5 did not undergo CHMI because of restrictions related to coronavirus disease 2019 (COVID-19) arm 7: CIS43LS (5 mg/kg) administered by SC injection (Day 0) arm 8: CIS43LS (20 mg/kg) administered by IV infusion (Day 0)

Part B, Group 7 participants included participants previously enrolled in Part A who received either 5 mg/kg IV (1), 5 mg/kg SC (1) or 20 mg/kg IV (2) in the first part of the study and newly enrolled Part B participants arm 9: Part B, Group 8 participants included participants previously enrolled in Part A who received CIS43LS (40 mg/kg IV) in the first part of the study but did not receive CIS43LS in Part B of the study. Group 8 participants were enrolled to complete the controlled human malaria infection (CHMI). arm 10: CIS43LS (40 mg/kg) administered by IV infusion (Day 0) arm 11: Control participants who did not receive CIS43LS and were enrolled to complete the controlled human malaria infection (CHMI) arm 12: CIS43LS (1 mg/kg) administered by IV infusion (Day 0) arm 13: CIS43LS (5 mg/kg) administered by IV infusion (Day 0) arm 14: CIS43LS (5 mg/kg) administered by SC injection (Day 0) arm 15: CIS43LS (10 mg/kg) administered by IV infusion (Day 0) arm 16: CIS43LS (10 mg/kg) administered by SC injection (Day 0) arm 17: Control participants who did not receive CIS43LS and were enrolled to complete the controlled human malaria infection (CHMI)
Interventions: intervention 1: VRC-MALMAB0100-00-AB intervention 2: Plasmodium falciparum (P. falciparum) sporozoite challenge
Intervention descriptions: intervention 1: VRC-MALMAB0100-00-AB (CIS43LS) is a monoclonal antibody that recognizes a unique and conserved region of the Plasmodium falciparum (P. falciparum) circumsporozoite protein and incorporates an LS mutation to increase product half-life in plasma. intervention 2: Participants were exposed to bites on the forearm from Anopheles stephensi mosquitoes infected with P. falciparum (3D7 strain).

Protocol documents:
Prot_SAP_001.pdf: 
Protocol Title: A Phase 1, Dose Escalation, Open-Label Clinical Trial with
ExperimentalControlledHumanMalariaInfections(CHMI)toEvaluateSafetyand
Protective
Efficacy
of
an Anti-Malaria
Human
Monoclonal
Antibody,
VRC-MALMAB0100-00-AB
(CIS43LS),
in
Healthy,
Malaria-Naive
Adults
(VRC612)

NCT:04206332

Protocol(v8.026OCT2021)-StatisticalAnalysisConsiderationslocatedinSection6
oftheProtocol





Version8.0
October26,2021

VACCINERESEARCHCENTER

ProtocolVRC612
(NIH20I0017)

Title:APhase1,DoseEscalation,Open-LabelClinicalTrialwithExperimentalControlled
HumanMalariaInfections(CHMI)toEvaluateSafetyandProtectiveEfficacyofanAnti-
MalariaHumanMonoclonalAntibody,VRC-MALMAB0100-00-AB(CIS43LS),in
Healthy,Malaria-NaiveAdults

AbbreviatedTitle:APhase1TrialtoEvaluateCIS43LSinHealthyAdults


INDSponsor
VaccineResearchCenter(VRC)
NationalInstituteofAllergyandInfectiousDiseases(NIAID)
Bethesda,Maryland,US

IND142,632

InvestigationalProductCIS43LSManufacturer:
VaccineClinicalMaterialsProgram(VCMP)operatedundercontract
byLeidosBiomedicalResearch,Inc.,
Frederick,Maryland,US


NIHPrincipalInvestigatorand
ProtocolChair:
MartinGaudinski,M.D.
ClinicalTrialsProgram
VRC/NIAID
UMBPrincipalInvestigator: KirstenLyke,M.D.
UniversityofMarylandSchoolofMedicine
CenterforVaccineDevelopmentandGlobalHealth


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page2of84


TABLEOFCONTENTS

TABLEOFCONTENTS.................................................................................................................2
LISTOFTABLES...........................................................................................................................5
ABBREVIATIONS.........................................................................................................................7
PRINCIPALINVESTIGATORPROTOCOLSIGNATUREPAGE.............................................9
PRÈCIS
....................................................................................................................................10
STATEMENTOFCOMPLIANCE...............................................................................................11
1.
INTRODUCTION......................................................................................................12
1.1.
StudyRationale...........................................................................................................12
1.1.1.
CIS43LSDevelopment...............................................................................................12
1.1.2.
StudyDesign...............................................................................................................13
1.2.
Background.................................................................................................................14
1.2.1.
PreviousHumanExperience.......................................................................................14
1.2.2.
ControlledHumanInfections(CHI)...........................................................................15
1.3.
LaboratoryAssessmentsofCIS43LS.........................................................................15
1.3.1.
Pharmacokinetic(PK)Analysis..................................................................................16
1.3.2.
DetectionofAnti-DrugAntibody...............................................................................16
1.4.
MeasuresofmAb-MediatedProtectionandParasitemia...........................................16
2.
STUDYPRODUCTANDCHMI..............................................................................18
2.1.
StudyProduct:CIS43LS.............................................................................................18
2.2.
PreclinicalExperience................................................................................................18
2.2.1.
InvitroStudies............................................................................................................18
2.2.2.
InvivoStudies.............................................................................................................18
2.3.
ClinicalExperience.....................................................................................................20
2.4.
ControlledHumanMalariaInfection(CHMI)...........................................................21
3.
STUDYOBJECTIVES..............................................................................................22
3.1.
PrimaryObjectives.....................................................................................................22
3.2.
SecondaryObjectives.................................................................................................22
3.3.
ExploratoryObjectives...............................................................................................22
4.
STUDYDESIGNANDCLINICALPROCEDURES...............................................23
4.1.
StudyPopulation.........................................................................................................24
4.1.1.
InclusionCriteria........................................................................................................24


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page3of84
4.1.2.
ExclusionCriteria.......................................................................................................25
4.2.
InclusionofVulnerableSubjects................................................................................26
4.2.1.
Children......................................................................................................................26
4.2.2.
ParticipationofSiteEmployees..................................................................................26
4.3.
ClinicalProceduresandEvaluations..........................................................................27
4.3.1.
RecruitmentandRetention.........................................................................................27
4.3.2.
Screening....................................................................................................................28
4.3.3.
EnrollmentandStudyDay0.......................................................................................28
4.3.4.
ProductAdministration...............................................................................................29
4.3.5.
Post-ProductAdministrationFollow-up.....................................................................29
4.3.6.
SolicitedAdverseEvents(Reactogenicity)................................................................30
4.3.7.
CHMIProcedures.......................................................................................................30
4.3.8.
Post-CHMIFollow-Up...............................................................................................31
4.3.9.
ParasitemiaManagement............................................................................................32
4.3.10.
Follow-UpthroughEndofStudy...............................................................................32
4.4.
ConcomitantMedications...........................................................................................33
4.5.
DoseEscalationPlan..................................................................................................33
4.6.
CriteriaforDiscontinuationofProductAdministrationorProtocol
Participation................................................................................................................34
4.6.1.
DiscontinuationofStudyProductAdministration.....................................................34
4.6.2.
DiscontinuationfromProtocolParticipation..............................................................34
4.7.
CriteriaforPausingandResumingtheStudy.............................................................35
4.7.1.
PlanforReviewofPausesandResumingRules........................................................35
5.
SAFETYANDADVERSEEVENTS........................................................................36
5.1.
AdverseEvents...........................................................................................................36
5.2.
SeriousAdverseEvents..............................................................................................36
5.3.
AdverseEventReportingtotheINDSponsor...........................................................37
5.4.
INDSponsorReportingtotheFDA...........................................................................37
5.5.
ReportingtotheInstitutionalReviewBoard..............................................................38
5.5.1.
UnanticipatedProblem...............................................................................................38
5.5.2.
Non-Compliance.........................................................................................................38
5.5.3.
ProtocolDeviation......................................................................................................39
5.5.4.
Death...........................................................................................................................40


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page4of84
5.5.5.
NewInformation.........................................................................................................40
5.5.6.
SuspensionorTerminationofResearchActivities....................................................40
5.5.7.
ExpeditedReportingtotheIRB.................................................................................40
5.5.8.
AnnualReportingtotheIRB......................................................................................40
6.
STATISTICALCONSIDERATIONS.......................................................................41
6.1.
Overview.....................................................................................................................41
6.2.
SampleSizeandAccrual............................................................................................41
6.3.
StatisticalAnalysis......................................................................................................42
6.3.1.
AnalysisVariables......................................................................................................42
6.3.2.
SafetyAnalysis...........................................................................................................42
6.3.3.
PharmacokineticsAnalysis.........................................................................................43
6.3.4.
EfficacyAnalysis........................................................................................................44
6.3.5.
Interimanalyses..........................................................................................................45
7.
PHARMACYPROCEDURES...................................................................................46
7.1.
StudyProduct..............................................................................................................46
7.2.
StorageandTemperatureExcursions.........................................................................46
7.3.
LabelingofStudyProductVial..................................................................................46
7.4.
PreparationofStudyProductforAdministration.......................................................46
7.4.1.
PreparationforIVAdministration..............................................................................46
7.4.2.
PreparationforSCAdministration.............................................................................47
7.4.3.
HandlingofPreparedProductforIVorSCAdministration......................................47
7.5.
StudyProductAccountability.....................................................................................47
7.6.
StudyProductDisposition..........................................................................................48
8.
HUMANSUBJECTPROTECTIONSANDETHICALOBLIGATIONS................49
8.1.
InstitutionalReviewBoard.........................................................................................49
8.2.
InformedConsent.......................................................................................................49
8.3.
StudyDiscontinuationandClosure............................................................................49
8.4.
ConfidentialityandPrivacy........................................................................................50
8.5.
Risk/BenefitAssessment............................................................................................51
8.5.1.
PotentialRisks............................................................................................................51
8.5.2.
PotentialBenefits........................................................................................................52
8.5.3.
AssessmentofPotentialRisksandBenefits...............................................................52
8.6.
PlanforUseandStorageofBiologicalSamples........................................................53


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page5of84
8.6.1.
UseofSamples,SpecimensandData.........................................................................53
8.6.2.
StorageandTrackingofBloodSamplesandOtherSpecimens.................................53
8.6.3.
DispositionofSamples,SpecimensandDataatCompletionoftheProtocol............53
8.6.4.
LossorDestructionofSamples,SpecimensorData..................................................53
8.7.
SafetyOversight.........................................................................................................54
9.
ADMINISTRATIVEANDOPERATIONALOBLIGATIONS................................55
9.1.
ProtocolAmendmentsandStudyTermination...........................................................55
9.2.
StudyDocumentationandStorage.............................................................................55
9.3.
ClinicalMonitoring....................................................................................................55
9.4.
DataCollectionandSharing.......................................................................................56
9.4.1.
DataCollection...........................................................................................................56
9.4.2.
SourceDocuments......................................................................................................56
9.4.3.
DataSharing...............................................................................................................56
9.5.
QualityAssuranceandQualityControl......................................................................56
9.6.
Language.....................................................................................................................57
9.7.
Research-RelatedInjuries...........................................................................................57
9.7.1.
NIH.............................................................................................................................57
9.7.2.
WRAIR.......................................................................................................................57
9.7.3.
UMB...........................................................................................................................57
9.8.
CHMIFacilitiesandManagement..............................................................................58
9.8.1.
RolesandResponsibilitiesfortheCHMI...................................................................58
9.9.
WRAIRProtocolReviewandReportingRequirements............................................58
10.
REFERENCES...........................................................................................................60
APPENDIXI:SCHEDULEOFEVALUATIONS.......................................................................62
PARTASCHEDULES.................................................................................................................63
PARTBSCHEDULES..................................................................................................................66
PARTCSCHEDULES..................................................................................................................73
APPENDIXII:ASSESSMENTOFAERELATIONSHIPANDSEVERITYGRADING.........83

LISTOFTABLES
Table1:
StudySchema.............................................................................................................23
Table2:
ProbabilityofEventsforDifferentSafetyScenarioswithinaGroup(n=6or
4).................................................................................................................................41


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page6of84
Table3:
95%ConfidenceIntervalsfortheTrueRateatPossibleObservedNumberof
EventsinaGroup(n=6orn=4)oracrossGroups(n=24)..........................................42


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page7of84
ABBREVIATIONS

Abbreviation
Definition
ADA
Anti-DrugAntibody
AE
Adverseevent
ALT
Alanineaminotransferase
ANA
Anti-nuclearantibody
AST
Aspartateaminotransferase
CBC
Completebloodcount
cGLP
CurrentGoodLaboratoryPractices
cGMP
CurrentGoodManufacturingPractices
CHI
Controlledhumaninfection
CHMI
Controlledhumanmalariainfection
CMP
ComprehensiveMetabolicPanel
CRF
CaseReportForm
CRO
ContractResearchOrganization
CSP
Circumsporozoiteprotein
CTP
ClinicalTrialsProgram
DoD
DepartmentofDefense
DoDI
DepartmentofDefenseInstruction
DNA
DeoxyribonucleicAcid
DOT
Directlyobservedtherapy
EKG
Electrocardiogram
ELISA
Enzyme-linkedimmunosorbentassay
FDA
FoodandDrugAdministration
GCP
GoodClinicalPractice
HBsAg
HepatitisBsurfaceantigen
HCV
HepatitisC virus
HIV
HumanImmunodeficiencyVirus
HRPP
HumanResearchProtectionsProgram
HSBP
HumanSubjectsProtectionBranch
ICH
InternationalConferenceonHarmonization
IND
InvestigationalNewDrugApplication
IV
Intravenous
LIMS
LaboratoryManagementInformationSystem
mAb
MonoclonalAntibody
MCG
Micrograms
MedDRA
Medicaldictionaryforregulatoryactivities
MO
MedicalOfficer
NAT
Nucleicacidtest
NHP
Non-HumanPrimate
NIAID
NationalInstituteofAllergyandInfectiousDiseases
NIH
NationalInstitutesofHealth
NIHCC
NIHClinicalCenter


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page8of84
Abbreviation
Definition
PBMC
Peripheralbloodmononuclearcell
PCR
PolymeraseChainReaction
Pf
Plasmodiumfalciparum
PfCSP
Plasmodiumfalciparum circumsporozoiteprotein
PfSPZ
Plasmodiumfalciparum whole-sporozoite
PI
PrincipalInvestigator
PK
Pharmacokinetics
PSRT
ProtocolSafetyReviewTeam
QA
QualityAssurance
RBC
Redbloodcells
rPfCSP
RecombinantPlasmodiumfalciparum circumsporozoiteprotein
SAE
Seriousadverseevent
SARS-CoV-2
Severeacuterespiratorysyndromecoronavirus2
SC
Subcutaneous
SPZ
Sporozoite
SUSAR
Seriousandunexpectedsuspectedadversereaction
ULN
Upperlimitofnormal
UMB
UniversityofMaryland,Baltimore
U.S.
UnitedStates
UPnonAE
UnexpectedProblemthatisnotanAdverseEvent
VCMP
VaccineClinicalMaterialsProgram
VEC
VaccineEvaluationClinic
VIS
VolunteerInfectionStudies
VIP
VaccineImmunologyProgram
VRC
VaccineResearchCenter
WBC
Whitebloodcells
WHO
WorldHealthOrganization
WRAIR
WalterReedArmyInstituteofResearch


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page9of84
PRINCIPALINVESTIGATORPROTOCOLSIGNATUREPAGE

VRC612:APhase1,DoseEscalation,Open-LabelClinicalTrialwithExperimental
ControlledHumanMalariaInfections(CHMI)toEvaluateSafetyandProtective
EfficacyofanAnti-MalariaHumanMonoclonalAntibody,VRC-MALMAB0100-00-AB
(CIS43LS),inHealthy,Malaria-NaiveAdults

I,thePrincipalInvestigatorforthestudysiteindicatedbelow,agreetoconductthestudyinfull
accordancewiththeprovisionsofthisprotocolandallapplicableprotocol-relateddocuments.I
agreetoconductthestudyincompliancewithUnitedStates(US)HealthandHumanServices
(HHS)regulations(45CFR46);applicableUSFoodandDrugAdministration(FDA)regulations;
standardsoftheInternationalConferenceonHarmonizationGuidelinesforGoodClinicalPractice
(E6);InstitutionalReviewBoard/EthicsCommittee(IRB/EC)determinations;allapplicablein-
country,state,andlocallawsandregulations;andotherapplicablerequirements(e.g.,USNational
InstitutesofHealth)andinstitutionalpolicies.Iwillcomplywithallrequirementsregardingthe
obligationsofinvestigatorsasoutlinedintheStatementofInvestigator(FormFDA1572),whichI
havealsosigned.Theprotocolsignaturepagewillbesignedforsubsequentprotocolapprovals.
Iagreetomaintainallstudydocumentationpertainingtotheconductofthisstudy,includingbut
notlimitedto,casereportforms,sourcedocuments,laboratorytestresults,andmedication
inventoryrecords,perFDAregulation(21CFR312.62)andallapplicablerequirements.Nostudy
recordswillbedestroyedwithoutpriorauthorizationfromVRC/NIAID.
PublicationoftheresultsofthisstudywillbegovernedbytheVRC/NIAIDpolicies.Any
presentation,abstract,ormanuscriptwillbemadeavailablebytheinvestigatorstoVRC
Leadershipforreviewpriortosubmission.
Ihavereadandunderstandtheinformationinthisprotocolandwillensurethatallassociates,
colleagues,andemployeesassistingintheconductofthestudyareinformedabouttheobligations
incurredbytheircontributiontothestudy.


_____________________________________________________________________
Name/TitleofPrincipalInvestigator
StudySiteName

___________________________________ __________________________________
SignatureofPrincipalInvestigator Date





APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page10of84
PRÈCIS
Title:
VRC612:APhase1,DoseEscalation,Open-LabelClinicalTrialwithExperimentalControlled
HumanMalariaInfections(CHMI)toEvaluatetheSafetyandProtectiveEfficacyofanAnti-
MalariaHumanMonoclonalAntibody,VRC-MALMAB0100-00-AB(CIS43LS),inHealthy,
Malaria-NaïveAdults.
Design:
ThisisthefirststudyoftheVRC-MALMAB0100-00-AB(CIS43LS)monoclonalantibody(mAb)
targetingthePlasmodiumfalciparum(Pf)circumsporozoiteprotein(PfCSP)inhealthyadults.
Thistwo-part,dose-escalation,adaptivedesignstudywillevaluatethesafety,tolerability,
pharmacokinetics(PK),andprotectiveefficacyofCIS43LS.Theprimaryhypothesisisthat
CIS43LSwillbesafeandtolerablewhenadministeredbyeitherintravenous(IV)orsubcutaneous
(SC)routes.ThesecondaryhypothesesarethatCIS43LSwillbedetectableinhumanserawitha
definablehalf-lifeandconferprotectionfollowingacontrolledhumanmalariainfection(CHMI).
StudyProduct: VRC-MALMAB0100-00-ABwasisolatedanddevelopedbytheVaccineResearchCenter(VRC),
NationalInstituteofAllergyandInfectiousDiseases(NIAID),NationalInstitutesofHealth(NIH)
andbindsauniqueandconservedepitopeatthejunctionoftheN-andrepeatregionsofPfCSP.
Subjects:
Healthysubjects,18-50yearsofage,whoaremalaria-naive.
StudyPlan:
PartA:PartAevaluatedthedosesandroutesasshownbelowintheStudySchematableinan
open-label,doseescalationdesign.
PartB:PartBevaluatedCIS43LSdosesandroutespriortoCHMIinPartAveteransubjectsand
newPartBenrollees.
PartC:PartCwillevaluateCIS43LSdosesandroutesneededtoreachathresholdofprotection
byassessingserumconcentrationpriortoCHMIinadosedowndesign.
VRC612StudySchema
Site
Group
Subjects
CIS43LSAdministration
CHMI
Dose(mg/kg)
Route
PartA
VRC
1
6
5
IV
Cancelled
2
6
5
SC
3
6
20
IV
4A
6
40
IV
4B
3
40
IV
N/A
5
6
Control
Cancelled
PartB
VRC
6
6
5
SC
X
7
61
20
IV
X
8
61
--
--
X
9
6
40
IV
X
10
61,2
Control
X
PartC
UMB
11
7
1
IV
X
12
4
5
IV
X
13
4
5
SC
X
14
4
10
IV
X
15
4
10
SC
X
16
62
Control
X

Total
923
1GroupincludesPartAsubjects
2Two(2)additionalcontrolsubjectswillbeenrolledasCHMIback-ups
3Upto100subjectsmaybeenrolledifneededforadditionalsafetyorefficacyevaluations. 
Duration:
SubjectswhoreceiveCIS43LSwillbefollowedthrough24weeksafterproductadministration.
Controlsubjectswillbefollowedthrough8weeksafterCHMI.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page11of84
STATEMENTOFCOMPLIANCE
ThetrialwillbecarriedoutinaccordancewithInternationalConferenceonHarmonisationGood
ClinicalPractice(ICHGCP)andthefollowing:
• UnitedStates(US)CodeofFederalRegulations(CFR)applicabletoclinicalstudies(45
CFRPart46,21CFRPart50,21CFRPart56,21CFRPart312,and/or21CFRPart812)
NationalInstitutesofHealth(NIH)-fundedinvestigatorsandclinicaltrialsitestaffwhoare
responsiblefortheconduct,management,oroversightofNIH-fundedclinicaltrialshave
completedHumanSubjectsProtectionandICHGCPTraining.
Theprotocol,informedconsentform(s),recruitmentmaterials,andallparticipantmaterialswill
besubmittedtotheInstitutionalReviewBoard(IRB)forreviewandapproval.Approvalofboth
theprotocolandtheconsentformmustbeobtainedbeforeanyparticipantisenrolled.Any
amendmenttotheprotocolwillrequirereviewandapprovalbytheIRBbeforethechangesare
implementedtothestudy.Inaddition,allchangestotheconsentformwillbeIRB-approved;a
determinationwillbemaderegardingwhetheranewconsentneedstobeobtainedfrom
participantswhoprovidedconsent,usingapreviouslyapprovedconsentform.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page12of84
1.
INTRODUCTION
Malariaisamosquito-borneprotozoandiseasebelongingtothegenusPlasmodiumthataffects
250-500millionpeople,andkillsapproximately500,000individualsannually,withanenormous
economicimpactinthedevelopingworld,especiallysub-SaharanAfrica[1-3].Thefive
recognizedspeciesofPlasmodiumthatcausehumanmalariainfectionarePlasmodium
falciparum(Pf),P.vivax,P.ovale,P.malariae,andP.knowlesi.Amongthese,Pfcausesmore
deathsinchildrenworldwidethananyothersingleinfectiousagent.Anestimated30,000
travelersfromNorthAmerica,Europe,andJapancontractmalariaperyear.Althoughmalariais
preventablewithchemoprophylaxisandcompletelycurablewithearlyintervention,drug
treatmentisnotreadilyaccessibleinmanypartsoftheworld.Additionally,theuseof
antimalarialdrugsovertimehasbeenassociatedwiththeemergenceofdrug-resistantstrains.
Lackofcompliancewithpreventivedrugtreatmentbyindividualstravellingtoendemicareas
mayalsoresultinfatalmalariainfection.Theworld’sfirstmalariavaccine,RTS,S/AS01
(Mosquirix™),arecombinantprotein-basedvaccinetargetingPf,wasapprovedforuseby
Europeanregulatoryauthoritiesin2015.Itiscurrentlybeingevaluatedinimmunization
programsinsub-SaharanAfricadespitehavingbeenfoundtoprovideonlypartialprotection(of
about30-50%)againstclinicalmalariatochildrenandinfants[4,5].Therefore,thedevelopment
ofasafeandmoreeffectivemalariavaccineisanurgentpriorityandmaytakemanyadditional
years.Alternatively,theuseofantibodiesforpassivepreventionofmalariaprovidesanewand
moreimmediateapproachformalariapreventionthat,ifsuccessful,wouldhaveamajorimpact
onimprovingpublichealthworldwide.Recentdevelopmentofhighlypotenthumanmonoclonal
antibodiesthathavechangesmadetoimprovetheirdurationinvivoandprotectindifferentpre-
clinicalmodelswillprovidethefirstassessmentofthisapproach.
1.1.
StudyRationale
1.1.1.
CIS43LSDevelopment
TheVaccineResearchCenter(VRC),NationalInstituteofAllergyandInfectiousDiseases
(NIAID),NationalInstitutesofHealth(NIH)hasbeeninvestigatingbroadly-neutralizinghuman
monoclonalantibodies(bNAbs)targetedatavarietyofpathogensthatmaybeutilizedinclinical
applicationsincludingpreventiveandtherapeuticmeasures.Inthecaseofmalaria,prevention
bypassiveimmunizationhaspotentialapplicationsforuseintravelers,militarypersonnel,
seasoncontrolandeliminationcampaignsinendemicareas.
VRCinvestigatorsisolatedthemonoclonalantibody(mAb),termedCIS43,fromasubject
immunizedwithanattenuatedPlasmodiumfalciparum(Pf)whole-sporozoite(SPZ)vaccine
(PfSPZVaccine(Sanaria)).ThemAbwasthenadaptedusingsite-directedmutagenesisinthe
Fcregion,resultinginanLSmutation(CIS43LS)thathasbeenfoundtoincreaseproducthalf-
lifeinplasma[6,7],whichwillbecriticalforoptimizingitsuse.ThisLSmodificationhasbeen
appliedtomultipleVRCclinicalmAbsandhasbeenshowntobesafeandsignificantlyincrease
thehalf-lifeinplasma[8,9].
CIS43LSrecognizesauniqueandhighlyconservedepitopeatthejunctionoftheN-andcentral
repeatregionsofthePlasmodiumfalciparum(Pf)circumsporozoiteprotein(PfCSP).Ina
publishedstudyintwodifferentmousemodelsofmalariainfection,passiveimmunization
withCIS43conferredhigh-levelprotection(70-100%)followingmalariachallengewith


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page13of84
concentrationsofantibodyinvivorangingbetween10-200mcg/mlrespectively[10].Similar
protectiondatawereobservedwithCIS43LS[unpublisheddata].Thesedatashowthat
CIS43LSishighlyprotectiveinvivoandsuggestfurtherexplorationiswarrantedforpassive
preventionofmalariainhumans.
1.1.2.
StudyDesign
Thisstudyisaproof-of-conceptstudytoevaluateCIS43LS.ThePartAdoses(5,20,40mg/kg
intravenous(IV)and5mg/kgsubcutaneous(SC))wereselectedbasedonefficacydatafrom
challengestudiesperformedinmiceshowingthattheprotectiveconcentrationofantibodyin
vivoisbetween10-200µg/mlintwodifferentmodelsofmalariainfection.Pharmacokinetic
(PK)datafromnon-humanprimate(NHP)studieswithCIS43LSandourpriorclinical
experienceinhealthyadultswithhumanmAbstargetingHumanImmunodeficiencyVirus(HIV,
i.e.,VRC01,VRC01LS,andVRC07-523LS)andEbolavirus(mAb114)atthesamedosesand
regimens[11-14]suggestthatwewouldachieveadynamicrangeofantibodyconcentrationsin
vivoinhumanswiththisdoseescalationregimenthatshouldbeidealfordeterminingthe
expectedprotectivetiterfollowingcontrolledhumanmalariainfection(CHMI).Asthisisthe
firststudyinhumanstoassesstheprotectiveefficacyofamalariamAbs,itisimportanttoassess
protectiveefficacywithalldosesgiven.
TreatmentswithVRCmAbshavebeengenerallywelltoleratedatalldoselevelsevaluated(1to
40mg/kg).ThedesignoftheCHMIphaseofthestudywasbasedonpreviousclinicaltrial
experienceinpublishedPhase1malariavaccinetrialsthatinvolvedhumanPfcontrolledhuman
infections(CHI)[15,16].Toourknowledge,thisisthefirsttrialtoperformCHMIfollowing
administrationofamalariamAb.
Beyondacquiringsafetyandtolerabilitydata,theinitialintendedpurposeofPartAwasto
determinewhetheraCIS43LSserumconcentrationlevelcorrelatedwithprotectionfrommalaria
infectionfollowingCHMI.Thedoseescalationdesignwastoevaluatesafetyandtolerabilityof
theproductwhilealsoensuringthatparticipantspresentedatthetimeofCHMIwithawide
rangeofCIS43LSserumconcentrations.Asexpected,basedonreviewofavailablePKdata,
Group1participantswhoreceived5mg/kgIVofCIS43LSearlyinPartAhadalowerserum
concentrationattheintendedtimeofCHMIcomparedtosubjectsreceiving40mg/kgIVnearer
tothistime.
Twenty-onesubjectswereenrolledintoPartAbeginninginJanuary2020.Safetydataindicated
thatCIS43LSadministrationbytheIVandSCrouteswaswelltolerated;initialPK
measurementsshoweddoselinearitywithadefinedhalf-lifewithintheexpectedrange.
Unfortunately,thePartACHMIscheduledforMarch17,2020wascancelledduetoemerging
casesofCOVID-19inMarylandandtheWashingtonMetroarea.Theconsequenttravel
restrictions,localandstatestay-at-homeorders,andinterruptedNIHClinicalCenterpatientcare
servicesalsoalteredfollow-upvisits.Thus,subjectswhoreceivedstudyproductinPartAwere
primarilyfollowedviaremotecontacttocontinuesafetyoversightduringtheCOVID-19
pandemic.
WithprotocolVersion4.0,thestudydesignforPartBwasfinalizedfollowingreviewof
preliminarysafetyandPKdatafromPartAandinaccordancewiththeoverallgoalofattaininga
widerangeofCIS43LSserumconcentrationsinsubjectstosupportevaluationofcorrelatesof
protectionfollowingtheCHMI.PartBsubjectsprovidedadditionalsafetyandtolerabilitydata


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page14of84
forCIS43LSwhilealsocontributingtothefirstefficacydataset.PartBgroupswereenrolled
basedonsubjectavailabilityandscientificpriorityduringtheongoingCOVID-19pandemic.
NewlyenrolledparticipantsinPartBreceived40mg/kgIVdosesofCIS43LSpriortotheCHMI
whileotherparticipantswhoreceivedCIS43LSinPartAwerere-dosedwithasingle20mg/kg
IVinfusiontoensuresubjectspresentedwithagradientofserumconcentrationspriortothe
CHMI.AsubsetofPartAsubjectswhoreceived40mg/kgIValsoparticipatedinthePartB
CHMIwithoutCIS43LSredosingtoassessfordurabilityafteradistantinfusionroughly8
monthspriortoCHMI.Group6(5mg/kgSCinPartB)wasneverenrolledinordertofocuson
thegroupsreceivingCIS43LSbyIV.ActualCIS43LSconcentrationsinbloodweremeasured
fromsamplescollected1daypriortoPartBCHMIforallsubjects.
ThePartBCHMIwasconductedonOctober20,2020,with9recipientsofCIS43LSplus6
controlsubjectsundergoingchallenge.Noneofthe9CIS43LSrecipientsdevelopedparasitemia
duringthe21-daypost-CHMImonitoringperiod,whereas5of6controlsubjectsbecame
parasitemiconday8or9.ThisindicatedthatCIS43LScouldprotecthumansubjectsinaCHMI
model.TherangeofCIS43LSserumconcentrationsatthetimeofCHMIwasapproximately50
to500mcg/mL.ThelackofinfectionsintheCIS43LSgroupsoverarangeofserum
concentrationswasunexpectedbecausethepreclinicalmousedatawouldnothavepredicteda
serumconcentrationof50mcg/mLtobeprotective.Thelackofinfectionsalsoprevented
completionofaregressionanalysistodeterminetheprotectiveserumconcentrationthreshold.
Thisthresholdwasstillfelttobescientificallyimportant,thereforeathirdparttothetrialis
neededinordertoassessforthiscriticalendpoint.
WithprotocolVersion6.0,PartCisbeingaddedtothetrialwiththeobjectiveofidentifyingthe
lowestdoseofCIS43LSthatcouldconferprotectionfollowingCHMI.PartCwillbeconducted
attheUniversityofMaryland,Baltimore(UMB)CenterforVaccineDevelopmentandGlobal
Health.UMBwillperformsubjectscreening,enrollment,productadministration,andthe
CHMI.ThesamplesizeforPartCgroupsisinformedbyPartBdatathatsuggestedmoredata
fromspecificlowerdosegroupsisneededtodefinethelowerthaninitiallypredictedserum
concentrationthreshold.Therefore,PartCwillallocategreaternumbersofsubjectstothe1
mg/kggroupinordertoaccumulatesufficientdata.
1.2.
Background
1.2.1.
PreviousHumanExperience
TherewasnohumanexperiencewithCIS43LSpriortothistrial.PreliminaryVRC612PartA
andPartBdataareprovidedinSection2.3.Priorclinicalexperienceincompletedandongoing
Phase1and2trialsofhealthyadultswithhumanmAbsmanufacturedandformulatedbythe
VRCthatrecognizepathogen-specificepitopes(i.e.,VRC01,VRC01LS,VRC07-523LS,and
mAb114)[11-14]areusedtosummarizethegeneralsafetyriskassociatedwithmAbs.
TreatmentswiththesemAbshavebeengenerallywelltolerated,withnoreporteddeathsor
seriousadverseevents(SAEs)assessedasrelatedtothestudyproducts.TypicalformAbs,the
predominantlocalreactogenicitycomplainthasbeenmildpain/tenderness,althoughreportsof
mildinjectionsitepruritus,rednessandswellinghaveoccurredatmodestlyhigherfrequencies
withSCadministration.Malaise,musclepain,andheadachehavebeenthemostfrequently
reportedsolicitedcomplaintsnotedinthe3dayspostproductadministrationandthesehavealso


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page15of84
beenmostlytransientandmildinseverity.Urticariaandinfusionreactionscomprisedofchills,
rigors,myalgia,headache,and/orfeverhavebeenreportedafterIVinfusionsatproductdosesof
10to40mg/kg;thesereactionshavebeentransient,resolvedwithoutsequelaewithin24hoursof
onset,andtreatedwithover-the-counteranalgesicsandantipyretics.
1.2.2.
ControlledHumanInfections(CHI)
Controlledhumaninfection(CHI)trials(alsoreferredtoasVolunteerInfectionStudies(VIS))
resultintheexperimentalinfectionofhealthysubjectswiththeinfectiousagentofchoiceandare
anunparalleledtoolininfectiousdiseaseresearch.CHItrialsallowfortheaccelerated
evaluationofnoveldrugsandvaccinesforpotentialefficacy,whilealsoprovidingthe
opportunitytoprospectivelystudyclinicaldiseaseprogression.Thefirstcontrolledhuman
malariainfection(CHMI)wasperformedinthemid-1980s[17].Thisprocessinvolvesthe
deliberateinfectionwithmalariaparasiteseitherbymosquitobiteordirectinjection.VRChas
successfullyconductedthreePhase1CHMIstudies:VRC312[15],VRC314[18]andVRC612
PartB[9].
AccordingtoacomprehensivereviewofCHItrialsusingavarietyofpathogens,anestimated
6000subjectshavereceivedCHI[19].Onlyfourpossibly-relatedSAEshavebeenpublished,of
whichtwowereobservedfollowingmalariavaccinationandCHMI[19].Thefirstcardiacevent
ofpossiblemyocarditis,reportedin2008[20],promptedrecommendationbyapanelofexperts
thatconsiderationofcardiacriskberequiredforclinicalchallengetrialsandthatindividuals
identifiedasatincreasedcardiovascularriskbeexcludedfrommalariaclinicalchallengetrials
[21].Asecondcardiaceventwasobservedin2013followingmalariavaccinationandCHMI
[22].VRCwasalsoinformedofapossible3rd,unpublished,myocarditiseventin2014.Asa
resultoftheseeventsandtherecommendations,evidenceofincreasedcardiovasculardisease
riskoranelectrocardiogram(ECG)withclinicallysignificantabnormalitieswillprecludetrial
enrollmentasdescribedinSection4.1.2.
AllchallengephasesinthisstudywillbeperformedwithPfstrain3D7,sensitivetoChloroquine
andMalarone(atovaquoneandproguanil),viamosquitobite,whichisthenaturalrouteof
exposureandtransmissioninthefield.Whilesubjectswillbemonitoredcloselythroughout
studyduration,monitoringintensitywillincreasefollowingexposuretoPf-infectedmosquitoes
toensurerapiddiagnosisandtreatment.Appropriatedrugtherapywillbeusedtotreatandcure
anysubjectwithaconfirmedPfinfectionafterdiagnosisbyPCR,themostsensitiveassessment
fordetectingearlymalariainfection,inordertominimizetheriskofdevelopingaserious
complication.ThePfstraintobeusedforCHMIinthisstudycanbeeffectivelytreatedwithand
curedbytheantimalarialmedicationstobeusedinthistrial[23,24].
Thereisnegligibleriskoftransmittingmalariatoapersoninthecommunitysincesubjectsare
exposedtomalaria-infectedmosquitosonlyduringtheCHMIatacontainedfacility.
1.3.
LaboratoryAssessmentsofCIS43LS
Somelaboratoryassessmentsinthisstudyarealsodesignedtocharacterizetheinvestigational
product.ThisincludesPKanalysisandevaluationforanti-drugantibody(ADA)development
afterproductexposure.Thesearefurtherdescribedinthesubsequentsections.Otherassays
mayalsobecompletedfromstoredsamplesatalaterdateifadditionalassessmentsareneeded.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page16of84
TheVRC’sVaccineImmunologyProgram(VIP),formerlyNVITAL,Gaithersburg,MD,will
processbloodandstorecodedsamples,andwilleitherperformsampletestingorshipcoded
samplestodesignatedresearchlaboratoriesattheVRCorotherapprovedcollaborators.See
APPENDIXIforschedules,volumesandtubetypestobeusedforresearchsamplecollection.
Researchassayswillbeperformedonsamplesfrombothstudyproductrecipientsandinfectivity
controlsatbaselineandthroughoutthestudy.
Tubetypesforclinicallabsareaccordingtoinstitutionalrequirementsandareshowninthe
ScheduleofEvaluationstoestimatebloodvolumes.Differenttubesforclinicalevaluationsmay
beusedtomeetsiterequirements.Researchsampletubetypesandbloodvolumesmustbeused
asshownorasotherwiseinstructedbytheINDSponsor.Insomeinstances,codedsamplesmay
betransporteddirectlybystudystafftothelaboratoryofanapprovedcollaborator.
1.3.1.
Pharmacokinetic(PK)Analysis
ConcentrationsofCIS43LSwillbemeasuredbyMesoScaleDiscovery(MSD)based
automationplatformandsimilarmethodologyaspreviouslydescribedforotherVRCmAb
products[12].
1.3.2.
DetectionofAnti-DrugAntibody
AssaysfordetectionofADAwillbeperformedatspecifiedtimepointsfollowingproduct
administrationandCHMIcomparedtobaselinestatususingasimilarmethodologyaspreviously
describedforotherVRCmAbproducts[12].Athree-leveltieredapproachwillbeusedto
screen,confirm,andfunctionallycharacterizeforADAintheclinicalserumsamplesaccording
totheFoodandDrugAdministration(FDA)guidance.Screeningandconfirmationwillinvolve
aMesoScaleDiscovery(MSD)electrochemiluminescence(ECL)bridgingassay.Intheabsence
ofanadequateinvivosporozoiteentryinhibitionassay,acompetitivetargetbindingassayof
CIS43LStoitscognateepitopeswillbeusedasaproxyforsporozoiterecognitionand
neutralization.
1.4.
MeasuresofmAb-MediatedProtectionandParasitemia
CIS43LS-mediatedprotectionwillfirstbeassessedafterCHMIandcomparedtoinfectionin
controlsubjects.TheendpointdefiningmAb-mediatedprotectionfortheCHMIistheabsence
ofPfparasitesinbloodsamplesobtainedfromCIS43LS-recipientscollectedfromDay7through
Day21post-CHMI.Thecriteriaforacaseofmalariaisconfirmationofparasitemiaeitherby
theMalariareal-timePCRassayorbloodsmear.TheMalariareal-timePCRassaytargetsthe
18SrRNA(ribosomalRNA)geneofPfparasites,whichisaDNAtarget.Itisthedefaultmeans
ofmonitoringforparasitemiainthisprotocol,andasinglepositivePCRresultwillconfirm
infection[15,25,26].Themalariareal-timePCRassaywillbeperformedbytheNIHClinical
CenterDepartmentofLaboratoryMedicineforPartBortheUMBDivisionofMalaria
LaboratoriesResearchforPartC.
AbloodsmearwillbeperformedbytheNIHClinicalCenterMicrobiologyServiceorUMB
MalariaGrouppersonnelpertheirdepartmentalSOPsforanysubjectwhodevelopssymptoms
likelyduetomalariadespitenothavingapositivePCRresult.Withtraditionalmicroscopy,
positivityisdefinedasthepresenceoftwoormoreparasitesin0.5mcLofblood.Laboratory
personnelperformingPCRandbloodsmeartestingwillbeblindedtosubjectgroupand


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page17of84
treatmentreceivedorlackthereof,inthecaseofcontrols.Researchbloodsamplesmayalsobe
usedforparasitegenomeanalysis.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page18of84
2.
STUDYPRODUCTANDCHMI
2.1.
StudyProduct:CIS43LS
MAbVRC-MALMAB0100-00-AB(CIS43LS)wasdiscoveredanddevelopedbytheVRC,
NIAID,NIH.CIS43LSbindsauniqueandconservedepitopeatthejunctionoftheN-and
centralrepeatregionsofthePfCSP.ThestudyproductwasmanufacturedundercurrentGood
ManufacturingPractice(cGMP)bytheVaccineClinicalMaterialsProgram(VCMP)operated
undercontractbyLeidosBiomedicalResearch,Inc.,Frederick,MD.
2.2.
PreclinicalExperience
ToassessCIS43LSasacandidateforclinicaltrials,recombinant,researchgrademAbwas
evaluatedonbindingproperties,auto-reactivity,pharmacokinetics,twomousemodelsofinvivo
protectionfollowingchallenge,andPKstudiesinNHPswereperformed.Inmice,CIS43LS
conferred100%protectionfollowingmosquitobitechallenge.InNHPPKstudies,CIS43LS
exhibitedsubstantiallylongerhalf-life,bothinbloodandinskinbiopsysamplesascomparedto
CIS43antibodywithouttheLSmutation.
PreclinicaltoxicologystudieswereconductedtoassesssafetyincompliancewithcurrentGood
LaboratoryPractices(cGLP)inSpragueDawleyratsusingCIS43LS.Thetoxicologypre-
clinicalmaterialwastestedinthefinalformulationbufferandmanufacturedusingthesame
VCMPmanufacturingprocessasusedtoproduceclinicaltrialmaterial.Therewerenofindings
oftoxicologicsignificanceattributedtoCIS43LSfromtheresults.
2.2.1.
InvitroStudies
DifferencesinthebindingpropertiesofCIS43LSandCIS43wereassessed.Bindingof
CIS43LSandCIS43toaspecifictargetantigenexpressedonmalariaparasiteswasdetermined
byELISA.CIS43LSandCIS43exhibitedsimilarbindingtorecombinantPlasmodium
falciparumcircumsporozoiteprotein(rPfCSP).AvidityandstoichiometryofCIS43LSand
CIS43bindingtorPfCSPwerealsocomparableasassessedbyisothermaltitrationcalorimetry
(ITC).
CIS43LSautoreactivitywasassessedusingtheanti-nuclearantibody(ANA)HEp2cellstaining
systemfromZeusScientific(Branchburg,NJ).Antibodiesweretestedat25and50mcg/mL.At
25mcg/mL,testantibodieswerescoredincomparisontonegativeandpositivecontrolsamples.
NeitherCIS43norCIS43LSshowsanautoreactivitysignalbyANAstaining.Autoreactivity
wasalsoassessedbyananti-cardiolipinQUANTALiteACAIgGIIIELISA(InovaDiagnostics,
SanDiego,CA).UsingasimilarcontrolschematothatdescribedforANAHEp2Cellstaining,
anti-cardiolipinreactivitywasnegativebyELISA.
2.2.2.
InvivoStudies
a. ProtectionstudiesinC57BL/6miceandRhesusmacaques
ToassessprotectionfollowingpassivetransferofmAb,naïveC57BL/6micereceived300mcg
byIVinoculationofCIS43,CIS43LS,ornegativecontrolantibody.Chimericparasites
comprisingPlasmodiumberghei(Pb)sporozoites(SPZ)whichnaturallyinfectmicethat
expressedPlasmodiumfalciparumCSP(Pb-PfCSPSPZ)wereadministeredbyoneoftworoutes


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page19of84
(injectedbytailveinorbyexposuretobitesbyinfectedmosquitos).Inthetwomousechallenge
models,passivetransferofCIS43andCIS43LSyieldednearlyindistinguishableresults.
AdministrationofeitherCIS43orCIS43LSreducedliverparasiteburdenbyabouttwologs
whenchallengedbyIVroute,whichdeliverstheparasitesdirectlyintotheliverandbypassesthe
normalrouteofinfectionthroughtheskin.Moreover,passivetransferofCIS43orCIS43LS
conferred100%sterileprotectioninmiceasassessedbyparasitemiainbloodfollowinganatural
challengebyfivemosquitobitesintheskin.Thistypeofchallengeissimilartowhatisusedin
thehumanCHMI.
Toconfirmtheimprovedhalf-lifeofCIS43LSandinformclinicalprotocoldevelopment,
particularlyconcerningthetimingofCHMI,a20-weekPKstudywasconductedinNHPs
(Rhesusmacaques).TwoanimalspergroupreceivedCIS43orCIS43LS,administeredbyIV
routeatadoseof10mg/kg.CIS43LSexhibitedsubstantiallylongerhalf-life,bothinbloodand
skinbiopsysamplesthanCIS43.Inblood,CIS43LSmaintainedatiterofmorethan35mcg/mL
onthelastsampleday(day140).Incontrast,CIS43droppedtoapproximately30ug/mLbyDay
49.Skinbiopsydatawereconcordant.
b. ToxicologyStudiesinSpragueDawleyRats
Astudyofrepeatdosingat10-dayintervalsbyIVandSCadministrationofCIS43LSinmale
andfemaleSpragueDawleyrats(SRIStudyNo.M416-19)wasconductedincompliancewith
cGLPtoevaluatetoxicityandtoxicokinetics.Thetestarticleandcontrol(formulationbuffer)
wereadministeredonDays1and11byIVadministrationatdosesof0,40or400mg/kg/day
(Groups1−3,respectively)orbySCadministrationatdosesof5or50mg/kg/day(Groups4−5,
respectively).NecropsieswereperformedonDays12and46.Endpointsincludedclinical
observations,bodyweight,foodconsumption,bodytemperature,dosesiteirritation,clinical
pathology,andorganweights.
Allanimalssurvivedtotheirscheduledsacrificetimepoint.Notestarticle-relatedchangeswere
observedinclinicalobservations,bodyweights,foodconsumption,dosesiteirritation,clinical
chemistry,coagulation,andorganweights.Bodytemperaturewasnormal(≤101.0°F)forall
malesat24hourspost-dose.Elevatedbodytemperaturesrangingfrom101.1to102.1°Fwere
seenfromoneormorefemalesinhigh-doseIVorbothSCtreatedgroupsforatleast24hours
afterdosingonDays1and/or11.Bodytemperaturereturnedtonormallevelswithin48hours
post-dose.Thesefindingsareconsideredtestarticle-relatedalthoughreversibleandatlevels
consideredtobenon-adverse.
Statisticallysignificantanddose-dependentchangesinsomehematologyparameterswere
observedonDays12and46.Thechangesincludedincreasedplateletcount(1.4fold)and
absolutereticulocytecount(1.2fold)inGroup5females;anddecreasedpercentmonocyte(by
30.6to32.2%)inGroup3and4femalesonDay12.OnDay46,increasedabsoluteneutrophils
(2.0to2.3fold)inGroup3and4malesanddecreasedhemoglobin(by6.1to7.6%)and/or
hematocrit(by5.6to7.6%)inalltreated-groupfemaleswereobserved.Thechangesin
neutrophilsandmonocytesseenafterSCadministrationareconsistentwithanimmuneresponse
andareconsideredtestarticle-relatedalthoughreversibleandatlevelsconsideredtobenon-
adverse.Withoutchangesinredbloodcell(RBC)counts,thefindingsinplateletcount,
reticulocytes,hemoglobinorhematocritarenotconsideredtobebiologicallymeaningfulor
toxicologicallyadverse.Insummary,nofindingsoftoxicologicsignificancewereattributedto
CIS43LSfromtheresultsavailableasofthisreport.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page20of84
Takentogether,thesestudiessupportthecontinueddevelopmentofCIS43LSforclinical
evaluation.Thedataconfirmthepredictedlongerhalf-lifeeffectoftheLSmutationandshow
thatthereisnofunctionaldifferenceintermsofinvitrobindingorinvivoprotectioncompared
toCIS43.Nosafety,efficacy,ormanufacturabilityconcernswerenotedthatprecluded
proceedingtofurthertoxicologystudies,GMPmanufacturing,INDfiling,andclinical
investigations.
2.3.
ClinicalExperience
PartAandBdatafromthistrialisthefullextentofcurrenthumanexperiencewithCIS43LS.
SeeSection1.2.1formoreinformationaboutsimilarVRCmAbproducts.
VRC612wasinitiatedinJanuary2020withaccrualintoPartA.PartBofthetrialbeganin
September2020.AsofFebruary15,2021,25subjectsreceived29administrationsofCIS43LS.
Whilemostsubjects(n=21)receivedonlyasingledose,4subjectsoriginallydosedinPartA
receivedaseconddoseof20mg/kgIVinPartB.CIS43LSadministrationsweregivenbyIV
(n=25)andSC(n=4)routes.Atthetimeofthissummary,subjectsareinfollowup;dataquality
assuranceandmonitoringareongoing.
Humanexperiencedatacollectedthusfar,includingfrequencyandseverityofsolicitedand
unsolicitedadverseevents,aresummarizedbelow.Overall,VRC612datademonstratethat
CIS43LSissafeandwelltolerateduponIVandSCadministration.Therehavebeennoreported
SAEsrelatedtostudyproductandnostudypausecriteriamet.
LocalReactogenicity:Mildpain/tendernessattheinjectionsitewasthemostfrequently
reportedsolicitedlocalsymptom,reportedby4/25(16%)IVrecipientsand3/4(75%)SC
recipients.Allpaineventsresolvedwithinthe7-daysolicitedperiod.Oneeventofmoderate
bruisingbeganonDay4inanIVrecipientandcontinuedthrough4daysafterthesolicited
periodtoDay11.Nootherlocalsymptomswerereported.
SystemicReactogenicity:Mildheadachewasthemostfrequentlyreportedsolicitedsystemic
symptom,reportedby5/25(20%)IVrecipientsand1/4(25%)SCrecipients.Mildmyalgiawas
reportedby3/25(12%)IVrecipientsand2/4(50%)SCrecipients.OthereventsreportedbyIV
recipientsincludemild(2/25,8%)andmoderate(1/25,4%)malaise,moderatenausea(1/25,
4%),mildjointpain(1/25,4%),andmildfever(1/25,4%).Alleventsresolvedwithinthe7-day
solicitedperiodwiththeexceptionofonereporteachofmoderatemalaiseandmildheadacheby
anIVrecipientthatbeganonDay4andlasteduntilDay10,andonereportofmildmyalgiaby
anIVrecipientthatbeganonthedayofproductadministration(Day0)andlasteduntilDay10.
UnsolicitedAEs:Ofthe25subjectswhoreceivedCIS43LS,9subjects(36%)hadatleastone
AEwiththehighestseverityofmildfor5(20%)subjects,moderatefor3(12%)subjectsand
severefor1(4%)subject.ThemostfrequentlyreportedunsolicitedAEby3of21(14%)
subjectswasupperrespiratorytractinfection(URTI),whichwasassessedasnotrelatedtothe
studyproductforallsubjects.ThreemildAEswereassessedasrelatedtostudyproduct
includingoneeventeachofbloodcreatinineincreaselasting7days,transientasymptomatic
neutropenialasting6daysanddizzinesslasting1day.Allrelatedeventsresolvedwithno
residualeffects.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page21of84
2.4.
ControlledHumanMalariaInfection(CHMI)
PreparationofinfectedmosquitoesforCHMIwillbeperformedaccordingtoaTypeIIMaster
File033797,MalariaChallengeModel,StandardOperatingProceduresforthePfmodelused.
Toprepareinfectedmosquitoes,Pfasexualandsexualerythrocyticstageparasiteswillbegrown
innormalhumanerythrocytesusingstandardculturemediumcontaining10%normalhuman
serum.ThebloodandserumforculturearepurchasedfromaFoodandDrugAdministration
(FDA)-accreditedbloodbank.Eachshipmentcarriesacertificateofanalysiscertifyingthatthe
bloodproductsarenegativeornon-reactiveforimmunologicevaluationandinfectiousdisease
testing.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page22of84
3.
STUDYOBJECTIVES
3.1.
PrimaryObjectives
• ToevaluatethesafetyandtolerabilityofCIS43LSadministeredIVat1,5,10,20,and40
mg/kginhealthy,malaria-naiveadults
• ToevaluatethesafetyandtolerabilityofCIS43LSadministeredSCat5and10mg/kgin
healthy,malaria-naiveadults
3.2.
SecondaryObjectives
• ToevaluatethepharmacokineticsofCIS43LSateachdoselevelthroughoutthestudy
• TodetermineifIVorSCadministrationofCIS43LSmediatesprotectionagainst
infectiousP.falciparumfollowingCHMI
• ToestimatethelowestdoseofCIS43LSadministeredIVandSCthatconfersprotection
againstinfectiousP.falciparumfollowingCHMI
3.3.
ExploratoryObjectives
• Todeterminewhetheranti-drugantibody(ADA)toCIS43LScanbedetectedinseraof
recipientsatspecifictimepointsthroughoutthestudy
• ToassessforIgG1allotypesandallotype-specificeffectsonCIS43LSpharmacokinetics
• ToexploreandcharacterizethehumoralandcellularresponsetoCIS43LS
• ToassessdurabilityofmAb-mediatedprotectionofCIS43LS


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page23of84
4.
STUDYDESIGNANDCLINICALPROCEDURES
PartsAandBofthisopen-label,doseescalationstudywereconductedattheVRCVaccine
EvaluationClinic(VEC)intheNIHClinicalCenter(NIHCC)andtheCHMIwasconductedat
theWalterReedArmyInstituteofResearch(WRAIR)insectarywiththeoversightofNIHCC
staff.AllofPartC(includingtheCHMI)willbeconductedattheUMBCenterforVaccine
DevelopmentandGlobalHealth.TheprimaryhypothesisisthatCIS43LSwillbesafeand
tolerablewhenadministeredbyeitherIVorSCroutes.Thesecondaryhypothesesarethat
CIS43LSwillbedetectableinhumanserawithadefinablehalf-lifeandwillconferprotection
followingaCHMI.
PartA:ThestudybeganwithsubjectenrollmentintoGroup1.Thedoseescalationsafety
reviewsproceededasdescribedinSection4.5.PartAsafetydatashowthatCIS43LSissafeand
tolerableatalldosegroups.PreliminaryPKdatasuggestthatagradientofserumconcentrations
willbepresentacrossgroupsatthetimeofCHMI.
PartBfurtherevaluatedtheCIS43LSdosesandroutesneededtoreachathresholdofprotection
byassessingserumconcentrationspriortoCHMIinPartAveteransubjectsaswellasinnew
enrollees.
PartCwillevaluateCIS43LSdosesandroutesneededtoreachathresholdofprotectionby
assessingserumconcentrationpriortoCHMIinadosedowndesign.
Theoverallstudyschemaisasfollows:
Table1:
StudySchema
VRC612StudySchema
Site
Group
Subjects
CIS43LSAdministration
CHMI
Dose(mg/kg)
Route
PartA
VRC
1
6
5
IV
Cancelled
2
6
5
SC
3
6
20
IV
4A
6
40
IV
4B
3
40
IV
N/A
5
6
Control
Cancelled
PartB
VRC
6
6
5
SC
X
7
61
20
IV
X
8
61
--
--
X
9
6
40
IV
X
10
61,2
Control
X
PartC
UMB
11
7
1
IV
X
12
4
5
IV
X
13
4
5
SC
X
14
4
10
IV
X
15
4
10
SC
X
16
62
Control
X

Total
923
1GroupincludesPartAsubjects
2Two(2)additionalcontrolsubjectswillbeenrolledasCHMIback-ups
3Upto100subjectsmaybeenrolledifneededforadditionalsafetyorefficacyevaluations.



APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page24of84
4.1.
StudyPopulation
SubjectswillbescreenedtoconfirmeligibilityrequirementsforparticipationusingtheVRC500
screeningprotocol.Thescreeningandeducationprocessrequiredpriortoenrollmentisdesigned
toensurethatsubjectscomprehendthepurpose,detailsandrisks/benefitsofthestudy.
Eligibilitywillbere-assessedpriortoPartBenrollmentforanyPartAsubjectswhoareinvited
toparticipateinPartB.
4.1.1.
InclusionCriteria
Asubjectmustmeetallofthefollowingcriteriatobeincluded:
1. Ableandwillingtocompletetheinformedconsentprocess
2. Abletoprovideproofofidentitytothesatisfactionofthestudycliniciancompletingthe
enrollmentprocess
3. Availableforclinicalfollow-upthroughthelaststudyvisit
4. 18to50yearsofage
5. Ingoodgeneralhealthwithoutclinicallysignificantmedicalhistory
6. Physicalexaminationwithoutclinicallysignificantfindingswithinthe56dayspriorto
enrollment
7. Weight≤115kg(forallgroupsexceptGroups5,10,and16)and<100kgforGroup15
8. AdequatevenousaccessifassignedtoanIVgrouporadequatesubcutaneoustissueif
assignedtoaSCgroup
9. Willingtohavebloodsamplescollected,storedindefinitely,andusedforresearch
purposes
10.Agreestoparticipateinacontrolledhumanmalariainfection(CHMI)andtocomplywith
post-CHMIfollow-uprequirements(exceptGroup4B)
11.Agreestorefrainfromblooddonationtobloodbanksfor3yearsfollowingparticipation
inCHMI(exceptGroup4B)
12.Agreesnottotraveltoamalariaendemicregionduringtheentirecourseofstudy
participation
LaboratoryCriteriawithin56dayspriortoenrollment:
13.WBC2,500-12,000/mm3
14.WBCdifferentialeitherwithininstitutionalnormalrangeoraccompaniedbythe
PrincipalInvestigator(PI)ordesigneeapproval
15.Platelets=125,000–500,000/mm3
16.HemoglobinwithininstitutionalnormalrangeoraccompaniedbythePIordesignee
approval
17.Creatinine≤1.1xupperlimitofnormal(ULN)
18.Alanineaminotransferase(ALT)≤1.25xULN


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page25of84
19.NegativeforHIVinfectionbyanFDAapprovedmethodofdetection
LaboratoryCriteriadocumentedanytimepriortoenrollment:
20.Negativesicklecellscreeningtest
21.Negativetroponintest(exceptGroup4B)
22.Electrocardiogram(ECG)withoutclinicallysignificantabnormalities(examplesmay
include:pathologicQwaves,significantST-Twavechanges,leftventricular
hypertrophy,anynon-sinusrhythmexcludingisolatedprematureatrialcontractions,right
orleftbundlebranchblock,advancedA-Vheartblock).ECGabnormalitiesdetermined
byacardiologisttobeclinicallyinsignificantasrelatedtostudyparticipationdonot
precludestudyenrollment(exceptGroup4B)
23.Noevidenceofincreasedcardiovasculardiseaserisk;definedas>10%five-yearriskby
thenon-laboratorymethod[27](exceptGroup4B)
CriteriaSpecifictoWomen:
24.Postmenopausalforatleast1year,post-hysterectomyorbilateraloophorectomy,orifof
childbearingpotential:
a. Negativebeta-humanchorionicgonadotropin(β-HCG)pregnancytest(urineor
serum)ondayofenrollment,andpriortoproductadministrationandCHMI,and
b. Agreestouseaneffectivemeansofbirthcontrolthroughthedurationofstudy
participation
4.1.2.
ExclusionCriteria
Asubjectwillbeexcludedifoneormoreofthefollowingconditionsapply:
1. Womanwhoisbreast-feedingorplanningtobecomepregnantduringstudyparticipation
2. Previousreceiptofamalariavaccine
3. Historyofmalariainfection
4. Historyofsevereinfectionwithsevereacuterespiratorysyndromecoronavirus2(SARS-
CoV-2)definedperFDAguidance[28]
5. ActiveSARS-CoV-2infection
6. Anyhistoryofasevereallergicreactionwithgeneralizedurticaria,angioedemaor
anaphylaxispriortoenrollmentthathasareasonableriskofrecurrenceduringthestudy
7. Hypertensionthatisnotwellcontrolled
8. Receiptofanyinvestigationalstudyproductwithin28dayspriortoenrollment(note:
EmergencyUseAuthorizationCOVID-19vaccineisnotexclusionary)
9. Receiptofanyliveattenuatedvaccineswithin28dayspriortoenrollment
10.Bleedingdisorderdiagnosedbyadoctor(e.g.factordeficiency,coagulopathy,orplatelet
disorderrequiringspecialprecautions)orsignificantbruisingorbleedingdifficultieswith
intramuscularinjectionsorblooddraws


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page26of84
11.Historyofasplenectomy,sicklecelldiseaseorsicklecelltrait
12.Historyofskeetersyndromeoranaphylacticresponsetomosquito-bites(exceptGroup
4B)
13.Knownintolerancetochloroquinephosphate,atovaquoneorproguanil(exceptGroup
4B)
14.Useorplanneduseofanydrug,includingantibiotics,withantimalarialactivitywithin4
weekspriortoCHMI
15.Historyofpsoriasisorporphyria,whichmaybeexacerbatedaftertreatmentwith
chloroquine(exceptGroup4B)
16.Anticipateduseofmedicationsknowntocausedrugreactionswithchloroquineor
atovaquone-proguanil(Malarone)suchascimetidine,metoclopramide,antacids,and
kaolin(exceptGroup4B)
17.Anyotherchronicorclinicallysignificantmedicalconditionthatintheopinionofthe
investigatorwouldjeopardizethesafetyorrightsofthevolunteer,includingbutnot
limitedto:diabetesmellitustypeI,chronichepatitis;ORclinicallysignificantformsof:
drugoralcoholabuse,asthma,autoimmunedisease,psychiatricdisorders,heartdisease,
orcancer
4.2.
InclusionofVulnerableSubjects
4.2.1.
Children
Childrenarenoteligibletoparticipateinthisclinicaltrialbecausethestudyproducthasnotbeen
previouslyevaluatedinadults.Iftheproductisassessedassafeforfurtherstudy,otherprotocols
specificallydesignedforchildrenmaybeconducted.
4.2.2.
ParticipationofSiteEmployees
4.2.2.1.
VRCSite
NIHemployeesandmembersoftheirimmediatefamiliesmayparticipateinthisprotocol.We
willfollowtheGuidelinesfortheInclusionofEmployeesinNIHResearchStudiesandwillgive
eachemployeeacopyofthe“NIHInformationSheetonEmployeeResearchParticipation”and
acopyofthe“LeavePolicyforNIHEmployeesParticipatinginNIHMedicalResearch
Studies.”
Neitherparticipationnorrefusaltoparticipatewillhaveaneffect,eitherbeneficialoradverse,on
theparticipant’semploymentorworksituation.FortheVRCsite,theNIHinformationsheet
regardingNIHemployeeresearchparticipationwillbedistributedtoallpotentialsubjectswho
areNIHemployees.Theemployeesubject’sprivacyandconfidentialitywillbepreservedin
accordancewithapplicablepoliciesatthestudysite.Foranyemployeesubjects,consentwillbe
obtainedbyanindividualwhoisindependentoftheemployee’steam.AtNIH,iftheindividual
obtainingconsentisaco-workertothesubject,independentmonitoringoftheconsentprocess
willbeincludedthroughtheBioethicsConsultationService.Protocolstudystaffwillbetrained
onobtainingpotentiallysensitiveandprivateinformationfromco-workersorsubordinates.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page27of84
4.2.2.2.
UMBSite
TheUMBsitewillfollowinstitutionalpoliciesrelatedtostudyparticipationofstudentsor
Universityemployees.Neitherparticipationnorrefusaltoparticipatewillhaveaneffect,either
beneficialoradverse,onthesubject’seducational,employmentorworksituation.
4.3.
ClinicalProceduresandEvaluations
Evaluationofstudyproductsafetywillincludelaboratorystudies,medicalhistory,physical
assessmentbyclinicians,andsubjectself-assessment.Thestudyscheduleispresentedinthe
ScheduleofEvaluations,APPENDIXI.Totalbloodvolumedrawnfromeachsubjectwillnot
exceedtheNIHClinicalCenterGuidelines(PartAandPartB)orUMBCenterforVaccine
DevelopmentandGlobalHealthlimits(PartC).
4.3.1.
RecruitmentandRetention
StudyenrollmentswillbeconductedattheNIHClinicalCenter(PartAandPartB)andatthe
UMBCenterforVaccineDevelopmentandGlobalHealth(PartC).Studysubjectswillbe
recruitedthroughon-siteandoff-siteIRB-approvedadvertisingdonethroughtheVRC’s
screeningprotocol,VRC500(NCT01375530).Effortwillbemadetoincludewomenand
minoritiesinproportionssimilartothatofthecommunityfromwhichtheyarerecruited.
4.3.1.1.
Costs
Therearenocoststosubjectsfortheirparticipationinthistrial.
4.3.1.2.
Compensation
4.3.1.2.1. NIHCompensation
Subjectswillbecompensatedfortimeandinconvenienceinaccordancewiththestandardsfor
compensationoftheClinicalResearchVolunteerProgram.Compensationforstudyproduct
administrationintheIVgroupsaccompaniedbythesamedayPKblooddrawswillbe$430;
productadministrationvisitsintheSCgroupwithoutPKblooddrawswillbe$375.
Compensationwillbe$200forscheduledvisitsthatincludeblooddraws,$85forclinicvisits
thatdonotincludeablooddraworprocedure,$55forSARS-CoV-2testinginPartsAandBof
thestudybynasopharyngealswab,and$25fortimelycompletionoftheelectronicdiarycard.
CompensationforaCHMIvisitincludingthepre-CHMIvisitthepriordayis$400.
Thetotalamountofcompensationvariesdependingupongroupandthevisitscompleted.
Compensationmayalsovarydependinguponthenumberofdaysrequiredforthedaily
evaluationsintheperiodafteraCHMIasthosewhobecomeparasitemicearlywillrequirefewer
daysofin-clinicevaluationvisitsthanthosewhohavedelayedornoparasitemia.CHMIcontrol
subjectswillbecompensatedsimilarlyforcomparablevisittypes.
4.3.1.2.2. UMBCompensation
Subjectswillbecompensatedfortimeandinconvenienceinaccordancewiththestandardsfor
compensationoftheUMBCenterforVaccineDevelopmentandGlobalHealth.Compensation
forstudyproductadministrationintheIVgroupsaccompaniedbythesamedayPKblooddraws
willbe$400;productadministrationvisitsintheSCgroupwithoutPKblooddrawswillbe


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page28of84
$175.Compensationwillbe$75forscheduledin-personvisits,withorwithoutblooddraws;
and$10/dayfortimelycompletionofthe7-daydiarycard,toatotalofupto$70.Compensation
foraCHMIvisitincludingthepre-CHMIvisitthepriordayis$325.
Thetotalamountofcompensationvariesdependingupongroupandthevisitscompleted.
Compensationmayalsovarydependinguponthenumberofdaysrequiredforthedaily
evaluationsintheperiodafteraCHMIasthosewhobecomeparasitemicearlywillrequirefewer
daysofin-clinicevaluationvisitsthanthosewhohavedelayedornoparasitemia.CHMIcontrol
subjectswillbecompensatedsimilarlyforcomparablevisittypes.
4.3.2.
Screening
ScreeningforthisstudywillbecompletedthroughtheVRC’sscreeningprotocol,VRC500
(NIH11-I-0164).SubjectswillberecruitedthroughInstitutionalReviewBoard(IRB)-approved
advertising.Screeningevaluationsareperformedtoconfirmeligibilityandwillincludemedical
historyreview,physicalexam,andtheclinicallaboratorytestsdetailedinAPPENDIXI.
Womenpresumedtobeofreproductivepotentialwillbegivenapregnancytest.Abaseline
electrocardiogram(EKG)willbeperformed.Additionalassessmentsofhealthmaybe
conductedatscreeningbasedonclinicaljudgment.Pre-exposureresearchbloodsamplesmaybe
collectedanytimeduringscreeningthroughenrollmentandwillnotbesubjecttothe“56-day
priortoenrollment”restriction.
Informedconsentdocumentswillbereviewedduringscreening.Counselingrelatedtopotential
risksofthestudyproduct,pregnancyprevention,andavoidingexposuretomalariawillbe
performed.AnAssessmentofUnderstanding(AoU)willbecompletedinassociationwith
enrollmentintoVRC612.Recordswillbekeptdocumentingthereasonthatscreenedsubjects
donotenroll.
4.3.3.
EnrollmentandStudyDay0
Inthisstudy,enrollmentisdefinedastheassignmentofastudyidentificationnumberanda
studygroupintheclinicaldatabase.Aclinicianwilldiscussthetargetdatesandtimingofthe
studyproductadministration,CHMI,andsamplecollectionsbeforecompletinganenrollmentto
helpensurethatthesubjectcancomplywiththeprojectedschedule.Informedconsentmustbe
obtainedpriortoenrollment.ForCIS43LSrecipients,enrollmentwilloccuratVisitA1Ror
B1R(Day-28toDay0)andmayoccuronthesamedayasproductadministrationatVisitA2or
B2(Day0)inadvanceofproductadministration.ForCHMIcontrolsubjects,VisitA1RorB1R
(Day-56toDay-1)istheenrollmentday,whichwillbewithin56dayspriortotheCHMI.
ForCIS43LSrecipients,Day0isdefinedasthedayofproductadministration.IfDay0doesnot
coincidewithenrollment,thentheenrollmentdaymaybereferredtobyanegativenumberof
days(i.e.,Day-1).ForcalculatingelapseddaysfollowingDay0,eachsubsequentcalendardate
islabeledbythenextsequential“StudyDay”asshowninAPPENDIXI.Sincetheremaybe
morethanoneresearchsamplingtimepointofinterestperstudyday,eachsamplecollection
timepointhasitsown“VisitNumber.”Forthisreason,theremaybemorethanonevisitnumber
recordedonthesamecalendardate.
ThestudystartedinPartAwithsubjectenrollmentdirectlyintoGroup1.Additionaldose
groups(Groups2,3,4A,and4B)openedperthedoseescalationrulesasoutlinedinSection4.5,
andsubjectsweredirectlyenrolledintothesubsequentopengroups.SubjectsinGroup5were


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page29of84
abletochoosetoparticipateinthecontrolgroup(andwillbeofferedtoenrollintoGroup10as
PartBCHMIcontrols)andundergoCHMIwithoutreceivingproductadministration.PartB
subjectswillalsobedirectlyenrolled.Becausethisisanopen-labeldesign,subjectswillknow
whatgrouptheyareinonthedayofenrollment.
MedicalhistoryandDay0evaluations(priortoproductadministration,asapplicableperstudy
group)arethebaselineforsubsequentsafetyassessmentsexceptthatthescreeningevaluations
willbethebaselineforthoseonlydoneatscreening.
InPartC,thegroupswillbeenrolleddirectlystartingwiththelowestdosegroup(Group11)and
thenenrollmentswillcontinueintotheadditionaldosegroups.Group16maybefilledatany
timeinordertoensureanadequatenumberofcontrolparticipantsforCHMI.
4.3.4.
ProductAdministration
Allproductadministrationswillbecompletedaccordingtotheassignedgroup.
Onthedayof,andpriortoproductadministration,vitalsigns(temperature,bloodpressure,heart
rateandrespiratoryrate)willberecorded,atargetedphysicalexamination(basedonsigns,
reportedsymptomsorinterimmedicalhistory)maybeconductedasneeded,andwomenof
childbearingpotentialmusthaveanegativepregnancytest.
IfasubjectisassignedtoanIVadministrationgroup,theIVaccesswillbeplacedinanarmvein
inanasepticmanner.AdifferentsitemaybeusedforcollectionofPKbloodsamples;however,
thesamesitemaybeusedafterflushingthelineifanothersiteisnotavailable.CIS43LSwillbe
administeredwithapproximately100mLofnormalsalineIVoverabout15-30minutes,witha
targetof30minutesfortheinitialinfusionforeachsubject.Infusionslastinglongerthan30
minutesareallowed.Ifthesubjectexperiencessideeffectsduringtheinfusion,therateof
infusionmaybeslowedorstoppedtoalleviatethesymptoms.
IfasubjectisassignedtoaSCadministrationgroup,theSCadministrationsite(s)tobeused
mustbeassessedasacceptablebytheclinicianandthesubject.ThepreferredSCadministration
siteistheabdomen,buttheupperarmorthighmaybeused.Giventheweightcriterioninthis
studygroup,themaximumvolumeneededtoadministera10mg/kgSCdoseisnotexpectedto
exceed10mL.TheSCdosewillbeadministeredbystandardneedleinamaximumvolumeof
about2.5mLperinjectionsite.Upto6SCinjectionsitesmaybeusedifdeemednecessaryby
theclinician.SCadministrationsitesshouldbeatleast2inchesapart.
ProceduresforCIS43LSpreparationandadministrationaredescribedinSection7.
4.3.5.
Post-ProductAdministrationFollow-up
InallstudygroupsinPartA,thefirstsubjectineachdosegrouptoreceiveauniquedoselevel
(5,20,or40mg/kg)orroutewillbeobservedforatleast4hoursfollowingcompletionofinitial
productadministration.Allothersubjects(includingthoseinPartsBandC)willbeobserved
foratleast2hoursfollowingcompletionofproductadministration.CollectionofPKsamples
willbeconductedaccordingtotheScheduleofEvaluationsforthesubject’sstudygroup.
Priortodischargefromtheclinic,subjectswillbeassessedforlocalandsystemicreactogenicity
andvitalsignswillberecorded.Anysubjectwhoisassessedasbeingunwellorhasongoing


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page30of84
reactogenicitysymptomswillbeaskedtoremainintheclinicuntilevaluationanddischargebya
studyclinician.Thisincludesthepossibilityofanovernightinpatientstaytoevaluateforsafety.
4.3.6.
SolicitedAdverseEvents(Reactogenicity)
Eachsubjectwillbegivena7-daydiary(paperandelectronic-basedavailable),athermometer,
andameasuringdevice.Subjectswillusethediarytorecordtheirhighesttemperature,localand
systemicsymptoms,andconcomitantmedicationsdailyfor7daysaftereachproduct
administration.Subjectswillbeprovidedtrainingondiarycompletionandproperusageofthe
thermometertomeasuretemperatureandthemeasuringdevicetomeasureinjectionsite
symptoms.Completionofdiarytrainingwillbenotedinthesourcedocuments.Whilethe
electronicdiaryispreferred,subjectswillhavetheoptiontouseapaperdiary.Thepaperdiary,
ifused,willbetranscribedintothestudydatabaseandstoredinthesubjectfileformonitoring
purposes.Whenneitherpapernorelectronicdiaryisavailablefromthesubject,thestudy
clinicianwilldocumentthesourceofreactogenicityinformationrecordedinthestudydatabase.
Thesignsandsymptomssolicitedbythediarywillincludesystemiceventsoftemperature,
feelingunusuallytiredorunwell,musclesaches,headache,chills,nausea,andjointpain,and
localeventsattheproductadministrationsiteofpain/tenderness,swelling,redness,bruising,and
pruritus.Subjectdiarieswillbereviewedbyaclinicianforaccuracyandcompletenessat
follow-upvisits.Clinicianswillfollowanysolicitedsymptomsthatareongoingafter7days
untiltheyhaveresolved.
Diarydatawillbeavailableinreal-timetocliniciansforsubjectswhousetheelectronicdiary.
Subjectsusingapaperdiarywillbeencouragedtocontacttheclinicassoonaspossibleforany
moderateorseveresideeffectsthattheyexperienceinthe7dayspostproductadministration.A
studyclinicianmaycontactthesubjectbyphoneifanymoderateorseveresideeffectis
reported.Eventsthatmayrequireaclinicvisitincluderash,urticaria,feverof38.6˚C(Grade2)
orhigherlastinggreaterthan24hoursorsignificantimpairmentintheactivitiesofdailyliving
(suchasthoseconsistentwithGrade2orhigherimpairment).Additionally,otherclinical
concernsmaypromptastudyvisitbasedonthejudgmentofastudyclinician.
4.3.7.
CHMIProcedures
TheintervalbetweenadministrationofstudyproductandCHMIwillvarydependingonwhena
subjectisenrolled.TheCHMIwillonlyoccurfollowinganevaluationofDay7safetydatapost
productadministrationandmaybeadministeredatanytime≥8daysthrough12weekspost
productadministration.SomeflexibilityaroundtheintervalbetweenthetimeofCIS43LS
administrationandCHMIispermittedgiventheneedtoworkwitheachsubject’spersonal
schedule,availabilityoftheCHMIfacilityandpost-CHMIfollow-up.
PriortoschedulingtheCHMI,atleasttwoemergencycontactnumberswillbeconfirmedand
verifiedasauthenticforeachsubjectwhowillparticipateinthechallenge.Theclinicalstudy
teamwillrevieweachsubject’sadherencetothescheduleandsafetyfollow-uptodate.This
reviewwillattempttoidentifyanylikelihoodofunreliabilityonthepartofthesubjectduringthe
CHMIphaseofthestudy.Anysubjectexpressinginabilitytocomplywithstudyrequirements
maybedeemedunsuitableforCHMIandwillbeexcludedfromtheCHMIphaseofthestudy.
Anysubjectwhoreceivesstudyproduct,however,willbeencouragedtoremaininthestudyfor
safetyfollow-upvisits.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page31of84
Womenofchildbearingpotentialmusthaveanegativepregnancytestwithin2dayspriorto
CHMI.UseofantibioticswithantimalarialactivitybyCHMIparticipantsshouldbeavoidedat
least4weekspriortoandduringtheCHMIunlessmedicallywarranted.
CHMIwillbeconductedbyexperiencedinsectaryandclinicalstaffatWRAIRandUMB.
MosquitoesinfectedviamembranefeedsinpreparationfortheCHMIcontainsporozoitesin
theirsalivaryglandsandupto5atatimewillbeallowedtofeedoneachsubjectunder
controlledconditions.Followingexposure,themosquitoeswillbeimmediatelydissectedto
confirmthepresenceofabloodmealandtodeterminetheinfectivityrateandthesalivarygland
score.Additionalmosquitoeswillbeallowedtofeeduntil5bitesshowingpresenceofablood
mealandaminimum2+salivaryglandscorehasbeenachievedforeachsubject.
OnthedayofCHMI,subjectswillbeprovidedwithcounselingandwrittenrecommendationsto
reduceriskofnaturalmosquitoexposurebeginning5daysafterCHMIandcontinuinguntil
completionoftreatment.
4.3.8.
Post-CHMIFollow-Up
Thestudyteamwillbeincontactwithsubjectsatleast2timesinthefirst7daysaftertheCHMI
toprovideclosemonitoringofclinicalstatus.Bloodsamplestoevaluateformalariaparasitemia
willbecollecteddailyandrunonPCRfromdays7through18post-CHMI.Regularparasitemia
evaluationswillstopaftertreatmentisinitiatedforpositivecasesofparasitemia.Intheabsence
ofmalariainfection,allsubjectswhohavenotalreadystartedtreatmentwillbeprovidedwith
directlyobserveddefinitiveantimalarialtreatmentatDay21.
TheCOVID-19pandemicdemonstratedthatlargescaledisruptionofclinicaltrialactivitiesis
possible.Whilesuchlarge-scaledisruptionsarenotexpectedatthetimeofPartBorPartC
CHMI,theprotocolisrevisingthepost-CHMIfollow-updurationfrom28daysto21daysasa
riskmitigationprocedure.Ashorterfollow-uptimelimitstravelandpublicexposuretoboth
subjectsandtrialstaffintheeventsocialdistancingisrequired,whileconcomitantlyensuring
thescientificintegrityofefficacydatafrombothcontrolsubjectsandCIS43LSrecipients.
Duringthepost-CHMIfollow-upperiod,subjectsmayparticipateintheirnormaldailyactivities.
Astudyphysicianwillbeavailable24hoursadaybytelephoneorinpersontothesitestaffin
caseneededforconsultationaboutsubjectsignsandsymptoms.Anysubjectwhoisassessedas
beingunwellduringthepost-CHMIfollow-upwillbeaskedtoremainintheclinicuntil
evaluationanddischargebyastudyclinician.Thisincludesthepossibilityofanovernight
inpatientstaytoevaluateforsafety.
AtroponinlevelwillbeobtainedatbaselineduringscreeningforallCHMIparticipants.Ifa
subjectinpost-CHMIfollow-upcomplainsofchestpainorhasothersignsand/orsymptoms
consistentwithacardiovascularevent,anothertroponinlevelwillbeobtainedandother
cardiovascularevaluationswillbeperformed,asmedicallyindicated.ConsultationwiththeNIH
CCCardiologyService(forPartsAandB)andUMBCardiologyService(forPartC)willbe
obtainedwhenindicatedbythesignsandsymptoms.
RegardlessofCHMIoutcomeandfollowingparasitemiaevaluations,subjectswhoreceived
CIS43LSwillcontinuetofollowtheScheduleofEvaluations,asoutlinedinAPPENDIXI.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page32of84
4.3.9.
ParasitemiaManagement
FollowingCHMI,acaseofmalariaparasitemiawillbedefinedaseitherasinglepositivePCR
resultorathickbloodsmearthatmeetsthecriteriaforpositivity.Thisallowsforcasesof
malariatobeidentifiedbeforegametocytescandevelopandthusbeforedetectionof
gametocytesbybloodsmeararedetectable.Malariainfectionwillbetreatedwhenthecriterion
foracaseismet.
RegardlessofPCRorbloodsmearresults,allCHMIparticipantswillreceivedirectlyobserved
antimalarialtreatmentatDay21postCHMI,iftheyhavenotalreadybeentreatedfor
parasitemiabythistimepoint.Subjectsmayalsobeprovidedwithtreatmentslikeantiemetics
andibuprofenasneededformanagementofsymptoms.
RefertotheScheduleofEvaluations,APPENDIXI,forthesafetylaboratoryevaluationsthatare
requiredtobeperformedattheonsetoftreatmentand2dayslater.
Malariainfectionsinallsubjectswillbetreatedpromptlyandadministeredasdirectlyobserved
therapy(DOT)byaclinicianuntilthespecifiedcourseoftreatment.Treatmentregimens
subsequentlydescribedareknowntobeeffectiveagainstthePfstrainbeingusedintheCHMI.
• Firstlineoftreatment:astandardatovaquone/proguanil(Malarone®)regimen:
FourMalaroneTablets(adultstrengthtablet=250mgatovaquone/100mgproguanil;
totaldailydose1gatovaquone/400mgproguanilhydrochloride)takenasasingle
dosedailyfor3consecutivedayswithfoodoramilkydrink.
• Alternativetreatment:astandardchloroquineregimen:
Totalof1500mgchloroquinebase(2500mgsalt)givenorallyindivideddoses:600
mgbase(1000mgsalt)initially,followedby300mgbase(500mgsalt)given6,24,
and48hourslater]
AlternativemedicationsandregimensknowntobeeffectiveincuringthePfstrainadministered
fortheCHMImaybeusedintheeventofallergies,intolerancesorlackofavailabilityof
treatmentslistedabove.
Followingtreatmentforapositivecaseofmalaria,curewillbedocumentedbyaPCRnegative
resultat26days(±5days)afterthecompletionoftreatment.
4.3.10.
Follow-UpthroughEndofStudy
Studyfollow-upwillcontinueviaclinicalvisitsthrough24weeksaftertheproduct
administrationor8weekspostfinalCHMI,whicheverismoststringent.Thevisitscheduleis
basedonintervalsoftimeafterproductadministrationorCHMI.Thescheduleofvisits,
allowablewindowsforcompletingthevisits,andevaluationsperformedateachvisitareshown
intheScheduleofEvaluations,APPENDIXI.Outofwindowstudyvisitswillbediscouraged
andrecordedasprotocoldeviationsbutmaybepermittedatthediscretionofthePIinthe
interestofobtainingsafetyandPKevaluationsfollowingexposuretotheinvestigationalstudy
productorconductofaCHMI.
Anysubjectwhoreceivesinvestigationalproductwillberequiredtofollowtheproduct
administrationscheduleforacompletesafetyandresearchevaluationthroughstudyduration.
SubjectswhoundergoCHMIwillberequiredtofollowtheCHMIScheduleofEvaluationsto


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page33of84
completion.Whenvisitsfrombothschedulesoccuronthesameday,allrequiredcomponentsof
therequiredvisitsforeachschedulemustbecompleted.
SubjectswhoreceivestudyproductbutdonotreceiveCHMIasscheduledareexpectedto
continuefollow-upaccordingtothescheduleforIVorSCgroupthrough24weeks,exceptthat
researchsamplecollectionsmaybediscontinuedforpregnantwomenorothersinwhichitis
contraindicated.
RefertoSection4.6forcriteriafordiscontinuingproductadministrationand/orstudy
participation.
4.4.
ConcomitantMedications
Onlyroutineprescriptionmedicationswillbeenteredinthedatabaseatthetimeofenrollment.
Subsequently,concomitantmedicationsareonlyupdatedorrecordedinthestudydatabaseif
thereisanoccurrenceofanadverseevent(AE)thatrequiresexpeditedreportingorifthesubject
developsanewchronicconditionthatrequiresongoingmedicalmanagement.Treatmentwith
antimalarialdrugswillberecordedonaMalariaEndpointCaseReportForm(CRF).Otherwise,
theconcomitantmedicationchangesthroughoutthestudywillberecordedinthesubject’schart
asneededforgeneralmedicalrecordsbutwillnotberecordedinthestudydatabase.
4.5.
DoseEscalationPlan
Therearetwodoseescalationreviewsinthisstudy.Theactivationofadditionaldosegroups
willproceedinastagedmannerthatisgovernedbytheoutcomeoftheseplannedinterimPSRT
datareviews.ThePSRTmustassessthedataasshowingnosignificantsafetyconcernsbefore
proceedingwithgroupactivation.
PartAofthestudywillbeginwithdirectenrollmentofsubjectsintoGroup1.Followingthe
firstproductadministrationinGroup1,thestudyteamwillwaitatleast3daysbefore
administeringCIS43LStoadditionalsubjectswithinthatgroup.
Thefirstdoseescalationreview(from5mg/kgIVto5mg/kgSCand20mg/kgIV)willoccur
when3subjectswhoreceivedthe5mg/kgdosebyIVhavecompletedtheDay7safetyfollow-
upvisit.ThePSRTreviewwilldeterminewhetherenrollmentintoGroups2and3maybegin.
Theseconddoseescalationreview(from20mg/kgIVto40mg/kgIV)willoccurwhen3
subjectswhoreceivedthe20mg/kgIVdosehavecompletedtheDay7safetyfollow-upvisit.
ThePSRTreviewwilldeterminewhetherenrollmentintoGroups4Aand4Bmaybegin.
Iftherearediscontinuationsfromthestudybeforetherearesufficientdatatoconductthedose
escalationreviewforaspecificgroup,thenadditionalsubjectsmaybeenrolledtocompletethe
doseevaluation.Additionally,AEsassessedasrelatedtostudyproductatthetimeofadose
escalationreviewmaywarrantenrollmentofadditionalsubjectsintoadosegrouptoreassess
safetybeforeproceedingtoahigherdose.
ConsultationwiththeIRBorFDA,ifneeded,asperstudypausecriteria(Section4.5)willoccur
ifindicated.Oneoutcomeofadoseescalationreviewmaybetorecommendevaluationof
additionalsubjectsatthecurrentdoselevelandreassessforsafetybeforeproceedingtoahigher
doselevel.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page34of84
4.6.
CriteriaforDiscontinuationofProductAdministrationorProtocol
Participation
DecisionsbythePIordesigneetodiscontinueasubjectfromreceivingadditionalproduct
administrationsorfromprotocolparticipationforasubjectwillbemadewiththefollowing
criteria.
4.6.1.
DiscontinuationofStudyProductAdministration
PartAsubjectswillnotbepermittedtoreceiveadditionalstudyproductinPartBifanyofthe
followingapply:
1. Pregnancy;
2. Malariainfection;
3. Grade3AEassessedasrelatedtostudyproduct(exceptGrade3solicitedreactogenicity
lastinglessthan48hours);
4. Grade4AEassessedasrelatedtostudyproduct;
5. AnSAEofanygradeassessedasrelatedtostudyproduct;
6. Immediatehypersensitivityreactionassociatedwithstudyproduct;
7. Intercurrentillnessthatisnotexpectedtoresolvepriortothenextscheduledproduct
administration(ifapplicable);
8. Diagnosisofanewchronicorclinicallysignificantmedicalconditionthatintheopinion
oftheinvestigatorwouldjeopardizethesafetyorrightsofthesubject;
9. Repeatedfailuretocomplywithprotocolrequirements;
10.TheINDSponsororthestudyPIdecidetoterminatethestudy;or
11.TheIRB,OfficeforHumanResearchProtections(OHRP)ortheFDAhaltthestudy.
4.6.2.
DiscontinuationfromProtocolParticipation
Asubjectwillbediscontinuedfromprotocolparticipationforthefollowingreasons:
1. Subjectvoluntarilywithdraws;
2. Subjectdevelopsamedicalconditionthatisacontraindicationtocontinuingstudy
participation;
3. TheINDSponsororregulatoryauthoritystopstheprotocol;or
4. TheINDSponsororPIassessesthatisitnotinthebestinterestofthesubjecttocontinue
participationinthestudyorthatthesubject’scompliancewiththestudyisnotsufficient.
Forsubjectswhowishtodiscontinueprotocolparticipation,thefollowingrulesapplywiththe
exceptionthatresearchsamplecollectionswillbediscontinuedforpregnantwomenorothersin
whichitiscontraindicated:
• SubjectswhohavereceivedatleastonedoseofCIS43LSbutdonotparticipateinthe
CHMIareexpectedtocontinuewithsafetyfollow-upthroughatleastVisitA9orB9.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page35of84
• SubjectswhohavecompletedtheCHMIareexpectedtocontinuewithsafetyfollow-up
throughVisitC20orC40asapplicable.
4.7.
CriteriaforPausingandResumingtheStudy
Thestudyteamwillcloselymonitorandreviewstudydataastheybecomeavailabletomake
determinationsregardingthepresence,severityandattributionofAEs.Studyproduct
administrationsandnewenrollmentswillbepausedifanyofthefollowingcriteriaaremet:
• One(ormore)subjectexperiencesaSAEthatisassessedasrelated(possibly,probablyor
definitely)tothestudyproduct,or
• Two(ormore)subjectsexperiencethesameGrade3orhigherAEthatisassessedas
related(possibly,probablyordefinitely)tothestudyproduct(otherthanself-limited
Grade3solicitedreactogenicity).
4.7.1.
PlanforReviewofPausesandResumingRules
Intheeventofapause,theINDSponsorMedicalOfficer(MO)andthePSRTwillbepromptly
notified.
TheINDSponsorMOandPI,inconsultationwiththePSRT,willconductareviewofavailable
information,includingtheeventsthatleadtothepause,andwillmakethedecisiontoresume,
amendorclosethestudy.Aspartofthepausereview,thereviewersmayalsoadviseonwhether
thestudyneedstobepausedagainforanysubsequenteventsofthesametype.
StudyproductadministrationsandnewenrollmentswouldresumeonlyifreviewoftheAEsthat
causedthepauseresultsinarecommendationtopermitfurtherstudyproductadministrationsand
studyenrollments.Safetydatareportsandchangesinstudystatuswillbesubmittedtorelevant
regulatoryauthoritiesinaccordancewithSection5andinstitutionalpolicy.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page36of84
5.
SAFETYANDADVERSEEVENTS
5.1.
AdverseEvents
Anadverseevent(AE)isanyuntowardorunfavorablemedicaloccurrenceinahumansubject,
includinganyabnormalsign(e.g.,abnormalphysicalexamorlaboratoryfinding),symptom,or
diseasetemporallyassociatedwiththesubject’sparticipationinresearch,whetherornot
consideredrelatedtothesubject’sparticipationintheresearch.InthecontextofFDA-required
reporting,anAEmeansanyuntowardmedicaloccurrenceassociatedwiththeuseofadrugin
humans,whetherornotconsidereddrugrelated.
• SolicitedAEs(i.e.,reactogenicityparametersasdefinedinSection4.3.6)willbe
recordedwithoutattributionassessmentsbythesubjectonpaperoranelectronicdiary
for7daysaftereachproductadministration.
• UnsolicitedAEswillberecordedinthestudydatabasewithattributionassessments
duringthefollowingperiods:
1)fromproductadministrationthroughtheDay28post-productadministrationvisit;and
2)fromCHMIthroughtheDay28post-CHMIvisit.
Afterandbetweentheindicatedtimeperiods,onlySAEs(asdetailedinSection5.3)andnew
chronicmedicalconditionswillberecordedasAEsthroughthelastexpectedstudyvisitor
contact.
Malariaandtheassociatedsignsandsymptomsofparasitemiaeventsoccurringatanytime
duringthestudywillberecordedonaMalariaEndpointCRFandwillnotberecordedasanAE.
APPENDIXIIdescribeshowattributionassessments,therelationshipbetweenanAEandthe
studyproduct,CHMIorboth,willbedetermined.AlsoavailableinAPPENDIXIIisthelinkto
theDivisionofAIDS(DAIDS)TableforGradingtheSeverityofAdultandPediatricAdverse
Events,CorrectedVersion2.1[July2017],whichwillbeusedtodeterminetheseveritygrades
ofAEsinthisprotocolwithseveralmodificationsasnoted.
5.2.
SeriousAdverseEvents
Theterm“SeriousAdverseEvent”(SAE)isdefinedin21CFR312.32asfollows:“Anadverse
eventorsuspectedadversereactionisconsideredseriousif,intheviewofeithertheinvestigator
orthesponsor,itresultsinanyofthefollowingoutcomes:Death,alife-threateningadverse
event,inpatienthospitalizationorprolongationofexistinghospitalization,apersistentor
significantincapacityorsubstantialdisruptionoftheabilitytoconductnormallifefunctions,ora
congenitalanomaly/birthdefect.Importantmedicaleventsthatmaynotresultindeath,belife-
threatening,orrequirehospitalizationmaybeconsideredseriouswhen,baseduponappropriate
medicaljudgment,theymayjeopardizethepatientorsubjectandmayrequiremedicalor
surgicalinterventiontopreventoneoftheoutcomeslistedinthisdefinition.Examplesofsuch
medicaleventsincludeallergicbronchospasmrequiringintensivetreatmentinanemergency
roomorathome,blooddyscrasiasorconvulsionsthatdonotresultininpatienthospitalization,
orthedevelopmentofdrugdependencyordrugabuse.”


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page37of84
“Lifethreatening”referstoanAEorsuspectedadversereactionthatrepresentsanimmediate
riskofdeathtothesubject.ItdoesnotincludeanAEorsuspectedadversereactionthat,hadit
occurredinamoresevereform,mighthavecauseddeath.Similarly,ahospitaladmissionforan
electiveprocedureisnotconsideredaSAE.
5.3.
AdverseEventReportingtotheINDSponsor
AEsthatmeetSAEcriteriamustbereportedandsubmittedbytheclinicalsiteonanexpedited
basistotheINDSponsor,VRC/NIAID/NIH,accordingtosponsorguidelinesasfollows:
• Resultsindeath;
• Islifethreatening(placesthesubjectatimmediateriskofdeathfromtheeventasit
occurred);
• Resultsininpatienthospitalizationorprolongationofexistinghospitalization;
• Resultsinapersistentorsignificantdisability/incapacity;
• Resultsinacongenitalanomaly/birthdefectintheoffspringofastudysubject;OR
• Baseduponappropriatemedicaljudgment,mayjeopardizethesubject’shealthandmay
requiremedicalorsurgicalinterventiontopreventoneoftheotheroutcomeslistedinthis
definition(examplesofsucheventsincludeallergicbronchospasmrequiringintensive
treatmentintheemergencyroomorathome,blooddyscrasiasorconvulsionsthatdonot
resultininpatienthospitalization,orthedevelopmentofdrugdependencyordrugabuse).
Inaddition,anyevent,regardlessofseverity,whichinthejudgmentofaninvestigatorrepresents
aSAE,maybereportedonanexpeditedbasis.
AninvestigatorwillcommunicateaninitialSAEreportwithin24hoursofsiteawarenessof
occurrencetotheINDSponsorbydataentryintothedatabase,whichtriggersanalerttotheIND
SponsorMO.Within3workingdays,awrittensummarybytheinvestigatorshouldbe
submittedtotheINDSponsor.
InorderfortheINDSponsortocomplywithregulationsmandatingsponsornotificationof
specifiedSAEstotheFDAwithin7and/or15calendardays,theinvestigatormustsubmit
additionalinformationassoonasitisavailable.
5.4.
INDSponsorReportingtotheFDA
TheINDSponsorisresponsibleformakingthedeterminationofwhichSAEsare“seriousand
unexpectedsuspectedadversereactions”(SUSARs)asdefinedin21CFR312.32.
• SuspectedAdverseReactionmeansanyAEforwhichthereisareasonablepossibilitythat
thedrugcausedtheAE.
• UnexpectedAdverseEventmeansanAEthatisnotlistedatthespecificityorseveritythat
hasbeenobserved.
AllSUSARs(asdeterminedbytheINDSponsor)willbereportedtotheFDAasINDSafety
Reportsper21CFR312.32assoonaspossiblebutnotexceeding7calendardaysforunexpected


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page38of84
fatalorlife-threateningevents,andnotexceeding15calendardaysforotherqualifyingevents.
INDSafetyReportswillalsobeprovidedtotheIRB.
TheINDSponsorwillalsosubmitanINDAnnualReportoftheprogressoftheinvestigationto
theFDAasdefinedin21CFR312.33.
5.5.
ReportingtotheInstitutionalReviewBoard
ThefollowinginformationisconsistentwithNIHIRBPolicy801:ReportingResearchEvents.
ReportableEvent-Aneventthatoccursduringthecourseofhumansubjectresearchthat
requiresnotificationtotheIRB.
Forthepurposesofthispolicy,reportableeventsincludethefollowing:
• UnanticipatedProblems(UPs)involvingriskstosubjectsorothers
• Non-compliance(includingmajorprotocoldeviationsandnoncompliancethatisnot
relatedtoaprotocoldeviation)
• Deathsrelatedorpossiblyrelatedtoresearchactivities
• Newinformationthatmightaffectthewillingnessofsubjectstoenrollorcontinue
participationinthestudy
5.5.1.
UnanticipatedProblem
AnUnanticipatedProblem(UP)isdefinedasanyincident,experience,oroutcomethatmeetsall
thefollowingcriteria:
• Unexpected(intermsofnature,severity,orfrequency)given(a)theresearchprocedures
thataredescribedintheprotocol-relateddocuments,suchastheIRBapprovedresearch
protocolandinformedconsentdocument;and(b)thecharacteristicsofthesubject
populationbeingstudied;and
• Relatedorpossiblyrelatedtoparticipationintheresearch(possiblyrelatedmeansthereis
areasonablepossibilitythattheincident,experience,oroutcomemayhavebeencaused
bytheproceduresinvolvedintheresearch);and
• Suggeststhattheresearchplacessubjects,orothers(whichmayincluderesearchstaff,
familymembersorotherindividualsnotdirectlyparticipatingintheresearch)atagreater
riskofharm(includingphysical,psychological,economic,orsocialharm)relatedtothe
researchthanwaspreviouslyknownorexpected.
AUPmustbereportedwithin7calendardaysofaninvestigatorbecomingawareoftheactualor
suspectedUP.
5.5.2.
Non-Compliance
Non-complianceisthefailureofinvestigator(s)tofollowtheapplicablelaws,regulations,or
institutionalpoliciesgoverningtheprotectionofhumansubjectsinresearch,ortherequirements
ordeterminationsoftheIRB,whetherintentionalornot.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page39of84
Non-compliancemaybeunintentional(e.g.duetolackofunderstanding,knowledge,or
commitment),orintentional(e.g.duetodeliberatechoicetoignoreorcompromisethe
requirementsofanyapplicableregulation,organizationalpolicy,ordeterminationoftheIRB).
Non-complianceisfurthercharacterizedasseriousorcontinuingasfollows:
• Seriousnon-compliance–Non-compliance,whetherintentionalornot,thatresultsin
harmorotherwisemateriallycompromisestherights,welfareand/orsafetyofthesubject.
Non-compliancethatmateriallyeffectsthescientificintegrityorvalidityoftheresearch
maybeconsideredseriousnon-compliance,evenifitdoesnotresultindirectharmto
researchsubjects.
• Continuingnon-compliance–Apatternofrecurringnon-compliancethateitherhas
resulted,or,ifcontinued,mayresultinharmtosubjectsorotherwisematerially
compromisetherights,welfareand/orsafetyofsubjects,affectthescientificintegrityof
thestudyorvalidityoftheresults.Thepatternmaycompriserepetitionofthesamenon-
compliantaction(s),ordifferentnoncompliantevents.
Anyactualorsuspectednon-compliancebyanyinvestigatororentityassociatedwiththe
protocolmustbereportedtotheIRBbythePI/designeewithin7calendardaysofany
investigatororindividualassociatedwiththeprotocolfirstbecomingaware.
5.5.3.
ProtocolDeviation
AProtocolDeviation(PD)isdefinedasanychange,divergence,ordeparturefromtheIRB-
approvedresearchprotocolandarefurthercharacterizedasmajorandminorasfollows:
• MajorDeviations–DeviationsfromtheIRBapprovedprotocolthathave,ormayhavethe
potentialto,negativelyimpact,therights,welfareorsafetyofthesubject,orto
substantiallynegativelyimpactthescientificintegrityorvalidityofthestudy.
• MinorDeviations–Deviationsthatdonothavethepotentialtonegativelyimpactthe
rights,safety,orwelfareofsubjectsorothers,orthescientificintegrityorvalidityofthe
study.
Forthereportingpurposes,failureofsubjectstocomplywiththeresearchprotocoldoesnot
representnon-complianceunlessthatfailureisduetoanactionoromissionofamemberofthe
researchteam,forexample,thefailuretogiveadequateinstructiontothesubject.
Amajordeviationmustbereportedwithin7calendardaysofaninvestigatorbecomingawareof
anactualorsuspecteddeviation.AlthoughPDsarealsonon-compliance,theseshouldonlybe
reportedonceasdeviations.Majordeviationsresultingindeathmustbereportedwithin24
hoursoftheoccurrenceoftheeventorofanymemberofthestudyteambecomingawareofthe
death.
Researchersareresponsibleformonitoringtheirstudiesthroughouttheyearforadherencetothe
IRBapprovedprotocol.Thepurposeofthismonitoringistoidentifymajordeviationsandto
lookfortrendsinminordeviationsthatmayindicateasystemicissueinhowthestudyisbeing
conductedthatcouldpotentiallynegativelyimpacttherights,safety,orwelfareofparticipantsor
thestudy’sabilitytoproducescientificallyvalidresults.Aseriesofminordeviationspointing
towardamoreglobalissuethatcouldaffecttherights,safetyorwelfareoftheparticipantor


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page40of84
affectthevalidityofthestudyshouldbereportedasamajordeviation.Inallotherinstances,a
summaryofminordeviationsshouldbeprovidedtotheIRBatthetimeofcontinuingreview.
5.5.4.
Death
Anydeathofaresearchsubjectthatispossibly,probablyordefinitelyrelatedtotheresearch
mustbereportedwithin24hoursofaninvestigatorbecomingawareofthedeath.
5.5.5.
NewInformation
Newinformationthatmightaffectthewillingnessofasubjecttoenrollorremaininthestudy
shouldbereportedwithin7calendardaysofaninvestigatorfirstbecomingaware.
5.5.6.
SuspensionorTerminationofResearchActivities
Anysuspensionorterminationofresearchactivities,includingholdsonnewenrollment,placed
upontheresearchbythestudysponsor,NIHorICleadership,oranyregulatoryagencymustbe
reportedwithin7calendardaysofaninvestigatorbecomingaware.
5.5.7.
ExpeditedReportingtotheIRB
Deathrelatedtoresearchmustbereportedwithin24hours.
Thefollowingwillbereportedwithin7calendardaysofinvestigatorawareness:
• ActualorsuspectedUPs;
• Actualorsuspectednon-compliance;
• ActualorsuspectedMajorPDs;
• SAEsthatareactualorsuspectedUPs;
• Newinformationthatmightaffectthewillingnessofasubjecttoenrollorremaininthe
study;
• Suspensionorterminationofresearchactivities,includingholdsonnewenrollment,
placedupontheresearchbythestudysponsor,NIHorICleadership,oranyregulatory
agency.
5.5.8.
AnnualReportingtotheIRB
ThefollowingwillbereportedtotheIRBinsummaryatthetimeofContinuingReview:
• SummaryofUPsandnon-compliance;
• AEs,includingSAEs,thatarenotUPs,asanarrativesummarystatementindicating
whethertheseeventswerewithintheexpectedrange;
• MinorPDs(aggregatesummary);
• Anytrendsoreventswhichintheopinionoftheinvestigatorshouldbereported.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page41of84
6.
STATISTICALCONSIDERATIONS
6.1.
Overview
ThisstudyisaPhase1,dose-escalationstudyinhealthyadultstoassessthesafety,PKand
protectiveefficacyofCIS43LS,aninvestigationalhumanantimalarialmAb.
6.2.
SampleSizeandAccrual
Trialrecruitmentwilltargetabout92healthyadults,ages18to50years,asshowninTable1.
Thepermittedaccrualis100subjectsintotaltoallowforadditionalenrollmentsintheeventthat
anenrolledsubjectdoesnotcompletetheminimumevaluationsneededtomeettheprotocol
criteriaforadose-escalationevaluation.DoseescalationrulesaredescribedinSection4.5.Ifa
subjectenrollsintoastudyproductgroupbutdoesnotreceiveaproductadministrationor
withdrawsbeforethechallengeforreasonsthatarenotsafetyrelated,oracontrolgroupsubject
withdrawsbeforethemalariachallengeoccurs,thenadditionalsubjectsmaybeenrolledto
achievetheaccrualtarget.Followingawithdrawalfromastudyproductgroup,additional
enrollmentsmaybemadeifthereissufficienttimetocompleteproductadministrationpriorto
thescheduledCHMI.
TheprimarygoalofthisstudyistoidentifysafetyconcernsassociatedwithCIS43LSatdifferent
doses.Primarysamplesizeconsiderationsareexpressedintermsoftheabilitytodetectserious
adverseexperiences.TheabilityofthestudytoidentifySAEswillbeexpressedintermsofthe
probabilityofobservingacertainnumberofseriousadverseevents.Withsamplesizen=6,there
isover90%chancetoobserveatleast1SAEifthetruerateisatleast0.319andover90%
chancetoobservenoSAEifthetruerateisnomorethan0.017.Withsamplesizen=4,thereis
over90%chancetoobserveatleast1SAEifthetruerateisnolessthan0.438andover90%
chanceofobservingnoSAEifthetruerateisnomorethan0.025.Probabilitiesofobserving0
ormorethan1SAEwithinagrouparepresentedinTable2forarangeofpossibletrueevent
rates.
Table2:
ProbabilityofEventsforDifferentSafetyScenarioswithinaGroup(n=6or
4)
TrueEventRate
n=6
n=4
Pr(0)
Pr(>1)
Pr(0)
Pr(>1)
0.005
0.970
0.000
0.980
0.000
0.01
0.941
0.001
0.961
0.001
0.02
0.886
0.006
0.922
0.002
0.035
0.808
0.017
0.867
0.007
0.05
0.735
0.033
0.815
0.014
0.1
0.531
0.114
0.656
0.052
0.15
0.377
0.224
0.522
0.110
0.2
0.262
0.345
0.410
0.181
0.3
0.118
0.580
0.240
0.348





APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page42of84
Table3givestheupperandlowerboundsfor95%exactbinomialconfidenceintervalsofthe
trueSAErateatpossiblenumbersofeventswithinagroup.Withinagroupofsizen=6,ifnone
experienceanSAE,the95%exactconfidenceintervalhasupperbound0.459.Withinagroup
ofsizen=4,ifnoneexperienceanSAE,theexact95%confidenceintervalhasanupperbound
0.602.
Table3:
95%ConfidenceIntervalsfortheTrueRateatPossibleObservedNumberof
EventsinaGroup(n=6orn=4)oracrossGroups(n=24)
Observed
Numberof
Events
95%ConfidenceInterval
(n=6)
95%ConfidenceInterval
(n=4)
95%ConfidenceInterval
(n=24)
Lower
Bound
Upper
Bound
Lower
Bound
Upper
Bound
Lower
Bound
Upper
Bound
0
0.000
0.459
0.000
0.000
0.000
0.142
1
0.004
0.641
0.001
0.001
0.001
0.211
2
0.043
0.777
0.010
0.010
0.010
0.270
3
0.118
0.882
0.027
0.027
0.027
0.324
4
0.223
0.957
0.047
0.047
0.047
0.374
5
0.359
0.996
0.071
0.071
0.071
0.422
6
0.541
1.000
0.098
0.098
0.098
0.467
6.3.
StatisticalAnalysis
EnrollmentofCIS43LSrecipientsmayoccuronthesamedayasproductadministrationatVisit
02(Day0)orinadvanceofproductadministrationatVisitA1RorB1R(Day-28toDay0),
exceptinthecaseofcontrols.Allsubjectswhoreceiveproductadministrationwillprovide
safetydata.
Threeanalysiscohortsareinvolvedinstatisticalanalysis.TheIntent-to-treat(ITT)cohortwill
includeallenrolledsubjectswhoreceiveproductadministrationandwillbeanalyzedaccording
totheassignedgroup.ThePer-Protocol(PP)cohortwillincludeallenrolledsubjectswho
receiveproductadministrationandwillbeanalyzedaccordingtotheactualdosetheyreceive.
TheModifiedintent-to-treat(mITT)cohortwillincludeallenrolledsubjectswhoreceiveproduct
administrationfollowedbyCHMIchallengeandwillbeanalyzedaccordingtotheassigned
group.
AllstatisticalanalyseswillbeperformedusingSASandRstatisticalsoftware.
6.3.1.
AnalysisVariables
Theanalysisvariablesconsistofbaseline,safetyparameters,PK,andpresenceorabsenceof
malariainfectionafterCHMI.Descriptivestatisticswillbeusedtosummarizebaseline
characteristics,inclusiveofdemographicsandsafetylaboratorymeasurements.
6.3.2.
SafetyAnalysis
SafetyevaluationwillbeperformedovertheITTcohort.Thenumberandpercentageofsubjects
withoneormoreAEswillbesummarizedbydosegroupalongwiththeexact95%confidence
intervalsoftheAErate.ForsubjectsexperiencingmorethanoneAE,theywillbecountedonce
undertheeventofhighestseverity.Inaddition,acompletelistingofAEsforeachsubjectwill
providedetailssuchasseverity,duration,andrelationshiptostudyproduct.Summarieswillbe
providedforanysolicitedorunsolicitedAEs.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page43of84
a. SolicitedReactogenicity
SolicitedAEdatawillbecollectedafterproductadministration.Thenumberandpercentageof
subjectsexperiencingeachtypeofsolicitedsignorsymptomwillbetabulatedbyseverityandby
dosegroupandoverall(i.e.,pooledIVdosegroupsandpooledSCandIVdosegroups).
Subjectswithmultipleoccurrencesofthesameeventwillbecountedonceusingtheeventof
highestseverity.
b. AdverseEvents
AllreportableAEswillberecordedandcodedbyMedicalDictionaryforRegulatoryActivities
(MedDRA)systemorganclass(SOC)andpreferredterm(PT).Thenumberandpercentagesof
subjectswitheachunsolicitedAEwillbetabulatedbyseverityandrelationshiptothestudy
product,andbydosegroupandoverall(i.e.,pooledIVdosegroupsandpooledSCandIVdose
groups).Subjectswithmultipleoccurrencesofthesameeventwillbecountedonceusingthe
eventhighestseverityorstrongestrelationshiptothestudytreatment.
Aby-subjectlistingofallunsolicitedAEswillprovidedetailsincludingseverity,relationshipto
treatmenttype,seriousness,newmedicalconditionstatus,onsetandenddate,duration,and
outcome.
c. LocalLaboratoryValues
Boxplotsoflocallaboratoryvalueswillbegeneratedforbaselinevaluesandforvaluesmeasured
duringthecourseofthestudy.Eachboxplotwillshowthe1stquartile,themedian,andthe3rd
quartile.Outliers,orvaluesoutsidetheboxplot,willalsobeplotted.Ifappropriate,horizontal
linesrepresentingboundariesforabnormalvalueswillbeplotted.
6.3.3.
PharmacokineticsAnalysis
PKanalysiswillbeperformedoverthePPcohort.BloodsamplesforPKevaluationswillbe
collectedatdefinedtime-pointsaslistedinAPPENDIXII.
IndividualSubjectPharmacokineticAnalysis:Anon-compartmental(NC)PKanalysiswill
beperformedusingPhoenix7.0(CertaraR),PKPlusorasimilarprogramontheCIS43LS
concentrationdatageneratedfromeachsubject.Individualsubjectanddosinggroup
concentrationvstimeprofileswillbeconstructedinlinearandsemi-logscales.IntheNC
analysisthemaximumconcentration(Cmax)andtimeofmaximalconcentration(Tmax)willbe
takendirectlyfromtheobserveddata.Theareaundertheconcentrationsvs.timecurve(AUC)
willbecalculatedusingthetrapezoidalmethodanddeterminedouttothefinalconcentration
collected.IfasubjectsCIS43LSconcentrationfallsbelowthequantitativelimit(QL)ofthe
assaybeforethefinalofPKsamplecollection,thesamplewithconcentrationbelowtheQLwill
beassignedaCIS43LSconcentrationvalueof“0”forAUCcalculations.LaterPKsamplesafter
theinitialconcentrationbelowtheQLsamplewillbeignoredinAUCcalculationsbecause
partialAUCisnotcontributorytothetotalAUC.InadditiontocalculationofthetotalAUC
fromTime=0tothelastCIS43LSconcentration(AUC0-last),partialAUCsfromTime=0toWeek
16(AUC0-16WK),Time=0totheCHMIchallenge(AUC0-CHMI)andTimeofCHMItoWeek16
(AUCCHMI-16WK)willbedetermined.Thetimeweightedaverageconcentrations(Cave)during
theseintervalswillbecalculatedastheAUCdividedbytheAUCcollectioninterval,e.g.Cave0-
16WK=(AUC0-16WK)/16weeks.Theterminalslope,λzwillbedeterminedbyregressionofthe
terminal,log-linearportionoftheconcentrationvs.timeprofile.IfthefinalPKsamplehas


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page44of84
measurableCIS43LSconcentrationsgreaterthantheassayQL,theAUCpostfinalPKcollection
(AUClast-infinity)willbeestimatedasClast/λzandAUC0-infinitywillbecalculatedassumAUC0-last+
AUClast-infinity.
PopulationPharmacokineticAnalyses:PopulationPKanalyseswillbeperformedonthePK
datafollowingIVandSCadministrationtodeterminecompartmentalPKparameterswiththe
PKprogramNONMEM7.3orlater(ICONR).BasedonpreclinicalPKresultsforCIS43LSand
knownPKbehaviorstudiesofmAbs,two-compartmentmodelwillbeused(subroutine
ADVAN4TRANS4).BothzeroorderandfirstorderabsorptionfollowingSCadministration
willbeevaluatedandalagtimeincludedifadelayisseenintherawdatafigures.TheFirst
OrderConditionalEstimationMethodwithInteraction(FOCEI)willbeused.Thepopulation
analysiswillgenerateestimatesforclearance(CL)centralandperipheralvolumesofdistribution
(Vd1andVd2),inter-compartmentalclearance(Q),CLandSCbioavailability(F).Totalvolume
ofdistributionatsteady-state(Vdss),willbecalculatedasthesumofVd1+Vd2.Alphaandbeta
half-liveswillbecalculatedfromCL,Q,Vd1andVd2usingstandardequations(M.Gilbaldiand
DPerrier,PharmacokineticsMarcelDekker,1975).Whilethenumberofsubjectsisexpectedto
besufficienttocharacterizethetypicalPKparametersandtheirbetween-subjectvariabilities
(BSVs),thesamplenumberistoosmallforarobustbroadpopulationPKcovariateanalysis.
Therefore,theimpactofsubjects’sizewillbeaccountedforusingallometricscalingnormalized
to70kgwithdoselevelandCHMIresponsebeingtheonlycovariatesexplored.Individual
subjects’empiricBayesianPKparameterestimateswillbegeneratedusingtheposthoc
subroutine.
Finalmodelselectionwillbebasedonchangesintheobjectivefunction,agoodnessoffit
statisticgeneratedbyNONMEM,andgraphicallybygoodnessoffitplots.Thefinalpopulation
PKmodelwillbeassessedusingbootstrapanalysis.Dosingstrategiesandtheirabilityto
achieveandmaintaintargetCIS43LSconcentrationswillbeperformedusingthefinalpopulation
PKmodelandMonteCarlosimulationswithatleast5000replicates.
6.3.4.
EfficacyAnalysis
EfficacyanalysiswillbeperformedoverthemITTcohort.Theprimaryefficacyanalysiswillbe
basedonatwo-sidedBarnardtestontheproportionofinfectionamongthosewhoreceive
CIS43LSversusthecontrolswhoundergoCHMIconcurrently.Thesecondaryefficacyanalyses
willbebasedontimetoparasitemia,whereCIS43LSrecipientswillbecomparedwiththe
controlsviaalog-ranktest.Kaplan-Meiercurveswillalsobeprovidedforeachgroup.Efficacy
analyseswillbeperformedforPartBandPartCseparately.Anefficacyanalysisoverall
participantsinPartBandPartCcombinedwillalsobeperformed.
Duetovariabletimingofchallengeamongstudyparticipants,alogisticregressionwillbe
performedtoestimatetheinfectionriskasafunctionofthemAbconcentrationatthetimeof
challenge.Forthesamereason,aCoxproportionalhazardsregressionwillbeperformedto
estimatethehazardfunctionwiththemAbconcentrationatthetimeofchallengeasaregressor.
BothregressionswillbecarriedoutoverthesubjectsinPartBandPartCcombined,aswellas
ineachPartseparately,providedthattherearecasesofinfectionamongCIS43LSrecipients.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page45of84
6.3.5.
Interimanalyses
SafetyandPKdatawillbeanalyzedatthecompletionofeachdosegroupinPartsAandB.
PreliminaryPKanalysesmaybedoneonceperdoselevelasthedataforeachdoselevelis
obtained.Thismaybeperformedbeforeadosegroup’sPKdataiscompleteandmayonly
generateasubsetofthefinalPKparameters.Theinterimanalyseswillbeusedtoinform
decisionsaboutdoselevels,timingofCHMI,andsubjectpopulationforPartsBandC.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page46of84
7.
PHARMACYPROCEDURES
ThestudygroupsareshowninTable1.
7.1.
StudyProduct
VRC-MALMAB0100-00-AB(CIS43LS)isasterilebufferedsolutionthatisfilledintosingle-
dosevials.Eachvialcontains5.5±0.10mLofCIS43LSataconcentrationof100±10mg/mL
informulationbuffercomposedof10mMAcetate-Phosphate,25mMSodiumChloride,10mM
SodiumCitrate,100mMArginineHydrochloride,and0.02%(w/v)Polysorbate-68atpH6.0.
7.2.
StorageandTemperatureExcursions
Thesitepharmacistmustpromptlyreportanystoragetemperatureexcursionsoutsideofthe
normalallowancetotheINDSponsor.Theaffectedproductmustbequarantinedinaseparate
areaunderprotocol-specifictemperaturerangesuntilfurthernoticefromtheSponsor.Ifthe
excursionresultsinthawedmaterial,DONOTREFREEZE;storethethawed,vialedmaterialat
2°Cto8°C.
Whenastorage/shipping/handlingexcursionoccurs,theINDSponsordesigneemustsenda
notificationoftheoccurrenceofanexcursionto
Anautomatic
emailreplywillbesenttothenotifier,including(asanattachment)theClinicalExcursion
ReportingForm,whichcanbefilledelectronically(ormanuallyandscanned,ifneeded).The
completedformandrelevantattachments(e.g.temperaturecharts)mustbeemailedtotheVRC
viathesameemailaddress
usingthe“reply”function.The
INDSponsorwillnotifythesitepharmacistifcontinuedclinicaluseoftheproductisacceptable
orwillprovidefurtherinstructions.
7.3.
LabelingofStudyProductVial
Vialsofstudyproductwillbeindividuallylabeledwiththenameofthematerial,volume,lot
number,concentration,storageinstructions,InvestigationalUseStatement(“LimitedbyFederal
LawtoInvestigationalUse”),andmanufacturerinformation.
7.4.
PreparationofStudyProductforAdministration
Thissectiondescribeshowtopreparestudyinjectionsandwillbeupdatedwheninformationis
available.
7.4.1.
PreparationforIVAdministration
ForeachIVinfusionorder,thesubject’sweight,doselevel,andstudygroupcodewillbe
includedinthepharmacyorder.ToprepareanIVinfusion,thepharmacistwill:1)calculatethe
totalmilligramsofCIS43LSneeded,2)retrievetheminimumnumberofthawedvialsrequired
topreparethefulldose,3)withdrawthenecessaryamountofCIS43LS,and4)addthisvolume
toa150mLcapacity,partialfill,100mLbagofnormalsalineusingsterilecompounding
techniquestomaintainsterility.
Thawandequilibratevialsforaminimumof1hourand30minutesatambienttemperature
(15°Cto32°C).Ifthawedvialsareremovedfrom2°Cto8°C,equilibrateatambient


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page47of84
temperatureforaminimumof30minutes.PriortopreparationforadministrationintheIVbag,
vialsshouldbegentlyswirledforapproximately30secondswhileavoidingfoaming.DONOT
SHAKETHEVIAL.
Anin-linefilterinfusionsetmustbeusedforIVproductadministrationsandMUSTcomply
withthefollowingspecifications:1.2-micronPES(polyethersulfone)filtermembrane,DEHP-
free,latex-free(equivalenttoBraun#473994filterextensionset).Whenthein-linefilteris
addedtothetubing,theadministrationsetmustthenbeprimed.
ThestudyproductsolutionwilltypicallybeadministeredIVoverabout15-30minutesusinga
volumetricpump.Thetotaltimeneededtoadministerthedosemaybelongerthan30minutes
basedonfactorssuchassubjecttolerance.Therateofinfusionmayrangefrom10-20mg/kg/hr
atthelowestdoselevelto80-160mg/kg/hratthehighestdoselevel.ThemL/hrinfusionrate
mayvarybasedonthetotalvolumeneededtoadministerafulldose.
Attheendofproductadministration,theIVadministrationsetmustbeflushedwithabout30mL
(orappropriatevolume)ofnormalsaline.
7.4.2.
PreparationforSCAdministration
ForeachSCadministrationorder,thesubject’sweight,doselevel,andstudygroupcodewillbe
includedinthepharmacyorder.ToprepareaSCadministrationdose,thepharmacistwill
calculatethetotalmgneededandretrievetheminimumnumberofvialsneededtopreparethe
fulldose.Thawandequilibratevialsforaminimumof1hourand30minutesatambient
temperature(15°Cto32°C).Ifthawedvialsareremovedfrom2°Cto8°C,equilibrateat
ambienttemperatureforaminimumof30minutes.Priortopreparationforadministration,vials
shouldbegentlyswirledforapproximately30secondswhileavoidingfoaming.DONOT
SHAKETHEVIALS.
TheneededvolumeofCIS43LSmustbewithdrawnfromthevialinto1to6syringesusinga5-
micronfilterneedle.Anewfilterneedlemustbeusedforeachsyringe.Thefilterneedlemust
bediscardedpriortodispensingandreplacedwithaneedlesuitableforSCinjectionatthetime
ofadministration.TheproductmaybeadministeredbydirectSCinjectionwithneedleand
syringe.TheclinicianwilluseproperSCtechniquetoensureadministrationintoSCfattylayer
andaslowpushtominimizediscomfortortheexcessivedistentionofoverlyingskin.
7.4.3.
HandlingofPreparedProductforIVorSCAdministration
AfterproductpreparationinanIVbag,thepreparedCIS43LSmaybestoredat2°Cto8°Cfora
maximumof24hoursand/oratambienttemperature(15°Cto32°C)foramaximumof4hours
totalincludingtheinfusiontime.Productmaynotbestoredindirectsunlight.
AfterpreparationinsyringesforSCadministration,thepreparedCIS43LSmaybestoredat2°C
to8°Cupto24hoursand/oratambienttemperature(15°Cto32°C)upto4hours.Productmay
notbestoredindirectsunlight.
7.5.
StudyProductAccountability
Astudypharmacistordesigneewillberesponsibleformaintaininganaccuraterecordofthe
studygroupcodes,inventory,andanaccountabilityrecordofstudyagentsupplies.Electronic
documentationaswellaspapercopiesmaybeused.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page48of84
7.6.
StudyProductDisposition
Theemptyvialsandtheunusedportionofavialwillbediscardedinabiohazardcontainment
bagandincineratedorautoclavedinaccordancewiththeinstitutionalorpharmacypolicy.Any
unopenedvialsthatremainattheendofthestudywillbereturnedtotheproductionfacilityor
discardedatthediscretionofthesponsorinaccordancewithpoliciesthatapplytoinvestigational
agents.Partiallyusedvialswillnotbeadministeredtoothersubjectsorusedforinvitro
experimentalstudies.Thesevialswillbedisposedofinaccordancewithinstitutionalor
pharmacypolicy.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page49of84
8.
HUMANSUBJECTPROTECTIONSANDETHICAL
OBLIGATIONS
Thisresearchwillbeconductedincompliancewiththeprotocol,InternationalConferenceon
Harmonisation(ICH)GoodClinicalPractice(GCP)guidelinesandallapplicableregulatory
requirements.
8.1.
InstitutionalReviewBoard
ARelianceAgreementwillbeestablishedwiththecollaboratingUMBsiteandWRAIRCHMI
facilitysuchthattheNIHIRBistheIRBofRecordfortheconductoftheVRC612protocol.
Theprotocol,proposedinformedconsentform,otherwrittensubjectinformation,andany
proposedadvertisingmaterialwillbesubmittedbytheCoordinatingSite(VRC)totheIRBfor
reviewandwrittenapproval.
TheProtocolChairmustsubmitand,wherenecessary,obtainapprovalfromtheIRBforall
subsequentprotocolamendmentsandchangestotheinformedconsentdocument.TheProtocol
ChairwillnotifytheNIHIRBofresearcheventsthatoccuronstudyasdescribedinSection5.5.
TheProtocolChairwillberesponsibleforobtainingIRBapprovaloftheannualContinuing
Reviewthroughoutthedurationofthestudy.
8.2.
InformedConsent
Thestudyinformedconsentform(ICF)isprovidedasaseparatedocumentanddescribesthe
investigationalproducttobeusedandallaspectsinvolvedinprotocolparticipation.
ThesitePIordesigneeisresponsibleforobtainingwritteninformedconsentfromthesubject
afteradequateexplanationoftheaims,methods,anticipatedrisksandbenefitsofthestudyand
beforeanyprotocol-specificproceduresorstudyproductisadministered.TheAoUwillbe
completedbeforethestudyICFissigned.
Theacquisitionofinformedconsentwillbedocumentedinthesubject’smedicalrecords,as
requiredby21CFR312.62,andtheICFwillbesignedandpersonallydatedbythesubjectand
thepersonwhoconductedtheinformedconsentdiscussion.ThesignedICFwillberetainedin
themedicalchartandacopyoftheICFwillbeprovidedtothesubject.
8.3.
StudyDiscontinuationandClosure
Thisstudymaybetemporarilysuspendedorprematurelyterminatedifthereissufficient
reasonablecause.Writtennotification,documentingthereasonforstudysuspensionor
termination,willbeprovidedbythesuspendingorterminatingpartytostudyparticipants,the
investigators,theInvestigationalNewDrug(IND)andregulatoryauthoritiesasappropriate.If
thestudyisprematurelyterminatedorsuspended,thePrincipalInvestigator(PI)willpromptly
informstudyparticipants,theInstitutionalReviewBoard(IRB),andSponsorandwillprovide
thereason(s)fortheterminationorsuspension.Studyparticipantswillbecontacted,as
applicable,andbeinformedofchangestostudyvisitschedule.
Circumstancesthatmaywarrantterminationorsuspensioninclude,butarenotlimitedto:
• Determinationofunexpected,significant,orunacceptablerisktoparticipants


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page50of84
• Demonstrationofefficacythatwouldwarrantstopping
• Insufficientcompliancetoprotocolrequirements
• Datathatarenotsufficientlycompleteand/orevaluable
• Determinationthattheprimaryendpointhasbeenmet
• Determinationoffutility
Thestudymayresumeonceconcernsaboutsafety,protocolcompliance,anddataqualityare
addressed,andsatisfytheSponsor,IRBand/orFDA.
8.4.
ConfidentialityandPrivacy
Participantconfidentialityandprivacyarestrictlyheldintrustbytheparticipatinginvestigators,
theirstaff,andtheSponsorandtheirrepresentatives.Thisconfidentialityisextendedtocover
testingofbiologicalsamplesinadditiontotheclinicalinformationrelatingtoparticipants.
Therefore,thestudyprotocol,documentation,data,andallotherinformationgeneratedwillbe
heldinstrictconfidence.Noinformationconcerningthestudyorthedatawillbereleasedtoany
unauthorizedthirdpartywithoutpriorwrittenapprovalofthesponsor.
Allresearchactivitieswillbeconductedinasprivateasettingaspossible.
Thestudymonitor,otherauthorizedrepresentativesoftheSponsor,representativesofthe
InstitutionalReviewBoard(IRB),and/orregulatoryagenciesmayinspectalldocumentsand
recordsrequiredtobemaintainedbytheinvestigator,includingbutnotlimitedto,medical
records(office,clinic,orhospital)andpharmacyrecordsfortheparticipantsinthisstudy.The
clinicalstudysitewillpermitaccesstosuchrecords.
Thestudyparticipant’scontactinformationwillbesecurelystoredattheclinicalsiteforinternal
useduringthestudy.Attheendofthestudy,allrecordswillcontinuetobekeptinasecure
locationforaslongaperiodasdictatedbythereviewingIRB,Institutionalpolicies,orSponsor
requirements.
Studyparticipantresearchdata,whichisforpurposesofstatisticalanalysisandscientific
reporting,willbetransmittedtoandstoredby
theDataCoordinatingCenter.Thiswill
notincludetheparticipant’scontactoridentifyinginformation.Rather,individualparticipants
andtheirresearchdatawillbeidentifiedbyauniquestudyidentificationnumber.Thestudydata
entryandstudymanagementsystemsusedbytheclinicalsiteandbyEmmesresearchstaffwill
besecuredandpasswordprotected.Attheendofthestudy,allstudydatabaseswillbede-
identifiedandarchived.
Tofurtherprotecttheprivacyofstudyparticipants,aCertificateofConfidentialityhasbeen
issuedbytheNationalInstitutesofHealth(NIH).Thiscertificateprotectsidentifiableresearch
informationfromforceddisclosure.Itallowstheinvestigatorandotherswhohaveaccessto
researchrecordstorefusetodiscloseidentifyinginformationonresearchparticipationinany
civil,criminal,administrative,legislative,orotherproceeding,whetheratthefederal,state,or
locallevel.Byprotectingresearchersandinstitutionsfrombeingcompelledtodisclose
informationthatwouldidentifyresearchparticipants,CertificatesofConfidentialityhelpachieve
theresearchobjectivesandpromoteparticipationinstudiesbyhelpingassureconfidentialityand
privacytoparticipants.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page51of84
8.5.
Risk/BenefitAssessment
8.5.1.
PotentialRisks
RiskofCIS43LS:WhileCIS43LShasbeenwell-toleratedtodateinthisstudy,only
preliminarysafetydatainhumansexistsandrisksarenotfullyknown.SeeSection2.3fora
summaryofavailableinterimdatacollectedinVRC612.
RisksofmAbAdministration:AdministrationofmAbsmaycauseimmunereactionssuchas
acuteanaphylaxis,serumsicknessandthegenerationofantibodies.However,thesereactions
arerareandmoreoftenassociatedwithmAbstargetedtohumanproteinsorwiththeuseof
mousemAbsthatwouldhaveariskofhumananti-mouseantibodies[29].Inthisregard,
becauseCIS43LSistargetedtoaparasiteantigenandisahumanmAb,itisexpectedtohavea
lowriskofsuchsideeffects.
Typically,thesideeffectsofmAbsaremildtomoderateandmayincludelocalreactionsatthe
injectionsite(includingpain,redness,bruising,swelling)andsystemicreactionssuchasfever,
chills,rigors,nausea,vomiting,pain,headache,dizziness,shortnessofbreath,bronchospasm,
hypotension,hypertension,pruritus,rash,urticaria,angioedema,diarrhea,tachycardiaorchest
pain.ClinicaluseofmAbsthataretargetedtocytokinesorantigensassociatedwithhumancells
maybeassociatedwithanincreasedriskofinfections[29];however,thisisnotexpectedtobea
riskforamAbtargetedtoaparasiteantigen.
Severereactions,suchasanaphylaxis,angioedema,bronchospasm,hypotensionandhypoxia,are
infrequentandmoreoftenassociatedwithmAbstargetedtohumanproteinsorwithnon-human
mAb,suchasamousemAb[29].Mostinfusion-relatedeventsoccurwithinthefirst24hours
afterinitiationofmAbadministration.
PublishedexperiencewithhumanmAbsdirectedagainstcellsurfacetargetsonlymphocytes
showsthatinfusionofamAbmaybeassociatedwithcytokinerelease,causingareactionknown
ascytokinereleasesyndrome(CRS)[30].CRSreactionscommonlyoccurwithinthefirstfew
hoursofinfusionstartandwiththefirstmAbinfusionreceived.Thisisbecausethecytokine
releaseisassociatedwithlysisofthecellstargetedbythemAbandtheburdenoftargetcellsis
greatestatthetimeofthefirstmAbtreatment.WithlicensedtherapeuticmAbs,CRSis
managedbytemporarilystoppingtheinfusion,administeringhistamineblockersandrestarting
theinfusionataslowerrate[31].Supportivetreatmentmayalsobeindicatedforsomesignsand
symptoms.
Delayedallergicreactionsthatincludeaserumsicknesstypeofreactioncharacterizedby
urticaria,fever,lymphnodeenlargement,andjointpains,typicallyoccurseveraldaysaftermAb
exposureandaremorecommonlyassociatedwithchimerictypesofmAbs[29].Ingeneral,and
withdueconsiderationoftheneedsdictatedbyindividualsubjectsymptomsandtreating
cliniciandiscretion,immediateanddelayedreactionstostudyproductwouldbemanaged
accordingtotheprinciplesoftheAmericanAcademyofAllergy,Asthma,andImmunology
guidelinesestablishedintheDrugAllergy:PracticeParameters(2010).
Participationinthisstudymaylimitasubject’seligibilityforfuturemAbstudies.
RisksofBloodDrawing:Blooddrawingmaycausepain,bruising,andafeelingof
lightheadednessorfainting.Rarely,itmaycauseinfectionatthesitewherebloodistaken.Inthis


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page52of84
study,anIVlinethatcanbeusedforbloodcollectionmaybeplacedinthearmandleftinplace
forseveralhoursondayswhenthereisproductadministrationforfrequentPKblooddraws.
ProblemsfromuseofanIVforblooddrawingaregenerallymildandmayincludepain,bruising,
minorswellingorbleedingattheIVsiteandrarely,infection,veinirritation(phlebitis),orblood
clot.
RisksofMosquitoBitesforCHMI:RisksassociatedwithCHMIincludelocalinflammatory
reactions,lymphadenitis,persistentlocalpruritusandlargerlocalreactionsinvolvingthewhole
forearm,allergicreactionstomosquitobites.Anotherremotelypossibleriskincludesasystemic
allergicreactiontothemosquitoes.
RisksofAcquiringMalariaInfection:Thereisalsothepossibilityofcomplicationsof
malaria,whichareseenduringnaturallyacquiredmalariawhendiagnosisandtreatmentare
delayedandhighlevelsofparasitemiadevelop.Underthecarefullycontrolledconditionsofthis
studythatsupportsearlydiagnosisandtreatment,thechanceofsuchcomplicationsishighly
unlikelyandtheriskofdeathfrommalariainfectionisverysmall.Transientabnormalities,e.g.
fever,headache,myalgia,shakingchills,abdominaldiscomfort,nausea,vomiting,mildanemia,
leukopenia,thrombocytopenia,hepatosplenomegaly,hepatictendernessandfatigue,areexpected
consequencesofmalaria,butarenearlyabsentwithearlyRT-qPCRdetection[32].In
uncontrolledcircumstances,malariainfectionscanleadtokidney,liverorbraininjury(seizures,
coma)anddeath.
RisksofAntimalarialMedication:Additionalrisksincludepossiblesideeffectsofthe
antimalarialmedicationtaken(chloroquine)followingchallengewithchloroquine-sensitivePf.
Thesesideeffectsincludenausea,vomiting,diarrhea,abdominalpain,dizziness,headaches,
sleepdisturbances,blurredvision,pruritus,skinrash,exacerbationofpsoriasisorporphyria,
tinnitus,andphotosensitivity.Rarely,theremaybechangesinelectrocardiogramsand
hypotension.Sideeffectsofatovaquone/proguanil(Malarone®)includenausea,vomiting,
abdominalpain,anorexia,diarrhea,headache,coughandrarely,anemia,oralulcerations,
insomnia,fever,edema,rashandalopecia.Anotherremotelypossibleriskincludesasystemic
allergicreactiontochloroquine(orMalarone®).Thestudyteamwilldiscussthesemedications
andtheirpossiblesideeffectsindetailbothaspartoftheinformedconsentprocess,priorto
CHMI,andpriortoinitiationoftreatmentfordiagnosedmalariainfections.
8.5.2.
PotentialBenefits
Studysubjectswillnotreceivedirecthealthbenefitfromstudyparticipation.Othersmaybenefit
fromknowledgegainedinthisstudythatmayaidinthedevelopmentofmalariaprevention.
8.5.3.
AssessmentofPotentialRisksandBenefits
Thisresearchstudywillbeconductedincompliancewiththeprotocol,GCPguidance,andall
applicableregulatoryrequirements.
Theplanforreductionofknownandunknownriskstoparticipantsincludesappropriatetraining
ofstudypersonnel;educationofstudysubjectsforparticipationincarethroughoutthestudy;
monitoringofstudysubject’shealthstatusandexperiences;withdrawalfromstudyprocedures
uponevidenceofdifficulty,contraindication,orasignificantadverseevent;andreferralfor
treatment,counselingorothernecessaryfollow-up.TheVRCCTPRiskManagementPlan


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page53of84
guidesthereductionandmitigationstrategiesappliedtotheknownandunknownrisks
associatedwithstudyparticipationandtrialmanagement/operations.
Asstudysubjectswillnotreceivedirecthealthbenefitfromstudyparticipationorproduct
administration,noalternativeproceduresareplanned.Thealternativecourseofactionisto
choosenottoparticipate.
8.6.
PlanforUseandStorageofBiologicalSamples
Theplanforuseandstorageofbiologicalsamplesfromthisprotocolisoutlinedinthefollowing
sections.
8.6.1.
UseofSamples,SpecimensandData
Samples,specimensanddatacollectedunderthisprotocolmaybeusedtoconductprotocol-
relatedsafety,parasitologyandimmunogenicityevaluations,exploratorylaboratoryevaluations
relatedtomalaria,exploratorylaboratoryevaluationsrelatedtomAb,vaccineorinfectious
diseaseresearchingeneralandforresearchassayvalidation.
8.6.2.
StorageandTrackingofBloodSamplesandOtherSpecimens
Allresearchsamplesusecodedlabelsthatonlythesitestaffcanlinktothesubject.Samplesare
storedatVIP,VRClaboratoriesin
Bethesda,MD,oratUMBlaboratories,which
areallsecurefacilitieswithlimitedaccess.Datawillbekeptinpassword-protectedcomputers.
Onlyinvestigatorsortheirdesigneeswillhaveaccesstothesamplesanddata.Sampleswillbe
trackedintheLaboratoryInformationManagementSystem(LIMS)databaseorusinganother
softwaredesignedforthispurpose(e.g.,Freezerworks).
8.6.3.
DispositionofSamples,SpecimensandDataatCompletionoftheProtocol
Inthefuture,otherinvestigators(bothatNIHandoutside)maywishtostudythesesamples
and/ordata.IRBapprovalmustbesoughtpriortoanysharingofsampleswithnon-NIH
investigatorsandanyclinicalinformationsharedaboutthosesampleswouldsimilarlyrequire
priorIRBapproval.Theresearchuseofstored,unlinkedorunidentifiedsampleswillbeexempt
fromtheneedforprospectiveIRBreviewandapproval.Exemptionrequestswillbesubmitted
inwritingtotheNIHOfficeofHumanSubjectsResearch,whichisauthorizedtodetermine
whetheraresearchactivityisexempt.
Atthetimeofprotocoltermination,sampleswillremainintheVIPfacility,VRClaboratories,or
UMBLaboratoriesor,afterIRBapproval,willbetransferredtoanotherrepository.Regulatory
oversightofthestoredsamplesanddatamaybetransferredtoastoredsamplesprotocolaspart
oftheIRBapprovedterminationplan.DatawillbearchivedbytheVRCincompliancewith
requirementsforretentionofresearchrecords,orafterIRBandstudysponsorapproval,itmay
beeitherdestroyedortransferredtoanotherrepository.
8.6.4.
LossorDestructionofSamples,SpecimensorData
Anylossorunanticipateddestructionofsamples(forexample,duetofreezermalfunction)or
data(forexample,misplacingaprintoutofdatawithidentifiers)willbereportedtotheIRB.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page54of84
TheProtocolChairorsitePIwillalsonotifytheIRBifthedecisionismadetodestroythe
remainingsamples.
8.7.
SafetyOversight
ClosecooperationbetweenthedesignatedmembersoftheProtocolTeamwilloccurtoevaluate
andrespondtoindividualAEsinatimelymanner.TheVRCclinicdesignatedSafetyOfficer
(SO)forthedayconductsadailysafetyreviewofclinicaldataperVRCStandardOperating
Procedures.
TheProtocolSafetyReviewTeam(PSRT)willbecomprisedoftheProtocolChair,Site
PrincipalInvestigator(PI),AssociateInvestigators,StudyCoordinator,ProtocolSpecialists,
otherstudyclinicians,theINDMO,andexternal(non-VRC)collaborators.ThePSRTwill
reviewthesummarystudysafetydatareportsonaweeklybasisthrough4weeksafterthelast
subjectreceivesthelastproductadministration.ThePSRTwillalsoperformweeklysafety
reviewthrough4weekspostCHMI.Otherwise,iftherehavebeennoproductadministrationsor
CHMIintheprior4weeks,thePSRTwillmonitorthestudysafetydatareportsonamonthly
basisthroughcompletionofthelaststudyvisit.ThePSRTwillevaluateandrespondtosafety
concernsinatimelymanner.



APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page55of84
9.
ADMINISTRATIVEANDOPERATIONALOBLIGATIONS
9.1.
ProtocolAmendmentsandStudyTermination
ProtocolamendmentsmustbemadeonlywithpriorapprovaloftheINDSponsorandwith
agreementfromtheProtocolChairandINDMO.Allstudyamendmentswillbesubmittedtothe
centralIRBforapproval.
TheINDSponsor,theIRB,OHRP,thesitePIs,ProtocolChairs,and/ortheFDAreservethe
righttoterminatethestudy.TheProtocolChairwillnotifytheIRBinwritingofthestudy’s
completionorearlytermination.
9.2.
StudyDocumentationandStorage
TheProtocolChairwilldelegatethestudyresponsibilitiestothestudyteam,andalistof
appropriatelyqualifiedpersonstowhomtrialdutieshavebeendelegatedwillbemaintained.
Sourcedocumentsareoriginaldocuments,data,andrecordsfromwhichthesubject’sdataare
obtained.Theseincludebutarenotlimitedtohospitalrecords,clinicalandofficecharts,
laboratoryandpharmacyrecords,andcorrespondence.Long-termstorageofsourcedocuments
maybeintheformofelectronicfiles.
TheProtocolChairandstaffareresponsibleformaintainingacomprehensiveandcentralized
filingsystemofallstudy-related(essential)documentation,suitableforinspectionatanytimeby
representativesfromtheINDSponsor,VRC/NIAID/NIH,IRB,NIH,FDA,and/orapplicable
regulatoryauthorities.Elementsinclude:
• Subjectfilescontainingcompletedinformedconsentforms,andsupportingcopiesof
sourcedocumentation.
• Studyfilescontainingtheprotocolwithallamendments,IBs,copiesofallcorrespondence
withtheIRB.
Inaddition,alloriginalsourcedocumentationmustbemaintainedandbereadilyavailable.
Allessentialdocumentationshouldberetainedbytheinstitutionforthesameperiodoftime
requiredformedicalrecordsretention.TheFDArequiresstudyrecordstoberetainedforupto
twoyearsaftermarketingapprovalorrefusal(21CFR312.62).Ifnomarketingapplicationis
filed,oriftheapplicationisnotapproved,therecordswillberetainedfortwoyearsafterthe
investigationisdiscontinuedandtheFDAisnotified.TheHHSprotectionofhumansubjects’
regulationsrequirethatinstitutionsretainrecordsofIRB/ECactivitiesanddocumentationof
informedconsentofsubjectsforatleast3yearsafterstudycompletion(45CFR46).
NostudydocumentshouldbedestroyedwithoutpriorwrittenagreementbetweentheVRCand
theinvestigator.Shouldtheinvestigatorwishtoassignthestudyrecordstoanotherpartyor
movethemtoanotherlocation,theymustnotifytheVRCinwritingofthenewresponsible
personand/orthenewlocation.
9.3.
ClinicalMonitoring
Clinicalsitemonitoringisconductedtoensurethattherightsandwell-beingoftrialparticipants
areprotected,thatthereportedtrialdataareaccurate,complete,andverifiable,andthatthe


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page56of84
conductofthetrialisincompliancewiththecurrentlyapprovedprotocol/amendment(s),with
ICHGCP,andwithapplicableregulatoryrequirement(s).
Monitoringforthisstudywillbeperformedbyadesignatedcontractresearchorganization
(CRO),
Detailsofclinicalsitemonitoringare
documentedinaClinicalMonitoringPlan.TheClinicalMonitoringPlandescribesindetailwho
willconductthemonitoring,atwhatfrequencymonitoringwillbedone,atwhatlevelofdetail
monitoringwillbeperformed,andthedistributionofmonitoringreports.
9.4.
DataCollectionandSharing
9.4.1.
DataCollection
Clinicalresearchdatawillbecollectedinasecureelectronicweb-basedclinicaldata
managementsystem(CDMS)throughaCRO,Emmes(Rockville,MD).Extracted,anonymized
datawillbesenttothePSRTforsafetyreviewandtoProtocolStatisticianforstatisticalanalysis.
9.4.2.
SourceDocuments
Thesitewillmaintainappropriatemedicalandresearchrecordsforthistrial,incompliancewith
ICHE6(R2)GCP,applicableregulations,andinstitutionalrequirementsfortheprotectionof
confidentialityofsubjects.Sourcedataareallinformation,originalrecordsofclinicalfindings,
observations,orotheractivitiesinaclinicaltrialnecessaryforthereconstructionandevaluation
ofthetrial.Examplesoftheseoriginaldocumentsanddatarecordsinclude,butarenotlimited
to,medicalrecords,laboratoryreports,pharmacyrecordsandotherresearchrecordsmaintained
fortheclinicaltrial.
9.4.3.
DataSharing
Datageneratedinthisstudywillbesharedasde-identifieddatainthegovernment-fundedpublic
repository,www.clinicaltrials.gov.Datamaybesharedpriortopublicationatapprovedpublic
presentationsorforcollaborativedevelopmentandwillbesharedatthetimeofpublicationor
withinoneyearoftheprimarycompletiondate.
9.5.
QualityAssuranceandQualityControl
Theclinicalsitewillperforminternalqualitymanagementofstudyconduct,dataandbiological
specimencollection,documentationandcompletion.TheVEC’sQualityManagementPlanwill
beusedtoperformqualitymanagementforthistrial.
Qualitycontrol(QC)procedureswillbeimplementedbeginningwiththedataentrysystemand
dataQCchecksthatwillberunonthedatabasewillbegenerated.Anymissingdataordata
anomalieswillbecommunicatedtothesiteforclarification/resolution.
Themonitorswillverifythattheclinicaltrialisconducted,anddataaregenerated,and
biologicalspecimensarecollected,documented(recorded),andreportedincompliancewiththe
protocol,ICHGCP,andapplicableregulatoryrequirements.
Thesitewillprovidedirectaccesstoalltrialrelatedsites,sourcedata/documents,andreportsfor
thepurposeofmonitoringandauditingbythesponsor,andinspectionbylocalandregulatory
authorities.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page57of84
9.6.
Language
Allwritteninformationandothermaterialtobeusedbysubjectsandinvestigativestaffmustuse
vocabularyandlanguagethatareclearlyunderstood.
9.7.
Research-RelatedInjuries
9.7.1.
NIH
TheNIHClinicalCenterwillprovideshort-termmedicalcareforanyinjuryresultingfrom
participationinresearchhere.Ingeneral,nolong-termmedicalcareorfinancialcompensation
forresearch-relatedinjurieswillbeprovidedbytheNIH,theNIHClinicalCenter,ortheFederal
Government.However,subjectshavetherighttopursuelegalremedyiftheybelievethattheir
injuryjustifiessuchaction.
9.7.2.
WRAIR
IfsubjectsareinjuredbecauseofparticipationinthisresearchduringtheCHMIandtheyarea
DODhealthcarebeneficiary(e.g.,activedutyinthemilitary,militaryspouseordependent,
retiree),theyareentitledtomedicalcarefortheirinjurywithintheDODhealthcaresystem,as
longastheyremainaDODhealthcarebeneficiary.
IfsubjectsareinjuredbecauseofparticipationinthisresearchduringtheCHMIandtheyarenot
aDODhealthcarebeneficiary,theyareentitledtomedicalcarefortheirinjuryataDODhospital
orclinic,butsuchcarefortheinjuryatDODhospitalsorclinicsmaybetime-limited,andthe
subject’sinsurancemaybebilled.ItcannotbedeterminedinadvancewhichDODhospitalor
clinicwillprovidecare.Ifsubjectsobtaincareforresearch-relatedinjuriesoutsideofaDOD
hospitalorclinic,theyortheirinsurancewillberesponsibleformedicalexpenses.
ForDODhealthcarebeneficiariesandnon-DODhealthcarebeneficiaries:Transportationtoand
fromhospitalsorclinicswillnotbeprovided.Noreimbursementisavailableifsubjectsincur
medicalexpensestotreatresearch-relatedinjuries.Nocompensationisavailableforresearch-
relatedinjuries.Subjectsarenotwaivinganylegalrights.Ifsubjectsbelievetheyhavesustained
aresearch-relatedinjury,theymaycontactthePI.Ifsubjectshaveanyquestions,theycan
contactthePI.
9.7.3.
UMB
TheCenterforVaccineDevelopmentandGlobalHealthandtheUniversityofMarylandwill
provideshort-termmedicalcareorassessmentforanyinjuryresultinginparticipatingin
research.Ifaninjuryisdirectlyrelatedtoparticipationinthisproject,andrequiresintervention,
UMBand/oroneofitsaffiliatedinstitutionsorhealthcaregroupswillhelpthesubjectobtain
medicaltreatmentforthespecificinjuryandprovidereferralstootherhealthcarefacilities,as
appropriate.UMBand/oritsaffiliatedinstitutionsorhealthcaregroupswillnotprovidesubjects
withfinancialcompensationorreimbursementforthecostofcareprovidedtotreataresearch-
relatedinjuryorforotherexpensesarisingfromaresearch-relatedinjury.Theinstitutionor
groupprovidingmedicaltreatmentwillchargethesubject’sinsurancecarrier.Subjectsdonot
waivetheirrighttopursuelegalcompensationordamagestorecoverlossesrelatedtoinjury.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page58of84
9.8.
CHMIFacilitiesandManagement
TheVRC,NIAID,NIHisthecoordinatingcenterforthisprotocol.Dr.MartinGaudinski,VRC,
NIAID,NIH,istheProtocolChairandNIHsitePIoverseeingthemanagementandmonitoring
oftheprotocolconductoverall.
UMBwillbeaclinicalsiteandalsotheCHMIadministratorforPartCoftheprotocol.Dr.
KirstenLykewillbetheUMBsitePI.UMBinvestigatorsandstaffwillberesponsiblefor
completionofallclinicalandpost-CHMIvisitsaswellasadministrationoftheCHMI(with
WRAIRstaffsupport)forparticipantsinPartC.
InvestigatorsfromWRAIR,thefacilitythatadministeredthePartBCHMI,willhavelimited
interactionwithstudysubjectsduringtheadministrationoftheCHMI.InPartC,WRAIR
investigatorswillprovideentomologicsupporttoUMBduringCHMI.Certainimmediatepre-
andpost-CHMIassessmentsofsubjectswilltakeplaceintheCHMIfacilitywithsome
participationbyCHMIfacilitypersonnelandNIHstaff.Allotherpost-CHMIclinicalvisitsfor
subjectswilltakeplaceattheNIHclinicalsite.
ARelianceAgreementwillbeestablishedwiththecollaboratingCHMIfacilitiessuchthatthe
NIHIRBistheIRBofRecordfortheconductoftheVRC612protocol.ReferringtoSection5
oftheVRC612protocol,anySeriousAdverseEvents,UnanticipatedProblemsorProtocol
DeviationwhicharereportabletotheNIHIRBwhichareinrelationtotheconductoftheCHMI
willalsobecommunicatedtothecollaboratingCHMIfacilitywithinthesamereportingperiod
specifiedintheprotocol.
9.8.1.
RolesandResponsibilitiesfortheCHMI
TheProtocolChairandsitePIwilldelegateresponsibilityforoverseeingtheadministrationof
theCHMIatthecollaboratingCHMIfacilities(i.e.,applicationofandassessmentofthe
mosquitobites)todesignatedAssociateInvestigatorsfromthosefacilities.Follow-upand
medicalcareofthestudysubjectsaftertheCHMIisadministeredremainstheresponsibilityof
thesitePIandthedesignatedpersonnelattheclinicalsite.
TheAuthorizedRepresentativefromtheCHMIfacilitymayreviewresearchrecordsrelatedto
theCHMIconductedattheirownfacility.
Therolesandresponsibilitiesforthiscollaboratinginstitutionandfacilitypersonnelforthe
conductofCHMIasdescribedabovearedelineatedinthecorrespondingVRC612Study
PersonnelPage.
9.9.
WRAIRProtocolReviewandReportingRequirements
InitialProtocolReview
WRAIRwilldefertheirIRBreviewtotheNIHIRBoncearelianceagreementisinplace.
WRAIRHumanSubjectsProtectionBranch(HSBP)willstillperformanadministrativereview
oftheprotocoltoensurethattheWRAIRreportingrequirementsaremet.WRAIRCommander
ApprovalAuthorizationwillbeissuedoncetheNIHIRBapprovalhasbeensubmittedtothe
WRAIRHSPBandtheadministrativeWRAIRcommentshavebeenadequatelyaddressed.
Headquarterslevelreviewwillbeconductedasappropriate.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page59of84
ProtocolModifications/Amendments
Allamendments/modificationstotheprotocolandsupportingdocuments(informedconsent,
recruitmentmaterials,etc.)mustbereviewedbytheWRAIRHSPBandaWRAIRCommander
AuthorizationApprovalissuedpriortoWRAIRparticipationontheamended/modifiedprotocol.
ContinuingReviewsandCloseoutReport
TheWRAIRPointofContactwillberesponsibleforpreparingandsubmittingcontinuingreview
reportsasperUWZ-C-618andacloseoutreportasperWRAIRPolicy12-12.TheWRAIR
HSPBwillreviewandacknowledgethereportsinorderforWRAIRpersonneltocontinuetheir
participationonthestudy.Onceallstudyactivitieshavebeencompleted,toincludedata
analysis,acloseoutreportwillneedtobesubmittedtotheWRAIRHSPBtoclosethestudy.
Thefollowingreportingrequirementsapply:
UnanticipatedProblemsInvolvingRiskstoSubjectsorOthers
Unanticipatedproblems,asdefinedinSection5.5.1,shouldbepromptlyreported(48hours)by
telephone,email,orfaxtotheWRAIRHSPB.Acompletewrittenreportshouldfollowthe
initialnotificationwithin10workingdays.Allunanticipatedproblemsoccurringwithinthe
reportingperiodshouldalsobesummarizedinthecontinuingreviewreportssubmittedtothe
WRAIRHSPB(contactinformationisbelowatendofsection).
SeriousAdverseEvents
AllrelatedSAEsanddeaths,asdefinedinSection5.2,shouldbereportedtotheWRAIRHSPB
within48hoursbytelephone,email,orfax.Acompletewrittenreportshouldfollowtheinitial
notificationwithin10workingdays.AllSAEsoccurringwithinthereportingperiodshouldalso
besummarizedinthecontinuingreviewreportssubmittedtotheWRAIRHSPB.
ProtocolDeviations
Allmajorprotocoldeviationsthatadverselyaffectthesafetyorrightsofasubjectorscientific
integrityofthestudy,asdefinedinSection5.5.3,willbereportedtotheWRAIRHSPBwithin
48hoursandawrittenreportshouldbesubmittedwithin10workingdays.Allprotocol
deviationsoccurringwithinthereportingperiodshouldbesummarizedinthecontinuingreview
reportsthataresubmittedtotheWRAIRHSPB.
PendingInspections/IssuanceofReports
Theknowledgeofanypendingcomplianceinspection/visitbytheFDA,OfficeforHuman
ResearchProtections(DepartmentofHealthandHumanServices),orothergovernmentagency
concerningclinicalinvestigationorresearch,theissuanceofInspectionReports,FDAForm483,
warningletters,oractionstakenbyanyregulatoryagencyincludinglegalormedicalactionsand
anyinstancesofseriousorcontinuingnoncompliancewiththeregulationsorrequirementswill
bereportedimmediatelytotheWRAIRHSPB.
WRAIRHSPBContactInformation
Director,HumanSubjectsProtectionBranch



APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page60of84
10.
REFERENCES

1.
Sachs,J.andP.Malaney,Theeconomicandsocialburdenofmalaria.Nature,2002.
415(6872):p.680-5.
2.
RollBackMalaria.GlobalMalariaActionPlan20082008;Availablefrom:
http://www.rbm.who.int/keyfacts.html.
3.
Breman,J.G.,Eradicatingmalaria.SciProg,2009.92(Pt1):p.1-38.
4.
EfficacyandsafetyofRTS,S/AS01malariavaccinewithorwithoutaboosterdosein
infantsandchildreninAfrica:finalresultsofaphase3,individuallyrandomised,
controlledtrial.Lancet,2015.386(9988):p.31-45.
5.
Mahmoudi,S.andH.Keshavarz,Efficacyofphase3trialofRTS,S/AS01malaria
vaccine:Theneedforanalternativedevelopmentplan.HumVaccinImmunother,2017.
13(9):p.2098-2101.
6.
Zalevsky,J.,etal.,Enhancedantibodyhalf-lifeimprovesinvivoactivity.NatBiotechnol,
2010.28(2):p.157-9.
7.
Roy,C.J.,etal.,Chikungunyavaccinecandidateishighlyattenuatedandprotects
nonhumanprimatesagainsttelemetricallymonitoreddiseasefollowingasingledose.J
InfectDis,2014.209(12):p.1891-9.
8.
Gaudinski,M.R.,etal.,SafetyandpharmacokineticsoftheFc-modifiedHIV-1human
monoclonalantibodyVRC01LS:APhase1open-labelclinicaltrialinhealthyadults.
PLoSMed,2018.15(1):p.e1002493.
9.
Gaudinski,M.R.,etal.,AMonoclonalAntibodyforMalariaPrevention.NewEngland
JournalofMedicine,2021.385(9):p.803-814.
10.
Kisalu,N.K.,etal.,Ahumanmonoclonalantibodypreventsmalariainfectionby
targetinganewsiteofvulnerabilityontheparasite.NatMed,2018.24(4):p.408-416.
11.
Gaudinski,M.R.,etal.,SafetyandpharmacokineticsoftheFc-modifiedHIV-1human
monoclonalantibodyVRC01LS:APhase1open-labelclinicaltrialinhealthyadults.
PlosMedicine,2018.15(1):p.e1002493.
12.
Ledgerwood,J.E.,etal.,Safety,pharmacokineticsandneutralizationofthebroadly
neutralizingHIV-1humanmonoclonalantibodyVRC01inhealthyadults.ClinExp
Immunol,2015.182(3):p.289-301.
13.
Gaudinski,M.R.,etal.,Safety,tolerability,pharmacokinetics,andimmunogenicityofthe
therapeuticmonoclonalantibodymAb114targetingEbolavirusglycoprotein(VRC608):
anopen-labelphase1study.Lancet,2019.393(10174):p.889-898.
14.
Gaudinski,M.R.,etal.,Safetyandpharmacokineticsofbroadlyneutralisinghuman
monoclonalantibodyVRC07-523LSinhealthyadults:aphase1dose-escalationclinical
trial.LancetHIV,2019.
15.
Seder,R.A.,etal.,Protectionagainstmalariabyintravenousimmunizationwitha
nonreplicatingsporozoitevaccine.Science,2013.341(6152):p.1359-65.
16.
Ishizuka,A.S.,etal.,Protectionagainstmalariaat1yearandimmunecorrelates
followingPfSPZvaccination.NatMed,2016.22(6):p.614-23.
17.
Chulay,J.D.,etal.,Malariatransmittedtohumansbymosquitoesinfectedfromcultured
Plasmodiumfalciparum.AmJTropMedHyg,1986.35(1):p.66-8.
18.
Lyke,K.E.,etal.,AttenuatedPfSPZVaccineinducesstrain-transcendingTcellsand
durableprotectionagainstheterologouscontrolledhumanmalariainfection.ProcNatl
AcadSciUSA,2017.114(10):p.2711-2716.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page61of84
19.
Roestenberg,M.,etal.,Experimentalinfectionofhumanvolunteers.LancetInfectDis,
2018.18(10):p.e312-e322.
20.
Nieman,A.E.,etal.,Cardiaccomplicationafterexperimentalhumanmalariainfection:
acasereport.MalarJ,2009.8:p.277.
21.
Moorthy,V.S.,etal.,Reportofaconsultationontheoptimizationofclinicalchallenge
trialsforevaluationofcandidatebloodstagemalariavaccines,18-19March2009,
Bethesda,MD,USA.Vaccine,2009.27(42):p.5719-25.
22.
vanMeer,M.P.,etal.,Idiopathicacutemyocarditisduringtreatmentforcontrolled
humanmalariainfection:acasereport.MalarJ,2014.13:p.38.
23.
Deye,G.A.,etal.,Prolongedprotectionprovidedbyasingledoseofatovaquone-
proguanilforthechemoprophylaxisofPlasmodiumfalciparummalariainahuman
challengemodel.ClinInfectDis,2012.54(2):p.232-9.
24.
Stanisic,D.I.,etal.,DevelopmentofculturedPlasmodiumfalciparumblood-stage
malariacellbanksforearlyphaseinvivoclinicaltrialassessmentofanti-malariadrugs
andvaccines.MalarJ,2015.14:p.143.
25.
Mejia,R.,etal.,Peripheralbloodstemcelltransplant-relatedPlasmodiumfalciparum
infectioninapatientwithsicklecelldisease.Transfusion,2012.52(12):p.2677-82.
26.
Shokoples,S.E.,etal.,Multiplexedreal-timePCRassayfordiscriminationof
Plasmodiumspecieswithimprovedsensitivityformixedinfections.JClinMicrobiol,
2009.47(4):p.975-80.
27.
Gaziano,T.A.,etal.,Laboratory-basedversusnon-laboratory-basedmethodfor
assessmentofcardiovasculardiseaserisk:theNHANESIFollow-upStudycohort.
Lancet,2008.371(9616):p.923-31.
28.
FDA,COVID-19:DevelopingDrugsandBiologicalProductsforTreatmentor
PreventionGuidanceforIndustry,U.S.D.o.H.a.H.Services,etal.,Editors.2020.
29.
Hansel,T.T.,etal.,Thesafetyandsideeffectsofmonoclonalantibodies.Naturereviews.
Drugdiscovery,2010.9(4):p.325-38.
30.
Bugelski,P.J.,etal.,Monoclonalantibody-inducedcytokine-releasesyndrome.Expert
reviewofclinicalimmunology,2009.5(5):p.499-521.
31.
Vogel,W.H.,Infusionreactions:diagnosis,assessment,andmanagement.ClinJOncol
Nurs,2010.14(2):p.E10-21.
32.
Friedman-Klabanoff,D.J.,etal.,TheControlledHumanMalariaInfectionExperienceat
theUniversityofMaryland.AmJTropMedHyg,2019.100(3):p.556-565.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page62of84
APPENDIXI:SCHEDULEOFEVALUATIONS
ThereisasystemincompatibilitybetweenthestudyclinicaldatabasesoftwareandtheLIMSsample
trackingsystemusedbytheVIP.Theincompatibilitycreatesadiscrepancyofvisitnumbernomenclature
betweentheapprovedprotocolandthedatabase.TheVRCclinicusedtheprotocol-basedconventionfor
sourcedocuments.
Inaddition,thevisitnumbernomenclatureintheclinicalstudydatabasemanagedbyEmmeshasbeen
modifiedfromthevisitnumbernomenclatureintheapprovedprotocolduetoaninabilitytomatchthe
protocolwithinitslimitations.ThisisbecausetheEmmesdatabaserequiresvisitnumberstohavea
leadingzerotoassurepropersorting.Theprotocolvisitnumbersdonotcontainaleadingzerobecause
suchaconventionwouldbeoutofspecificationsrequiredbytheLIMSsystem.Theselimitationswillnot
interferewiththeabilitytoidentifyandtrackstudysamples.
RefertothefollowingtableforanexampleofthedifferencesbetweentheEmmesdatabaseandthe
protocolScheduleofEvaluations,sourcedocumentsandLIMS:
ProtocolScheduleofEvaluations SourceDocumentation
LIMS
EmmesDatabase
VisitA1R
VisitA1R
VisitA1R
VisitA01R
VisitA2
VisitA2
VisitA02
VisitA02
VisitB1R
VisitB1R
VisitB1R
VisitB01R
VisitB2
VisitB2
VisitB02
VisitB02
VisitC2
VisitC2
VisitC02
VisitC02
VisitC2A
VisitC2A
VisitC2A VisitC02A





APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page63of84
PARTASCHEDULES


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page64of84
ScheduleofEvaluations:PartAIVGroups(Groups1,3,4A,4B)
VisitNumber
01
1A1R
1A2
A2A
A2B
A2C
A2D
A3
A4
A6
A7
A8
A9
A10
A11
A12
A13
A14
TimeAfterInfusion


Pre
EOI
1hr
3h
6h
24hr
48hr
Wk1 Wk2 Wk3 Wk4 Wk8 Wk12 Wk16 Wk20 Wk24
DayofStudy -56to-1 -28to0
D0
D0
D0
D0
D0
D1
D2
D7
D14
D21
D28
D56
D84 D112 D140 D168
StudyProcedures
Tube
Screen
Enroll
Dayofinfusion











VRC500ScreeningConsent

X

















VRC612InformedConsent,AoU


X
















2PhysicalExam

X
X
X
X



X
X
X
X
X
X
X
X
X
X
X
3MedicalHistory

X
X
X




X
X
X
X
X
X
X
X
X
X
X
EKG

X

















ConcomitantMedications

X
X
X




X
X
X
X
X
X
X
X
X
X
X
ProductAdministration



X















Begin7-dayDiaryCard



X















4PregnancyPreventionCounseling

X
X
X







X




X

X
ClinicalEvaluations
4PregnancyTest(urineorserum)

X
X
X







X




X

X
CBCwithdifferential
EDTA
3

3




3

3
3

3

3



ALT,creatinine
GLT
X

X




4

4
4

4

4



5CMP
GLT
4

4















HIVAg/AbCombo
EDTA
3

















SickleCellTest
EDTA
3

















Troponin
GLT
4

















ResearchSamples
6PK
SST


4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
PBMC
EDTA
20









40







Serum
SST
8

16†





8
8†
8
8
8†
8
8†
8
8
8†
DailyVolume(mL)

45
0
27
4
4
4
4
11
12
19
59
12
19
12
19
12
12
12
CumulativeVolume(mL)

45
45
72
76
80
84
88
99
111
130
189
201
220
232
251
263
275
287
Visitwindows:ScheduleVisitsA2A–A14withrespecttoVisitA2.VisitA2A(within10minofEOI);VisitsA2B,A2C(±10min);VisitA2D(-2hrs);VisitsA3,A4(±6hrs);VisitsA6,A7,A8,A9(±2
days);VisitsA10,A11,A12,A13,A14(±7days).VisitA5isnotapplicabletothisschedule.
1VisitA1RisthedayofenrollmentandmaybedoneonthesamedayasDay0.VA2/Day0isdayofproductadministrationandpreferablyscheduledwithin14daysafterenrollmentatVisitA1Rbutmaybe
scheduledupto28daysafterVisitA1R.
2Screeningincludesphysicalexam,vitalsigns(bloodpressure(BP),temperature,pulse,respiratoryrate(RR)),height,weight.Day0includesvitalsignsandweight(fororderingstudyproductdose).Atother
visits,performatargetedexamifmedicallyindicated,otherwiseonlyvitalsignsarerequired.
3Performfullmedicalhistoryatscreening.Atothervisits,performinterimmedicalhistory.
4Pregnancytestresultsmustbenegativeforwomenofreproductivepotentialbeforeproductadministration.CompletePregnancyPreventionCounselingFormwhenpregnancytestisdone.
5CMPincludessodium,potassium,chloride,totalCO2,creatinine,glucose,ureanitrogen,albumin,alanineaminotransferase,alkalinephosphatase,aspartateaminotransferase,totalbilirubin,calcium,totalprotein
6PKblooddraws,definedbytimeafteraninfusion,arerelativetotheexacttimeoftheendofinfusion(EOI).Recordtheexactstart/endtimesofproductadministrationandofblooddrawtoensureaccurate
PKanalysis.
†Anti-drugantibodies(ADA)assessedfromserumsamplesattimepointsasindicated.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page65of84
ScheduleofEvaluations:PartA SCGroup(Group2)
VisitNumber
01
1A1R
1A2
A2A
A3
A4
A5
A6
A7
A8
A9
A10
A11
A12
A13
A14
TimeafterInfusion


Pre
EOI
24hr
48hr
72hr
Wk1
Wk2
Wk3
Wk4
Wk8
Wk12 Wk16 Wk20 Wk24
StudyDay
-56to-1 -28to0
D0
D0
D1
D2
D3
D7
D14
D21
D28
D56
D84
D112
D140
D168
StudyProcedures
Tube
Screen
Enroll Dayofinjection












VRC500ScreeningConsent

X















VRC612InformedConsent,AoU


X














2PhysicalExam

X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
3MedicalHistory

X
X
X

X
X
X
X
X
X
X
X
X
X
X
X
EKG

X















ConcomitantMedications

X
X
X

X
X
X
X
X
X
X
X
X
X
X
X
ProductAdministration



X













Begin7-dayDiaryCard



X













4PregnancyPreventionCounseling

X
X
X





X




X

X
ClinicalEvaluations
4PregnancyTest(urineorserum)

X
X
X





X




X

X
CBCwithdifferential
EDTA
3

3

3


3
3

3

3



ALT,creatinine
GLT
X

X

4


4
4

4

4



5CMP
GLT
4

4













HIVAg/AbCombo
EDTA
3















SickleCellTest
EDTA
3















Troponin
GLT
4















ResearchSamples
6PK
SST


4

4
4
4
4
4
4
4
4
4
4
4
4
PBMC
EDTA
20







40







Serum
SST
8

16†


8
8
8†
8
8
8†
8
8†
8
8
8†
DailyVolume(mL)

45
0
27
0
11
12
12
19
59
12
19
12
19
12
12
12
CumulativeVolume(mL)

45
45
72
72
83
95
107
126
185
197
216
228
247
259
271
283
Visitwindows:ScheduleVisitsA2A–A14withrespecttoVisitA2.VisitA2A(within10minofEOI);VisitsA3,A4,A5(±6hrs);VisitsA6,A7,A8,A9(±2days);VisitsA10,A11,A12,A13,A14(±7
days).
1VisitA1RisthedayofenrollmentandmaybedoneonthesamedayasDay0.VA2/Day0isdayofproductadministrationandpreferablyscheduledwithin14daysafterenrollmentatVisitA1Rbutmaybe
scheduledupto28daysafterVisitA1R.
2Screeningincludesphysicalexam,vitalsigns(BP,temperature,pulse,RR),height,weight.Day0includesvitalsignsandweight(fororderingstudyproductdose).Atothervisits,performatargetedexamif
medicallyindicated,otherwiseonlyvitalsignsarerequired.
3Performfullmedicalhistoryatscreening.Atothervisits,performinterimmedicalhistory.
4Pregnancytestresultsmustbenegativeforwomenofreproductivepotentialbeforeproductadministration.CompletePregnancyPreventionCounselingFormwhenpregnancytestisdone.
5CMPincludessodium,potassium,chloride,totalCO2,creatinine,glucose,ureanitrogen,albumin,alanineaminotransferase,alkalinephosphatase,aspartateaminotransferase,totalbilirubin,calcium,totalprotein
6PKblooddraws,definedbytimeafterinfusion,arerelativetotheexacttimeoftheendofinfusion(EOI).Recordexactstart/endtimesofproductadministrationandofblooddrawtoensureaccurateanalysis.
†ADAassessedfromserumsamplesattimepointsasindicated.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page66of84
PARTBSCHEDULES


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page67of84
ScheduleofEvaluations:PartBIVGroups(Groups7and9)InitialorRepeatDose
VisitNumber
01
1B1R
1B2
B2A
B2B
B2C
B2D
B3
B4
B6
B7
B8
B9
B10
B11
B12
B13
B14
TimeAfterInfusion


Pre
EOI
1hr
3h
6h
24hr
48hr
Wk1 Wk2
Wk3
Wk4
Wk8 Wk12 Wk16 Wk20 Wk24
DayofStudy -56to-1 -28to0
D0
D0
D0
D0
D0
D1
D2
D7
D14
D21
D28
D56
D84 D112 D140 D168
StudyProcedures
Tube
Screen
Enroll
Dayofinfusion











VRC500ScreeningConsent

X

















VRC612InformedConsent,AoU7


X
















2PhysicalExam

X
X
X
X



X
X
X
X
X
X
X
X
X
X
X
3MedicalHistory

X
X
X




X
X
X
X
X
X
X
X
X
X
X
EKG

X
[X]
















ConcomitantMedications

X
[X]
X




X
X
X
X
X
X
X
X
X
X
X
ProductAdministration



X















Begin7-dayDiaryCard



X















4PregnancyPreventionCounseling

X
X
X







X




X

X
ClinicalEvaluations
4PregnancyTest(urineorserum)

X
X
X







X




X

X
CBCwithdifferential
EDTA
3
[X]
3




3

3
3

3

3



ALT,creatinine
GLT
X
[X]
X




4

4
4

4

4



5CMP
GLT
4
[X]
4















HIVAg/AbCombo
EDTA
3
[X]
















SickleCellTest
EDTA
37

















Troponin
GLT
4
[X]
















SARS-CoV-2(PCR)
Swab
X
[X]
















ResearchSamples
6PK
SST


4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
PBMC
EDTA
20









40







Serum
SST
8

16†





8
8†
8
8
8†
8
8†
8
8
8†
DailyVolume(mL)

45
0
27
4
4
4
4
11
12
19
59
12
19
12
19
12
12
12
CumulativeVolume(mL)

45
45
72
76
80
84
88
99
111
130
189
201
220
232
251
263
275
287
Visitwindows:ScheduleVisitsB2A–B14withrespecttoVisitB2.VisitB2A(within10minofEOI);VisitsB2B,B2C(±10min);VisitB2D(-2hrs);VisitsB3,B4(±6hrs);VisitsB6,B7,B8,B9(±2
days);VisitsB10,B11,B12,B13,B14(±7days).VisitB5isnotapplicable.
1VisitB1Risthedayofenrollmentorre-assessmentforGroup7andmaybedoneonthesamedayasDay0.VB2/Day0isdayofproductadministrationandpreferablyscheduledwithin14daysafter
enrollmentatVisitB1Rbutmaybescheduledupto28daysafterVisitB1R.[X]isonlyrequiredforGroup7.
2Screeningincludesphysicalexam,vitalsigns(bloodpressure(BP),temperature,pulse,respiratoryrate(RR)),height,weight.Day0includesvitalsignsandweight(fororderingstudyproductdose).Atother
visits,performatargetedexamifmedicallyindicated,otherwiseonlyvitalsignsarerequired.
3Performfullmedicalhistoryatscreening.Atothervisits,performinterimmedicalhistory.
4Pregnancytestresultsmustbenegativeforwomenofreproductivepotentialbeforeproductadministration.UsePregPreventionCounselingFormwhenpregnancytestisdone.
5CMPincludessodium,potassium,chloride,totalCO2,creatinine,glucose,ureanitrogen,albumin,alanineaminotransferase,alkalinephosphatase,aspartateaminotransferase,totalbilirubin,calcium,total
protein.
6PKblooddraws,definedbytimeafteraninfusion,arerelativetotheexacttimeoftheendofinfusion(EOI).Recordtheexactstart/endtimesofproductadministrationandofblooddrawtoensureaccurate
PKanalysis.
7NotrequiredforPartAveteransinPartB†Anti-drugantibodies(ADA)assessedfromserumsamplesattimepointsasindicated.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page68of84

ScheduleofEvaluations:PartBSCGroup(Group6)
VisitNumber
01
1B1R
1B2
B2A
B3
B4
B5
B6
B7
B8
B9
B10
B11
B12
B13
B14
TimeafterInfusion


Pre
EOI
24hr
48hr
72hr
Wk1
Wk2
Wk3
Wk4
Wk8
Wk12 Wk16 Wk20 Wk24
DayofStudy -56to-1 -28to0
D0
D0
D1
D2
D3
D7
D14
D21
D28
D56
D84
D112
D140
D168
StudyProcedures
Tube
Screen
Enroll Dayofinjection

VRC500ScreeningConsent

X















VRC612InformedConsent,AoU


X














2PhysicalExam

X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
3MedicalHistory

X
X
X

X
X
X
X
X
X
X
X
X
X
X
X
EKG

X















ConcomitantMedications

X
X
X

X
X
X
X
X
X
X
X
X
X
X
X
ProductAdministration



X













Begin7-dayDiaryCard



X













4PregnancyPreventionCounseling

X
X
X





X




X

X
ClinicalEvaluations
4PregnancyTest(urineorserum)

X
X
X





X




X

X
CBCwithdifferential
EDTA
3

3

3


3
3

3

3



ALT,creatinine
GLT
X

X

4


4
4

4

4



5CMP
GLT
4

4













HIVAg/AbCombo
EDTA
3















SickleCellTest
EDTA
3















Troponin
GLT
4















SARS-CoV-2(PCR)
Swab
X















ResearchSamples
6PK
SST


4

4
4
4
4
4
4
4
4
4
4
4
4
PBMC
EDTA
20







40







Serum
SST
8

16†


8
8
8†
8
8
8†
8
8†
8
8
8†
DailyVolume(mL)

45
0
27
0
11
12
12
19
59
12
19
12
19
12
12
12
CumulativeVolume(mL)

45
45
72
72
83
95
107
126
185
197
216
228
247
259
271
283
Visitwindows:ScheduleVisitsB2A–B14withrespecttoVisitB2.VisitB2A(within10minofEOI);VisitsB3,B4,B5(±6hrs);VisitsB6,B7,B8,B9(±2days);VisitsB10,B11,B12,B13,B14(±7
days).
1VisitB1RisthedayofenrollmentandmaybedoneonthesamedayasDay0.VB2/Day0isdayofproductadministrationandpreferablyscheduledwithin14daysafterenrollmentatVisitB1Rbutmaybe
scheduledupto28daysafterVisitB1R.
2Screeningincludesphysicalexam,vitalsigns(BP,temperature,pulse,RR),height,weight.Day0includesvitalsignsandweight(fororderingstudyproductdose).Atothervisits,performatargetedexam
ifmedicallyindicated,otherwiseonlyvitalsignsarerequired.
3Performfullmedicalhistoryatscreening.Atothervisits,performinterimmedicalhistory.
4Pregnancytestresultsmustbenegativeforwomenofreproductivepotentialbeforeproductadministration.CompleteaPregnancyPreventionCounselingFormwhenpregnancytestisdone.
5CMPincludessodium,potassium,chloride,totalCO2,creatinine,glucose,ureanitrogen,albumin,alanineaminotransferase,alkalinephosphatase,aspartateaminotransferase,totalbilirubin,calcium,total
protein.
6PKblooddraws,definedbytimeafteraninfusion,arerelativetotheexacttimeoftheendofinfusion(EOI).Recordexactstart/endtimesofproductadministrationandofblooddrawtoensureaccurate
analysis.†ADAassessedfromserumsamplesattimepointsasindicated.



APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page69of84
ScheduleofEvaluations:PartBCHMIforGroups8and10
VisitNumber
01
1B1R
B1S
C1
C2
2C2A
2C2B
C3
C4
C5
C6
C7
C8
C9
C10
TimeAfterCHMI





24hr
72hr
Wk1
Wk1
Wk1
Wk1
Wk1
Wk1
Wk1
Wk2
CHMIDay -56to-1-56to-1 -5to-1
-1
D0
D1
D3
D7
D8
D9
D10
D11
D12
D13
D14
StudyProcedures
Tube
Screen Enroll


CHMI


ParasitemiaCheck(dailyuntiltreatmentcriteriamet)
VRC500ScreeningConsent

X














VRC612InformedConsent,AoU9


X













3PhysicalExam,VitalSigns

X
X
X
X
X


X
X
X
X
X
X
X
X
4MedicalHistory

X
X
X
X
X


X
X
X
X
X
X
X
X
EKG

X
[X]













CHMI





X










PhoneContact






X
X








5PregnancyPreventionCounseling

X
X

X











ClinicalEvaluations
5PregnancyTest(urineorserum)

X
X

X











CBCwithdifferential
EDTA
3
[X]

3



3







ALT,creatinine
GLT
X
[X]

4











6CMP
GLT
4
[X]













HIVAb/AgCombo
EDTA
3
[X]













SickleCellTest
EDTA
39














Troponin
GLT
4
[X]













SARS-CoV-2(PCR)
Swab
X

X












7ParasitemiaEvaluation(PCR)
EDTA







3
[3]
[3]
[3]
[3]
[3]
[3]
[3]
ResearchSamples
8PK
SST



4



4






4
PBMC
EDTA
20






40






**60
Serum
SST
8






16






**16
DailyVolume(mL)

45
0
0
11
0
0
0
66
3
3
3
3
3
3
83
CumulativeVolume(mL)

45
45
45
56
56
56
56
122
125
128
131
134
137
140
223
1VisitB1Risthedayofre-assessmentforGroup8,andforGroup10inthecaseofPartAGroup5veteransubjects.[X]isonlyrequiredforGroup8andveteranGroup10
2AfterCHMI,scheduleVisitC2AonDay1or2,VisitC2BonDay3or4.
3Screeningincludesphysicalexam,vitalsigns(BP,temperature,pulse,RR),height,weight.OnD0,performatargetedphysicalexamifmedicallyindicated,otherwiseonlyvitalsignsarerequired.
4Performfullmedicalhistoryatscreening.Atothervisits,performinterimmedicalhistory.
5Pregnancytestresultsmustbenegativeforwomenofreproductivepotentialwithin2dayspriortoCHMI.UsePregPreventionCounselingFormwhentestingforpregnancy.
6CMPincludessodium,potassium,chloride,totalCO2,creatinine,glucose,ureanitrogen,albumin,alanineaminotransferase,alkalinephosphatase,aspartateaminotransferase,totalbilirubin,calcium,totalprotein.
7ParasitemiaevaluationsshouldcontinuedailyuntilasubjecthasonepositivePCRorbloodsmear;brackets[3]indicateoptionaldrawasneeded.ApositiveresultpriortoDay21isrequiredforinitiationof
antimalarialtreatment.
8PKdrawisforGroup8only;doesnotapplytoGroup10.
9NotrequiredforPartAveteransinPartB
**Researchbloodwillbedrawnat14dayspost-CHMI(VisitC10)fromALLsubjects.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page70of84
ScheduleofEvaluations:PartBCHMIforGroups8and10(continued)
VisitNumber
C11
C12
C13
C14
1C15
C16
C17
2C20
TimeafterCHMI
Wk2
Wk2
Wk2
Wk2
Wk3
Wk3
Wk4
Wk7
CHMIDay
D15
D16
D17
D18
D21
D23
D28
D49
StudyProcedures
Tube
ParasitemiaCheck
(dailyuntiltreatmentcriteriamet)




3PhysicalExam,VitalSigns

X
X
X
X
X
X

[X]
InterimMedicalHistory

X
X
X
X
X
X

[X]
PhoneContact







X
[X]
ClinicalEvaluations
CBCwithdifferential
EDTA




*3
*3

[3]
ALT,creatinine
SST




*4
*4

[4]
4ParasitemiaEvaluation(PCR)
EDTA
[3]
[3]
[3]
[3]
[3]


[3]
Anti-MalarialTreatment





[X]
[X]


ResearchSamples
5PK
SST




4


[4]
PBMC
EDTA







[60]
Serum
SST




8


[16]
DailyVolume(mL)

3
3
3
3
22
7
0
90
CumulativeVolume(mL)

226
229
232
235
257
264
264
354
1VisitC15isonlyrequiredforCHMIparticipantsnotpreviouslydiagnosedwithmalariaparasitemiatoruleoutadelayedcase.AtVisitC15(Day21),anysubjectnot
alreadyonantimalarialtreatmentwillbegivenDOT.SubjectsmustreturnforDOTfor2moredaysafterinitiation.Brackets[X]indicateoptionalasneededper
subjecttreatmentstatus.
2VisitC20isonlyrequiredforsubjectswhohadapositivePCRorbloodsmeartodocumenttestofcure.Itisscheduledtooccur26±5daysafterDOTcompletionandis
shownatDay49forconvenience.VisitC20maybecompletedviaphoneforsubjectswhoremainmalarianegative,brackets[X]indicateoptionalasneededper
subjectinfectionstatus.
3Performatargetedphysicalexamifmedicallyindicated,otherwiseonlyvitalsigns(BP,temperature,pulse,RR)arerequired.
4ParasitemiaevaluationsshouldcontinuedailyuntilasubjecthasonepositivePCRorbloodsmear;brackets[3]indicateoptionaldrawasneeded.Apositiveresult
priortoDay21isrequiredforinitiationofantimalarialDOT.Otherwise,initiateDOTatDay21.
5PKdrawisforGroup8only;doesnotapplytoGroup10.
*BloodforCBC,ALTandcreatininewillbedrawnatonsetofDOTandatabout2dayslater;shownatvisitsC15andC16toaccountforblooddraw.Parasitemia
evaluationsarenotperformedduringtreatmentthroughtotestofcure.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page71of84
ScheduleofEvaluations:PartBCHMIforGroups6,7,9
VisitNumber
B1S
C1
C2
1C2A
1C2B
C3
C4
C5
C6
C7
C8
C9
C10
TimeafterCHMI



24hr
72hr
Wk1
Wk1
Wk1
Wk1
Wk1
Wk1
Wk1
Wk2
CHMIDay -5to-1
-1
D0
D1
D3
D7
D8
D9
D10
D11
D12
D13
D14
StudyProcedures
Tube


CHMI


ParasitemiaCheck(dailychecksuntiltreatmentcriteriamet)
2PhysicalExam,VitalSigns

X
X
X


X
X
X
X
X
X
X
X
InterimMedicalHistory

X
X
X


X
X
X
X
X
X
X
X
CHMI



X










PhoneContact




X
X








PregnancyPreventionCounseling


X











ClinicalEvaluations
3PregnancyTest(urineorserum)


X











CBCwithdifferential
EDTA

3



3







ALT,creatinine
GLT

4











SARS-CoV-2(PCR)
Swab
X












4ParasitemiaEvaluation(PCR)
EDTA





3
3
[3]
[3]
[3]
[3]
[3]
[3]
ResearchSamples
PK
SST

4



4






4
PBMC
EDTA





40






**60
Serum
SST





16†






**16
DailyVolume(mL)

0
11
0
0
0
66
3
3
3
3
3
3
83
CumulativeVolume(mL)

0
11
11
11
11
77
80
83
86
89
92
95
178
1AfterCHMI,scheduleVisitC2AonDay1or2,VisitC2BonDay3or4
2Performatargetedphysicalexamifmedicallyindicated,otherwiseonlyvitalsigns(BP,temperature,pulse,RR)arerequired.
3Pregnancytestresultsmustbenegativeforwomenofreproductivepotentialwithin2dayspriortoCHMI.CompleteaPregnancyPreventionCounselingForm
whenpregnancytestisdone.
4ParasitemiaevaluationsshouldcontinuedailyuntilasubjecthasonepositivePCRorbloodsmear;brackets[3]indicateoptionaldrawasneeded.Apositive
resultpriortoDay21isrequiredforinitiationofantimalarialdirectlyobservedtherapy(DOT).
**Researchbloodwillbedrawnat14dayspost-CHMI(VisitC10)fromALLsubjects.
†ADAassessedfromserumsamplesattimepointsasindicated.



APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page72of84
ScheduleofEvaluations:PartBCHMIforGroups6,7,9(continued)
1VisitNumber
C11
C12
C13
C14
1C15
C16
C17
2C20
TimeafterCHMI
Wk2
Wk2
Wk2
Wk2
Wk3
Wk3
Wk4
Wk7
CHMIDay
D15
D16
D17
D18
D21
D23
D28
D49
StudyProcedures
Tube
ParasitemiaCheck
(dailyuntiltreatmentcriteriamet)




3PhysicalExam,VitalSigns

X
X
X
X
X
X

[X]
InterimMedicalHistory

X
X
X
X
X
X

[X]
PhoneContact







X
[X]
ClinicalEvaluations
CBCwithdifferential
EDTA




*3
*3

[3]
ALT,creatinine
SST




*4
*4

[4]
4ParasitemiaEvaluation(PCR)
EDTA
[3]
[3]
[3]
[3]
[3]


[3]
Anti-MalarialTreatment





[X]
[X]


ResearchSamples
PK
SST




4


[4]
PBMC
EDTA







[60]
Serum
SST




8†


[16]
DailyVolume(mL)

3
3
3
3
22
7
0
90
CumulativeVolume(mL)

181
184
187
190
212
219
219
309
1VisitC15isonlyrequiredforCHMIparticipantsnotpreviouslydiagnosedwithmalariaparasitemiatoruleoutadelayedcase.AtVisitC15(Day21),any
subjectwhohasnotalreadystartedantimalarialtreatmentwillbegivendefinitiveDOT.SubjectsmustreturnforDOTfor2moredaysafterinitiation.
Brackets[X]indicateoptionalasneededpersubjecttreatmentstatus.
2VisitC20isonlyrequiredforsubjectswhohadapositivePCRorbloodsmeartodocumenttestofcure.Itisscheduledtooccur26±5daysafterDOT
completionandisshownatDay49forconvenience.VisitC20maybecompletedviaphoneforsubjectswhoremainmalarianegative,brackets[X]indicate
optionalasneededpersubjectinfectionstatus.
3Performatargetedphysicalexamifmedicallyindicated,otherwiseonlyvitalsigns(BP,temperature,pulse,RR)arerequired.
4ParasitemiaevaluationsshouldcontinuedailyuntilasubjecthasonepositivePCRorbloodsmear;brackets[3]indicateoptionaldrawasneeded.Apositive
resultpriortoDay21isrequiredforinitiationofantimalarialDOT.Otherwise,initiateDOTatC15.
*BloodforCBC,ALT,andcreatininewillbedrawnatonsetofDOTandabout2dayslater;shownatvisitsC15andC16toaccountforblooddraw.Parasitemia
evaluationsarenotperformedduringtreatmentthroughtotestofcure.
†ADAassessedfromserumsamplesattimepointsasindicated.




APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page73of84















PARTCSCHEDULES




APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page74of84
ScheduleofEvaluations:PartCIVGroups(Groups11,12,14)
VisitNumber
01
1D1R
1D2
D2A
D2B
D2C
D2D
D3
D4
D6
D7
D8
D9
D10
D11
D12
D13
D14
TimeAfterInfusion


Pre
EOI
1hr
3h
6h
24hr
48hr
Wk1 Wk2 Wk3 Wk4 Wk8 Wk12 Wk16 Wk20 Wk24
DayofStudy -56to-1 -28to0
D0
D0
D0
D0
D0
D1
D2
D7
D14
D21
D28
D56
D84 D112 D140 D168
StudyProcedures
Tube*
Screen
Enroll
Dayofinfusion











VRC500ScreeningConsent

X

















VRC612InformedConsent,AoU


X
















2PhysicalExam

X
X
X
X



X
X
X
X
X
X
X
X
X
X
X
3MedicalHistory

X
X
X




X
X
X
X
X
X
X
X
X
X
X
EKG

X

















ConcomitantMedications

X
X
X




X
X
X
X
X
X
X
X
X
X
X
ProductAdministration



X















Begin7-dayDiaryCard



X















4PregnancyPreventionCounseling

X
X
X







X




X

X
ClinicalEvaluations
4PregnancyTest(urineorserum)

X
X
X







X




X

X
CBCwithdifferential
EDTA
3

3




3

3
3

3

3



ALT,creatinine
GLT
X

X




4

4
4

4

4



5CMP
GLT
4

4















HIVAg/AbCombo
EDTA
3

















SickleCellTest
EDTA
3

















Troponin
GLT
4

















ResearchSamples
6PK
SST


4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
PBMC
EDTA
20









40







Serum
SST
8

16†





8
8†
8
8
8†
8
8†
8
8
8†
DailyVolume(mL)

45
0
27
4
4
4
4
11
12
19
59
12
19
12
19
12
12
12
CumulativeVolume(mL)

45
45
72
76
80
84
88
99
111
130
189
201
220
232
251
263
275
287
Visitwindows:ScheduleVisitsD2A–D14withrespecttoVisitD2.VisitD2A(within10minofEOI);VisitsD2B,D2C(±10min);VisitD2D(-2hrs);
VisitsD3,D4(±6hrs);VisitsD6,D7,D8,D9(±2days);VisitsD10,D11,D12,D13,D14(±7days).VisitD5isnotapplicabletothisschedule.
Footnotes(continuetonextpage):
1VisitD1RisthedayofenrollmentandmaybedoneonthesamedayasDay0.VisitD2/Day0isdayofproductadministrationandpreferablyscheduled
within14daysafterenrollmentatVisitD1Rbutmaybescheduledupto28daysafterVisitD1R.
2Screeningincludesphysicalexam,vitalsigns(bloodpressure(BP),temperature,pulse,respiratoryrate(RR)),height,weight.Day0includesvitalsignsand
weight(fororderingstudyproductdose).Atothervisits,performatargetedexamifmedicallyindicated,otherwiseonlyvitalsignsarerequired.
3Performfullmedicalhistoryatscreening.Atothervisits,performinterimmedicalhistory.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page75of84
4Pregnancytestresultsmustbenegativeforwomenofreproductivepotentialbeforeproductadministration.CompletePregnancyPreventionCounselingForm
whenpregnancytestisdone.
5CMPincludessodium,potassium,chloride,totalCO2,creatinine,glucose,ureanitrogen,albumin,alanineaminotransferase,alkalinephosphatase,aspartate
aminotransferase,totalbilirubin,calcium,totalprotein
6PKblooddraws,definedbytimeafteraninfusion,arerelativetotheexacttimeoftheendofinfusion(EOI).Recordtheexactstart/endtimesofproduct
administrationandofblooddrawtoensureaccuratePKanalysis.
†Anti-drugantibodies(ADA)assessedfromserumsamplesattimepointsasindicated.
*Tubetypes/volumesareshowntoestimatebloodvolumesinmL.Differenttubesforclinicalevaluationsmaybeusedtomeetsiterequirementsbutresearch
sampletubesmustbeusedasshownorasinstructedbytheINDSponsor.




APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page76of84
ScheduleofEvaluations:PartCSCGroup(Groups13and15)
VisitNumber
01
1D1R
1D2
D2A
D3
D4
D5
D6
D7
D8
D9
D10
D11
D12
D13
D14
TimeafterInfusion


Pre
EOI
24hr
48hr
72hr
Wk1
Wk2
Wk3
Wk4
Wk8
Wk12 Wk16 Wk20 Wk24
StudyDay
-56to-1 -28to0
D0
D0
D1
D2
D3
D7
D14
D21
D28
D56
D84
D112
D140
D168
StudyProcedures
Tube*
Screen
Enroll Dayofinjection












VRC500ScreeningConsent

X















VRC612InformedConsent,AoU


X














2PhysicalExam

X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
3MedicalHistory

X
X
X

X
X
X
X
X
X
X
X
X
X
X
X
EKG

X















ConcomitantMedications

X
X
X

X
X
X
X
X
X
X
X
X
X
X
X
ProductAdministration



X













Begin7-dayDiaryCard



X













4PregnancyPreventionCounseling

X
X
X





X




X

X
ClinicalEvaluations
4PregnancyTest(urineorserum)

X
X
X





X




X

X
CBCwithdifferential
EDTA
3

3

3


3
3

3

3



ALT,creatinine
GLT
X

X

4


4
4

4

4



5CMP
GLT
4

4













HIVAg/AbCombo
EDTA
3















SickleCellTest
EDTA
3















Troponin
GLT
4















ResearchSamples
6PK
SST


4

4
4
4
4
4
4
4
4
4
4
4
4
PBMC
EDTA
20







40







Serum
SST
8

16†


8
8
8†
8
8
8†
8
8†
8
8
8†
DailyVolume(mL)

45
0
27
0
11
12
12
19
59
12
19
12
19
12
12
12
CumulativeVolume(mL)

45
45
72
72
83
95
107
126
185
197
216
228
247
259
271
283
Visitwindows:ScheduleVisitsD2A–D14withrespecttoVisitD2.VisitD2A(within10minofEOI);VisitsD3,D4,D5(±6hrs);VisitsD6,D7,D8,D9
(±2days);VisitsD10–D14(±7days).
Footnotes(continuetonextpage):
1VisitD1RisthedayofenrollmentandmaybedoneonthesamedayasDay0.VisitD2/Day0isdayofproductadministrationandpreferablyscheduledwithin
14daysafterenrollmentatVisitD1Rbutmaybescheduledupto28daysafterVisitD1R.
2Screeningincludesphysicalexam,vitalsigns(BP,temperature,pulse,RR),height,weight.Day0includesvitalsignsandweight(fororderingstudyproduct
dose).Atothervisits,performatargetedexamifmedicallyindicated,otherwiseonlyvitalsignsarerequired.
3Performfullmedicalhistoryatscreening.Atothervisits,performinterimmedicalhistory.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page77of84
4Pregnancytestresultsmustbenegativeforwomenofreproductivepotentialbeforeproductadministration.CompletePregnancyPreventionCounselingForm
whenpregnancytestisdone.
5CMPincludessodium,potassium,chloride,totalCO2,creatinine,glucose,ureanitrogen,albumin,alanineaminotransferase,alkalinephosphatase,aspartate
aminotransferase,totalbilirubin,calcium,totalprotein
6PKblooddraws,definedbytimeafterinfusion,arerelativetotheexacttimeoftheendofinfusion(EOI).Recordexactstart/endtimesofproductadministration
andofblooddrawtoensureaccurateanalysis.
†ADAassessedfromserumsamplesattimepointsasindicated.
*Tubetypes/volumesareshowntoestimatebloodvolumesinmL.Differenttubesforclinicalevaluationsmaybeusedtomeetsiterequirementsbutresearchsample
tubesmustbeusedasshownorasinstructedbytheINDSponsor.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page78of84
ScheduleofEvaluations:PartCCHMICIS43LSGroups(Groups11,12,13,14,15)
VisitNumber

C1
C2
1C2A
1C2B
C3
C4
C5
C6
C7
C8
C9
C10
TimeafterCHMI



24hr
72hr
Wk1
Wk1
Wk1
Wk1
Wk1
Wk1
Wk1
Wk2
CHMIDay

-1
D0
D1
D3
D7
D8
D9
D10
D11
D12
D13
D14
StudyProcedures
Tube*


CHMI


ParasitemiaCheck(dailychecksuntiltreatmentcriteriamet)
2PhysicalExam,VitalSigns


X
X


X
X
X
X
X
X
X
X
InterimMedicalHistory


X
X


X
X
X
X
X
X
X
X
CHMI



X










PhoneContact




X
X








PregnancyPreventionCounseling


X











ClinicalEvaluations
3PregnancyTest(urineorserum)


X











CBCwithdifferential
EDTA

3



3







ALT,creatinine
GLT

4











4ParasitemiaEvaluation(PCR)
EDTA





3
3
[3]
[3]
[3]
[3]
[3]
[3]
ResearchSamples
PK
SST

4



54






54
PBMC
EDTA





540






5**60
Serum
SST





516†






5**16
DailyVolume(mL)


11
0
0
0
66
3
3
3
3
3
3
83
CumulativeVolume(mL)


11
11
11
11
77
80
83
86
89
92
95
178
1AfterCHMI,scheduleVisitC2AonDay1or2,VisitC2BonDay3or4
2Performatargetedphysicalexamifmedicallyindicated,otherwiseonlyvitalsigns(BP,temperature,pulse,RR)arerequired.
3Pregnancytestresultsmustbenegativeforwomenofreproductivepotentialwithin2dayspriortoCHMI.CompleteaPregnancyPrevention
CounselingFormwhenpregnancytestisdone.
4ParasitemiaevaluationsshouldcontinuedailyuntilasubjecthasonepositivePCRorbloodsmear;brackets[3]indicateoptionaldrawasneeded.
ApositiveresultpriortoDay21isrequiredforinitiationofantimalarialdirectlyobservedtherapy(DOT).
5ResearchsamplesforVisitsC3andC10maybecollectedateitherVisitC3orC4,oratVisitC9,C10,orC11,respectively.
*Tubetypes/volumesareshowntoestimatebloodvolumesinmL.Differenttubesforclinicalevaluationsmaybeusedtomeetsiterequirementsbut
researchsampletubesmustbeusedasshownorasinstructedbytheINDSponsor.
**Researchbloodwillbedrawnat14dayspost-CHMI(VisitC10)fromALLsubjects.
†ADAassessedfromserumsamplesattimepointsasindicated.




APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page79of84
ScheduleofEvaluations:PartCCHMICIS43LSGroups(Groups11,12,13,14,15)
1VisitNumber
C11
C12
C13
C14
1C15
C16
C17
2C20
TimeafterCHMI
Wk2
Wk2
Wk2
Wk2
Wk3
Wk3
Wk4
Wk7
CHMIDay
D15
D16
D17
D18
D21
D23
D28
D49
StudyProcedures
Tube*
ParasitemiaCheck
(dailyuntiltreatmentcriteriamet)




3PhysicalExam,VitalSigns

X
X
X
X
X
X

[X]
InterimMedicalHistory

X
X
X
X
X
X

[X]
PhoneContact







X
[X]
ClinicalEvaluations
CBCwithdifferential
EDTA




**3
**3

[3]
ALT,creatinine
SST




**4
**4

[4]
4ParasitemiaEvaluation(PCR)
EDTA
[3]
[3]
[3]
[3]
[3]


[3]
Anti-MalarialTreatment





[X]
[X]


ResearchSamples
PK
SST




4


[4]
PBMC
EDTA







[60]
Serum
SST




8†


[16]
DailyVolume(mL)

3
3
3
3
22
7
0
90
CumulativeVolume(mL)

181
184
187
190
212
219
219
309
1VisitC15isonlyrequiredforCHMIparticipantsnotpreviouslydiagnosedwithmalariaparasitemiatoruleoutadelayedcase.AtVisitC15(Day21),any
subjectwhohasnotalreadystartedantimalarialtreatmentwillbegivendefinitiveDOT.SubjectsmustreturnforDOTfor2moredaysafterinitiation;
Day2ofDOT(Day22)visitwillbeassigned“C15S”.Brackets[X]indicateoptionalasneededpersubjecttreatmentstatus.
2VisitC20isonlyrequiredforsubjectswhohadapositivePCRorbloodsmeartodocumenttestofcure.Itisscheduledtooccur26±5daysafterDOT
completionandisshownatDay49forconvenience.VisitC20maybecompletedviaphoneforsubjectswhoremainmalarianegative,brackets[X]
indicateoptionalasneededpersubjectinfectionstatus.
3Performatargetedphysicalexamifmedicallyindicated,otherwiseonlyvitalsigns(BP,temperature,pulse,RR)arerequired.
4ParasitemiaevaluationsshouldcontinuedailyuntilasubjecthasonepositivePCRorbloodsmear;brackets[3]indicateoptionaldrawasneeded.A
positiveresultpriortoDay21isrequiredforinitiationofantimalarialDOT.Otherwise,initiateDOTatC15.
*Tubetypes/volumesareshowntoestimatebloodvolumesinmL.Differenttubesforclinicalevaluationsmaybeusedtomeetsiterequirementsbutresearch
sampletubesmustbeusedasshownorasinstructedbytheINDSponsor.
**BloodforCBC,ALT,andcreatininewillbedrawnatonsetofDOTandabout2dayslater;shownatvisitsC15andC16toaccountforblooddraw.
Parasitemiaevaluationsarenotperformedduringtreatmentthroughtotestofcure.
†ADAassessedfromserumsamplesattimepointsasindicated.




APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page80of84
ScheduleofEvaluations:PartCCHMIforControlGroup16
VisitNumber
01
1D1R

C1
C2
2C2A
2C2B
C3
C4
C5
C6
C7
C8
C9
C10
TimeAfterCHMI





24hr
72hr
Wk1
Wk1
Wk1
Wk1
Wk1
Wk1
Wk1
Wk2
CHMIDay -56to-1-56to-1

-1
D0
D1
D3
D7
D8
D9
D10
D11
D12
D13
D14
StudyProcedures
Tube* Screen Enroll


CHMI


ParasitemiaCheck(dailyuntiltreatmentcriteriamet)
VRC500ScreeningConsent

X














VRC612InformedConsent,AoU


X













3PhysicalExam,VitalSigns

X
X

X
X


X
X
X
X
X
X
X
X
4MedicalHistory

X
X

X
X


X
X
X
X
X
X
X
X
EKG

X














CHMI





X










PhoneContact






X
X








5PregnancyPreventionCounseling

X
X

X











ClinicalEvaluations
5PregnancyTest(urineorserum)

X
X

X











CBCwithdifferential
EDTA
3


3



3







ALT,creatinine
GLT
X


4











6CMP
GLT
4














HIVAb/AgCombo
EDTA
3














SickleCellTest
EDTA
3














Troponin
GLT
4














7ParasitemiaEvaluation(PCR)
EDTA







3
[3]
[3]
[3]
[3]
[3]
[3]
[3]
ResearchSamples
PK
SST



4











PBMC
EDTA
20






840






8**60
Serum
SST
8






816






8**16
DailyVolume(mL)

45
0

11
0
0
0
66
3
3
3
3
3
3
83
CumulativeVolume(mL)

45
45

56
56
56
56
122
125
128
131
134
137
140
223
Footnotes(continuetonextpage):
1VisitD1RisthedayofenrollmentandmaybedoneonthesamedayasDayC1.
2AfterCHMI,scheduleVisitC2AonDay1or2,VisitC2BonDay3or4.
3Screeningincludesphysicalexam,vitalsigns(BP,temperature,pulse,RR),height,weight.OnD0,performatargetedphysicalexamifmedicallyindicated,
otherwiseonlyvitalsignsarerequired.
4Performfullmedicalhistoryatscreening.Atothervisits,performinterimmedicalhistory.
5Pregnancytestresultsmustbenegativeforwomenofreproductivepotentialwithin2dayspriortoCHMI.UsePregPreventionCounselingFormwhentesting
forpregnancy.
6CMPincludessodium,potassium,chloride,totalCO2,creatinine,glucose,ureanitrogen,albumin,alanineaminotransferase,alkalinephosphatase,aspartate
aminotransferase,totalbilirubin,calcium,totalprotein.


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page81of84
7ParasitemiaevaluationsshouldcontinuedailyuntilasubjecthasonepositivePCRorbloodsmear;brackets[3]indicateoptionaldrawasneeded.Apositive
resultpriortoDay21isrequiredforinitiationofantimalarialtreatment.
8ResearchsamplesforVisitsC3andC10maybecollectedateitherVisitC3orC4,oratVisitC9,C10,orC11,respectively.
*Tubetypes/volumesareshowntoestimatebloodvolumesinmL.Differenttubesforclinicalevaluationsmaybeusedtomeetsiterequirementsbutresearch
sampletubesmustbeusedasshownorasinstructedbytheINDSponsor.
**Researchbloodwillbedrawnat14dayspost-CHMI(VisitC10)fromALLsubjects.



APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page82of84
ScheduleofEvaluations:PartCCHMIforControlGroup16
VisitNumber
C11
C12
C13
C14
1C15
C16
C17
2C20
TimeafterCHMI
Wk2
Wk2
Wk2
Wk2
Wk3
Wk3
Wk4
Wk7
CHMIDay
D15
D16
D17
D18
D21
D23
D28
D49
StudyProcedures
Tube*
ParasitemiaCheck
(dailyuntiltreatmentcriteriamet)




3PhysicalExam,VitalSigns

X
X
X
X
X
X

[X]
InterimMedicalHistory

X
X
X
X
X
X

[X]
PhoneContact







X
[X]
ClinicalEvaluations
CBCwithdifferential
EDTA




**3
**3

[3]
ALT,creatinine
SST




**4
**4

[4]
4ParasitemiaEvaluation(PCR)
EDTA
[3]
[3]
[3]
[3]
[3]


[3]
Anti-MalarialTreatment





[X]
[X]


ResearchSamples
PK
SST








PBMC
EDTA







[60]
Serum
SST




8


[16]
DailyVolume(mL)

3
3
3
3
22
7
0
90
CumulativeVolume(mL)

226
229
232
235
257
264
264
354
1VisitC15isonlyrequiredforCHMIparticipantsnotpreviouslydiagnosedwithmalariaparasitemiatoruleoutadelayedcase.AtVisitC15(Day21),any
subjectnotalreadyonantimalarialtreatmentwillbegivenDOT;Day2ofDOT(Day22)visitwillbeassigned“C15S”.SubjectsmustreturnforDOTfor2
moredaysafterinitiation.Brackets[X]indicateoptionalasneededpersubjecttreatmentstatus.
2VisitC20isonlyrequiredforsubjectswhohadapositivePCRorbloodsmeartodocumenttestofcure.Itisscheduledtooccur26±5daysafterDOT
completionandisshownatDay49forconvenience.VisitC20maybecompletedviaphoneforsubjectswhoremainmalarianegative,brackets[X]indicate
optionalasneededpersubjectinfectionstatus.
3Performatargetedphysicalexamifmedicallyindicated,otherwiseonlyvitalsigns(BP,temperature,pulse,RR)arerequired.
4ParasitemiaevaluationsshouldcontinuedailyuntilasubjecthasonepositivePCRorbloodsmear;brackets[3]indicateoptionaldrawasneeded.Apositive
resultpriortoDay21isrequiredforinitiationofantimalarialDOT.Otherwise,initiateDOTatDay21.
*Tubetypes/volumesareshowntoestimatebloodvolumesinmL.Differenttubesforclinicalevaluationsmaybeusedtomeetsiterequirementsbutresearch
sampletubesmustbeusedasshownorasinstructedbytheINDSponsor.
**BloodforCBC,ALTandcreatininewillbedrawnatonsetofDOTandatabout2dayslater;shownatvisitsC15andC16toaccountforblooddraw.
Parasitemiaevaluationsarenotperformedduringtreatmentthroughtotestofcure.



APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page83of84
APPENDIXII:ASSESSMENTOFAERELATIONSHIPANDSEVERITY
GRADING


APhase1TrialtoEvaluateCIS43LSinHealthyAdults

VRC612,Version8.0

October26,2021
Page84of84
AssessmentofRelationshipofanAdverseEvent
TherelationshipbetweenanAEandthestudyproductorCHMIwillbeassessedbythe
investigatoronthebasisofclinicaljudgmentandthedefinitionsbelow.
• DefinitelyRelated:TheAEandadministrationofstudyproductand/orCHMIare
relatedintime,andadirectassociationcanbedemonstrated.
• ProbablyRelated:TheAEandadministrationofstudyproductand/orCHMIare
reasonablyrelatedintime,andtheAEismorelikelyexplainedbystudyagentorCHMI
thanothercauses.
• PossiblyRelated:TheAEandadministrationofstudyproductand/orCHMIare
reasonablyrelatedintime,buttheAEcanbeexplainedequallywellbycausesotherthan
studyagentorCHMI.
• NotRelated:TheAEisclearlyexplainedbyanothercausenotrelatedtothestudy
productorCHMI.
ForpurposesofpreparingsummarydatareportsinwhichAEattributionsaresimplifiedto
“Related”or“NotRelated”,inthisprotocol,the“Definitely,ProbablyandPossibly”attributions
abovewillbemappedtothe“Related”category,whilethe“Unlikely/ProbablyNotRelated”and
“NotRelated”attributionsabovewillbemappedtothe“NotRelated”category.Thedefinitions
thatapplywhenthesetwoattributioncategoriesaloneareusedareasfollows:
• Related:ThereisareasonablepossibilitythattheAEmayberelatedtothestudy
productorCHMI.
• NotRelated:ThereisnotareasonablepossibilitythattheAEisrelatedtothestudy
productorCHMI.

GradingtheSeverityofanAdverseEvent
TheDivisionofAIDS(DAIDS)TableforGradingtheSeverityofAdultandPediatricAdverse
Events,CorrectedVersion2.1[July2017]willbeusedtodeterminetheseveritygradesofAEs
inthisprotocolandisavailablefrom:https://rsc.niaid.nih.gov/clinical-research-sites/daids-
adverse-event-grading-tables.

Severalmodificationsweremadetothetableasfollows:
• WeightlosswillberecordedasanAEonlyifitisconsidereddeleterioustothe
participant’shealth.
•
Forseveritygradingofthesolicitedbruisingparameterattheproductadministrationsite,
thedefinitionsbasedonsizeofthelargestdiameterandlistedforthe“InjectionSite
ErythemaorRedness”willbeused.Theseveritygradedefinitionfor“Bruising”
providedundertheDermatologicClinicalConditionswillbeusedonlyforunsolicited
AEsinvolvingbruisingatotherbodylocations.
• Creatininechangeswillbegradedonthebasisoftheupperlimitofnormalprovidedby
thegradingtableandnotchangefrombaseline.
• Creatinineclearancechangeswillbegradedaccordingtoml/minprovidedbythegrading
tableandnotchangefrombaseline.
• SubclinicalCMPresultsforsodium,potassium,chloride,bicarbonate,BUN,andglucose
willnotbeconsideredanAEunlessGrade2orhigher.

ICF_000.pdf: 
Protocol Title: A Phase 1, Dose Escalation, Open-Label Clinical Trial with Experimental 
Controlled Human Malaria Infections (CHMI) to Evaluate Safety and Protective Efficacy of an 
Anti-Malaria Human Monoclonal Antibody, VRC-MALMAB0100-00-AB (CIS43LS), in 
Healthy, Malaria-Naive Adults (VRC 612) 
 
NCT: 04206332 
 
ICF (v8.0 26OCT2021) IRB Approval/Document Date: 27OCT2021  


Consent to Participate in a Clinical Research Study
Version Date: 10/26/2021 UMB V8.0
Page 1 of 19
PRINCIPAL INVESTIGATOR: Kirsten E. Lyke, M.D.
STUDY TITLE: VRC 612 (20I0017): A Phase 1, Dose Escalation, Open-Label Clinical Trial 
with Experimental Controlled Human Malaria Infections (CHMI) to Evaluate Safety and 
Protective Efficacy of an Anti-Malaria Human Monoclonal Antibody, VRC-MALMAB0100-
00-AB (CIS43LS), in Healthy, Malaria-Naive Adults
STUDY SITE: The Center for Vaccine Development and Global Health (CVD), University 
of Maryland School of Medicine, Baltimore, MD
Cohort: Healthy Volunteer
Consent Version:  Version 8.0, October 26, 2021
WHO DO YOU CONTACT ABOUT THIS STUDY? 
Principal Investigator: Kirsten Lyke, MD, 
 
 
 
      
KEY INFORMATION ABOUT THIS RESEARCH 
This consent form describes a research study and is designed to help you decide if you would 
like to be a part of the research study. This study is taking place at more than one site.
You are being asked to take part in a research study at the Center for Vaccine Development 
and Global Health (CVD), University of Maryland, Baltimore (UMB) sponsored by the 
National Institutes of Health (NIH). This section provides the information we believe is most 
helpful and important to you in making your decision about participating in this study. 
Additional information that may help you decide can be found in other sections of the 
document. Taking part in research at UMB is your choice.
This is a study of an experimental drug called “CIS43LS”. CIS43LS is a monoclonal antibody 
that targets malaria. CIS43LS has not been tested in humans before this study. However, in the 
first 2 parts of this study, 25 participants got 29 administrations of CIS43LS. We do not know 
if CIS43LS will protect you from malaria infection. You cannot get malaria from CIS43LS 
because there is no malaria in it. 
The main purpose of this study is to see if CIS43LS is safe and how your body responds to it. 
Since this is the first time that CIS43LS will be given to people, we do not know how your 
body will respond. We will follow everyone who gets CIS43LS for about 24 weeks. If you 
have side effects from CIS43LS, we expect them to be like the side effects that occur with 
similar antibody products, which usually occur within the first 24 hours after the antibody is 
given. These include fever, chills, shaking, nausea, diarrhea, vomiting, pain, headache, 
dizziness, tiredness. The following side effects, although rare, may occur including trouble 
IRB NUMBER: 20I0017
IRB APPROVAL DATE: 10/27/2021


Consent to Participate in a Clinical Research Study
Version Date: 10/26/2021 UMB V8.0
Page 2 of 19
breathing, itchiness, rash, hives, swelling, or chest pain. Some antibody products have a risk of 
serious allergic reactions that can be life threatening.
Another purpose of this study is to test if CIS43LS prevents you from getting malaria when 
you are bitten by mosquitoes that carry live malaria parasites. This is called a “malaria 
challenge” or a “Controlled Human Malaria Infection” (CHMI). We will follow everyone who 
gets CHMI for about 2 months. Each CHMI will include the participants who get a dose of 
CIS43LS and “control” participants who do not get CIS43LS. Everyone who takes part in the 
CHMI may get malaria infection. You will need to come to the clinic every day for 12 days 
starting 7 days after the CHMI to be checked for malaria infection. 
At the first sign of malaria infection in your blood, we will treat you with a medication that 
will cure you. At Day 21 after CHMI, everyone will get treated with a malaria medication to 
make sure they are cured of malaria even if the test was never positive. The drugs that treat 
malaria may cause some side effects. The type of malaria used in the CHMI will not come 
back or re-infect you again after you are treated with the medication.
During the study, we will collect blood samples from you. Some of your blood will be stored 
for future research. You will be compensated for your time and inconvenience for taking part 
in this study.
The study will last about 2 to 6 months, depending on your study group. All clinical study 
visits and the CHMI will take place at the UMB. You must be available on the day of the 
CHMI and for at least 8 weeks afterwards for follow up so we can check your blood for 
malaria parasites. It is important that the level of malaria in your blood does not get to 
dangerous levels.
To be in this study, you must:

have completed the screening process and be eligible,

agree to take part in the CHMI and to comply with post-CHMI follow-up requirements,

agree not to travel to a malaria endemic region during the entire course of the study,

agree not to donate blood to a blood bank for 3 years after the CHMI,

use an effective birth control method and try not to become pregnant during your time 
in the study if you are a woman who is able to get pregnant,

agree to have your blood samples and data stored for future use.
The remaining document will now describe the research study in more detail. This information 
should be considered before you make your choice. Members of the study team will talk with you 
about the information in this document. Some people have personal, religious, or ethical beliefs 
that may limit the kinds of medical or research interventions in which they would want to 
participate. Take the time you need to ask any questions and discuss this study with UMB staff, 
and with your family, friends, and personal health care providers.
IT IS YOUR CHOICE TO TAKE PART IN THE STUDY
You may choose not to take part in this study for any reason. If you join this study, you may 
change your mind and stop participating in the study at any time and for any reason. In either 
IRB NUMBER: 20I0017
IRB APPROVAL DATE: 10/27/2021


Consent to Participate in a Clinical Research Study
Version Date: 10/26/2021 UMB V8.0
Page 3 of 19
case, you will not lose any benefits to which you are otherwise entitled. If you do choose to leave 
the study, please inform your study team to ensure a safe withdrawal from the research.  
WHY IS THIS STUDY BEING DONE?
Malaria is a disease that affects more than 250 million people throughout the world. The 
parasites that cause malaria are known as Plasmodium. They live in the mosquito saliva and are 
injected into the skin when a mosquito bites a human. This can cause malaria infection. Malaria 
occurs in most tropical parts of the world including Africa, Southeast Asia and South America. It 
is a serious threat to the local populations, to travelers and to military personnel stationed 
overseas. Although there are medicines to treat malaria, there is no vaccine that fully prevents 
infection and treatment is not easy to get in many areas of the world. If malaria is not treated 
right away, it can become a serious and sometimes deadly disease. If it is treated right away, it 
can be completely cured.
This is a research study. The purpose of this research study is to test a drug that could prevent 
malaria infection in humans called CIS43LS. CIS43LS is considered investigational, which 
means that it has not been approved by the U.S. Food and Drug Administration (FDA) to prevent 
malaria infection. It is a monoclonal antibody (MAb) that targets the parasites that cause malaria. 
Antibodies are naturally made by the immune system to fight infection by blocking germs 
(bacteria and parasites) like malaria. Monoclonal means that all the antibodies in CIS43LS are 
exactly the same.
CIS43LS was developed at the Vaccine Research Center (VRC) at NIH. It was made in a 
laboratory and looks like an antibody that your own body could make. It has shown promise for 
prevention of malaria in laboratory and animal studies but has not been studied in humans before 
this trial.
This is the first study to give CIS43LS to humans. We do not know if CIS43LS will protect 
you from malaria infection. You cannot get malaria from CIS43LS because there is no malaria in 
it.
The purpose of this research study is to see if CIS43LS is safe and how your body responds to it. 
We will give you a dose of CIS43LS and measure how much of it stays in your body over time. 
We will check to see if your immune system prevents CIS43LS from working. We also want to 
see the differences between getting CIS43LS as an infusion in a vein in your arm (intravenously, 
IV) or when injected under the skin (subcutaneously, SC).
In this study, you will be exposed to malaria through bites from mosquitos infected with malaria 
parasites. This is called a “malaria challenge” or a “Controlled Human Malaria Infection” 
(CHMI). We do this to find out if CIS43LS prevents you from getting malaria after you are 
bitten by the infected mosquitoes in a controlled setting. We will monitor you closely and test 
your blood over many days to see if you get infected with malaria. Even if your test is negative, 
we will give everyone malaria treatment by 21 days after CHMI.
We are asking you to join this research study because you are a healthy adult between the ages of 
18 and 50 who has never been infected with malaria. You must be willing to take part in the 
CHMI and comply with follow-up requirements after CHMI to be in this study. You must also 
IRB NUMBER: 20I0017
IRB APPROVAL DATE: 10/27/2021


Consent to Participate in a Clinical Research Study
Version Date: 10/26/2021 UMB V8.0
Page 4 of 19
agree not to travel to a malaria endemic region during the whole study and not to donate blood to 
a blood bank for 3 years after CHMI.
WHAT WILL HAPPEN DURING THE STUDY?
Most people who get CIS43LS on this study will get it by infusion into a vein (IV). Some people 
will get CIS43LS into the fat under the skin (SC). A group of people called “control” participants 
will not get the study product but will take part in the CHMI. This group helps us make sure the 
mosquitos can infect people. 
This study has 3 parts, Part A, Part B, and Part C. Part A and Part B were completed in 2020 at the 
Vaccine Research Center, part of NIH, in Bethesda, MD. In Parts A and B, doses of CIS43LS were 
tested and a CHMI occurred in Part B. 
Part C is being done at UMB. You are invited to participate in Part C of the study. 
In Part C, CIS43LS doses are being tested to better understand how much CIS43LS is needed to 
protect participants from malaria infection after CHMI. The lowest IV dose being tested (1 
mg/kg IV) and the highest SC dose (10 mg/kg SC) have not been given to humans before. All 
other doses given into the vein or under the skin have been tested in Parts A and B. 
VRC 612 Part C Study Schema
CIS43LS Administration
Site
Group
Participants
Dose (mg/kg)
Route
CHMI
11
7
1
IV
X
12
4
5
IV
X
13
4
5
SC
X
14
4
10
IV
X
15
4
10
SC
X
16
6*
Control
X
UMB
Total 
29
*Group will include 2 backup controls
If you decide to take part in this study, you will be asked to review and agree to this informed 
consent form and the procedures outlined within it. You will have completed the screening 
process which includes a physical exam and review of your medical history, vital signs and 
laboratory results. You must be healthy and qualify for enrollment before you can take part in 
Part C of the study.
Enrollment will begin at the lowest dose (Group 11) and will continue through to the higher 
doses. We will let you know the group you are in at the time of enrollment.
IRB NUMBER: 20I0017
IRB APPROVAL DATE: 10/27/2021


Consent to Participate in a Clinical Research Study
Version Date: 10/26/2021 UMB V8.0
Page 5 of 19
Participants can be enrolled in the control group (Group 16) at any time. If you are in the control 
group, you will not receive a dose of CIS43LS. After enrollment, we will check your health and 
draw blood before the CHMI.
If you are female and able to become pregnant, you must use an effective method of birth control 
for the entire study. You will be given a pregnancy test before you get any dose of CIS43LS and 
before the CHMI. If you are pregnant, we will not give you CIS43LS and you cannot take part in 
the CHMI.
CIS43LS Administration
You will be in the clinic for about 8 hours on the day CIS43LS is given.

IV Dosing (Groups 11, 12, 14): We will place an IV line (thin tube) in a vein in your 
arm. The IV line will be attached to a bag that has CIS43LS mixed with a liquid called 
“normal saline” or salt water. It will flow into your vein for about 30 minutes. If you have 
side effects during the infusion, it may be slowed down or stopped as needed. At the end 
of your infusion, we will monitor you for any side effects for at least 2 hours afterwards.
We will also place an IV line in your other arm for blood collection during this visit so 
that we do not have to perform multiple needle sticks. We will draw your blood before 
and right after the infusion, and then 3 more times during the 4-6 hours after the infusion. 
You will be allowed to go home about 4-6 hours after the infusion, as long as you do not 
have concerning side effects. If you have side effects, we will treat them. You will need 
to come back to the clinic 2 times during the same week for blood draws.

SC Dosing (Groups 13, 15): We will use a small needle to inject CIS43LS into the fatty 
tissue of your belly. We may use your arm or thigh area instead of your belly if those 
areas are more appropriate for your body. You will get 1 to 4 injections to get the full 
dose of CIS43LS. You will be monitored for at least 2 hours after getting all injections of 
CIS43LS. If there are no safety concerns, you will be allowed to leave the clinic after the 
safety check. You will need to come back to the clinic 3 times during the same week for 
blood draws.
We will give you a thermometer so that you can check your temperature every day for 7 days 
after you get CIS43LS. You will need to record your highest temperature and tell us about any 
symptoms you have. We will also give you a measuring device so that you can measure any 
redness, swelling, or bruising you may have at the injection site. You will get a password to a 
secure website to record this information. If you do not have internet access, you may use a 
paper diary that we will provide to you instead.
If you have any side effects or feel unwell after you get CIS43LS, you should tell a UMB nurse 
or doctor as soon as possible. You can reach the clinic staff by phone 24 hours a day. If you have 
symptoms, you may be asked to come into the clinic for an examination before your next 
scheduled visit. You may also stay overnight in the hospital, if needed. It is very important that 
you follow the instructions from the clinic staff.
IRB NUMBER: 20I0017
IRB APPROVAL DATE: 10/27/2021


Consent to Participate in a Clinical Research Study
Version Date: 10/26/2021 UMB V8.0
Page 6 of 19
Follow-Up after CIS43LS Administration
Follow-up visits will last 30 minutes to 2 hours and allow us to check you for any health changes 
or problems. We will ask you how you are feeling and if you have taken any medications, check  
your vital signs, and may perform a targeted physical exam based on how you are feeling. We 
will take about 1–11 tubes of blood at each visit for safety and/or research tests. Blood draw 
volumes will be within the UMD Center for Vaccine Development and Global Health limits. We 
will tell you right away if any of your test results show a health problem. You might need to have 
extra clinic visits and laboratory tests if you have health changes that need to be checked.
Clinical studies follow a set schedule. This helps us answer the research questions. The visit 
schedule is a little flexible, but it is important that you follow the schedule as closely as 
possible. You should try to not miss any visits. You should contact the clinic staff as soon as 
possible if you need to change the date or time of any study visit. When you complete Part C of 
this study, we may invite you to take part in another study for follow-up sample collection.
Controlled Human Malaria Challenge (CHMI)
In order for us to learn if CIS43LS can prevent malaria infection, a CHMI will be conducted. 
The CHMI will be performed at UMB by experienced staff, with support from U.S. Military staff 
from the Walter Reed Army Institute of Research (WRAIR). The CHMI visit will last about 4 to 
6 hours and will begin very early in the morning.
During the CHMI, we will put mosquitoes carrying the malaria parasite into a cup. The cup, 
which is covered with nylon tulle netting, allows the mosquitoes to bite you under controlled 
conditions. They cannot escape from the cup. No more than 5 mosquitoes are put in the cup at 
one time. You will hold the cup against your arm for 5 minutes, and then the mosquitos will be 
checked for blood feeding and presence of malaria parasites. If needed, more mosquitoes may be 
added until we are sure that a total of 5 infected mosquitoes have fed on your blood.
Follow up after the CHMI is very important so we can check your health. We know that it takes 
anywhere from 7-15 days to find malaria parasites in the blood. So, after the CHMI, we will call 
you by phone to check on you 2 times in the first week. Then, starting on day 7, you must come 
to the clinic every day for about 30-minute visits through day 18 so we can collect blood for 
diagnostic and research purposes. The visits may be longer if medical evaluation is needed. If 
you test positive for malaria parasites, you will be treated right away with antimalarial 
medication. We will also bring you back about 8 weeks after the CHMI to make sure you are 
cured. At day 21, anyone who still has a negative malaria test will be given antimalarial 
medication. This way we can make sure that anyone who might have malaria infection is treated, 
even if your tests are negative. If you are negative for malaria, we will call you by phone to 
check on you about 8 weeks after the CHMI.
This type of CHMI has been done for over 35 years for many malaria vaccine studies. The 
mosquitoes that will be used are raised in a laboratory for CHMIs. They are infected with a 
specific strain of the malaria parasite (Plasmodium falciparum) that is known to be treatable with 
the anti-malaria medication we will give you. While the mosquitos are being grown, they feed on 
transfusion quality human donor blood that has been screened following FDA requirements to 
make sure that the blood is not carrying any other infectious agents. This type of malaria does 
not cause recurrent infections after you are treated. 
IRB NUMBER: 20I0017
IRB APPROVAL DATE: 10/27/2021


Consent to Participate in a Clinical Research Study
Version Date: 10/26/2021 UMB V8.0
Page 7 of 19
HOW LONG WILL THE STUDY TAKE?
The study will last for at least 24 to 32 weeks for those who receive CIS43LS.  The study will 
last for up to 8 weeks for those who participate as controls for the CHMI. You will visit UMB 
for about 11 or 12 study visits based on if you get CIS43LS by IV or SC, respectively. You will 
also have up to 16 follow-up visits after the CHMI. We will discuss the exact schedule of these 
visits with you. If you participate in the CHMI, the study will last another 8 weeks after the 
CHMI.
HOW MANY PEOPLE WILL PARTICIPATE IN THIS STUDY?
A total of 50 people were enrolled into Part A and Part B of this study. We plan to enroll about 
30 people into Part C. This includes about 23 people who will get CIS43LS, 6 control 
participants and 2 backup control participants.
WHAT ARE THE RISKS AND DISCOMFORTS OF BEING IN THE STUDY?
Possible Risks of CIS43LS
This study is the first time that CIS43LS is given to people. As of February 15, 2021, 25 
participants received 29 administrations of CIS43LS in Part A and Part B of the study. CIS43LS 
was given 25 times by IV and 4 times by SC administration. The limited experience collected in 
this study so far suggests CIS43LS is safe and well tolerated for further investigation.  
The information described below is taken from studies with other antibodies that are like 
CIS43LS and may work the same. Some of those antibodies are approved for use in people. Like 
other drugs, monoclonal antibodies can cause side effects, some of which can be serious. Most 
side effects occur within the first 24 hours after an antibody is given. 

Side effects to antibodies given by IV may include: fever, chills, shaking, nausea, 
vomiting, pain, headache, dizziness. More serious but rare side effects may occur, 
including trouble breathing, high or low blood pressure, itchiness, rash, hives, lip or face 
swelling, diarrhea, racing heart, or chest pain. These symptoms usually go away within a 
few minutes to hours after the product is given. We are giving CIS43LS at a controlled 
rate. If you develop symptoms while getting CIS43LS, tell the nurse right away. Slowing 
or stopping the flow rate may help improve the symptoms.

Side effects to antibodies given by SC may include: mild itchiness, redness and/or 
swelling at the site of injection. Tiredness, muscle pain, and headache have also been 
reported. These symptoms usually go away within 1 to 2 days.
Some antibodies have a risk of serious allergic reactions that can be life threatening including:

Anaphylaxis is one type of allergic reaction that may happen soon after an antibody is 
given. This reaction can include difficulty breathing, low blood pressure, hives, rash, or 
swelling in the mouth and face. This reaction is rare but can be life threatening.

Serum sickness is a type of allergic reaction that may happen several days to weeks after 
an antibody is given. This reaction may include hives, rash, fever, enlarged lymph nodes, 
muscle pains, joint pains, chest discomfort or shortness of breath.
IRB NUMBER: 20I0017
IRB APPROVAL DATE: 10/27/2021


Consent to Participate in a Clinical Research Study
Version Date: 10/26/2021 UMB V8.0
Page 8 of 19
Some antibody products can increase the risk of serious infections. CIS43LS is not expected to 
increase the risk of serious infections because it attacks a parasite instead of the human immune 
system.
CIS43LS may have other side effects that are not yet known. Taking part in this study may affect 
your eligibility for future monoclonal antibody or malaria studies. We will give you any new 
information about risks or other information that may affect your decision to continue in the 
study as it becomes available. You may not donate blood while taking part in this study and you 
may not donate blood for one year after the date of your last dose of CIS43LS or three years after 
your last CHMI.
Possible Risks of IV or SC Dosing
General risks of methods that use a needle include stinging, discomfort, pain, soreness, redness, 
bruising, swelling or a tiny cut at the needle insertion site.
Possible Risks of Blood Drawing
Blood drawing may cause pain, bruising, and may cause a feeling of lightheadedness or fainting. 
Rarely, it may cause infection at the site where the blood is taken. An IV line will be placed in 
your vein for a few hours on a day CIS43LS is given by IV. Problems at the IV site are usually 
mild and may include pain, bruising, minor swelling, or bleeding. Rarely, there may be an 
infection, vein irritation, nerve problem, or blood clot.
Possible Risks of CHMI
During the CHMI, you will be bitten by mosquitoes that carry live malaria parasites which cause 
malaria infection. We do not know if CIS43LS will protect people from malaria. If you did not 
receive any CIS43LS, you are expected to get malaria. If you get malaria, you may experience 
the following symptoms:

Fever, chills, headache, dizziness, muscle aches, sweats, fatigue, insomnia

Nausea, vomiting, stomach cramps, diarrhea

Decrease in numbers of red blood cells, white blood cells, and platelets

Enlarged liver or spleen
Symptoms are usually mild to moderate but you may have some severe symptoms. You may 
have fevers for 1 to 3 days. You may miss time from work or school due to your illness. You will 
not be compensated for any loss of income for missing work. If malaria is not treated right away, 
it can lead to kidney, liver, heart or brain damage and death. The CHMI is considered to be safe 
because people are closely monitored and treated as soon as they are found to have malaria 
infection, but they must remain in close contact with the study team.
After the CHMI, it is important that you come to the clinic for your scheduled visits so that 
the level of malaria parasites in your blood does not increase to dangerous levels. From past 
studies we know that malaria parasites can be found in the blood anywhere from about 7 to 15 
days. About half of the people infected with malaria parasites develop fever that usually lasts less 
than 12 hours. Once treatment for malaria is started, the fever does not last longer than 48 hours.
IRB NUMBER: 20I0017
IRB APPROVAL DATE: 10/27/2021


Consent to Participate in a Clinical Research Study
Version Date: 10/26/2021 UMB V8.0
Page 9 of 19
Other symptoms of headache, nausea, vomiting, and loss of appetite may occur. These symptoms 
may last an average of 3 days, with a range of 1 to 6 days when treatment is started soon after 
malaria parasites are identified by blood tests. Failure to return for testing or treatment after 
a CHMI can result in a serious case of malaria that is life-threatening. For this reason, you 
must give the names and phone numbers of at least two emergency contacts to the study staff. 
We will contact them before the CHMI to confirm communication with them in case we are not 
able to reach you by phone, text, or email after CHMI. 
Among the over 2,700 participants who have taken part in a CHMI since 1971, two serious 
events have been reported. Both were cardiac events (chest pain) and occurred in people who got 
an investigational malaria vaccine. The pain was thought to be due to myocarditis (inflammation 
of the heart muscle). Myocarditis is a reported complication from vaccinations. Rarely, 
myocarditis has also been reported in association with naturally-acquired malaria infection. 
These are the only two cases we know about in which a cardiac event occurred after CHMI. In 
the unlikely event that you develop myocarditis, you will be evaluated and followed by a 
cardiologist until resolution.
If you feel unwell at any time after the CHMI, you may be asked to remain in the clinic until you 
are checked by a study doctor. You might stay in the hospital overnight if needed.
Possible Risks from Treatment for Malaria
Standard treatment for malaria takes 72 hours to complete. We will give you the medication at 
the first detection of infection in your blood. You should expect to have malaria symptoms for 
about 3 days. Only drugs approved by the U.S. FDA will be used for treatment of malaria. We 
will treat you with Malarone unless you have a known allergy. In that case, we would treat you 
with chloroquine. Both drugs are effective in treating the type of malaria parasite used for the 
CHMI.
The drugs that treat malaria may also cause some side effects. Treatments and their side effects 
are described below:
1. The first line of treatment will be Malarone. If you get Malarone, you may have the
following side effects:

Nausea, vomiting, abdominal pain, loss of appetite, diarrhea

Temporary elevation of liver function tests

Headache and coughing

Rarely, low blood count, oral irritation or ulcers, insomnia, fever, swelling, rash
and hair loss
2.  Another backup treatment option will be chloroquine. If you get chloroquine, you may
have the following side effects:

Nausea, vomiting, abdominal pain, diarrhea, dizziness, sleep disturbances and
photosensitivity

Headache, blurred vision, ringing in ears

Itching, skin rash, and make conditions of psoriasis (itchy skin rash) and 
porphyria (rare disturbance of metabolism that can be seen as disorders of the 
skin or other organs) worse
IRB NUMBER: 20I0017
IRB APPROVAL DATE: 10/27/2021


Consent to Participate in a Clinical Research Study
Version Date: 10/26/2021 UMB V8.0
Page 10 of 19

Long term use can cause permanent eye damage or deafness, but you will only 
be receiving a short course of treatment

Rarely, there may be changes in electrocardiograms (test of heart’s electrical 
activity) and low blood pressure
If you need treatment with any other antimalarial drug, we will give you information about the 
side effects of that drug. You can also take over-the-counter medicine, like acetaminophen 
(Tylenol) and/or ibuprofen for fever, headache or other symptoms of malaria.
Mosquito Bite Site Reactions
Local, allergic reactions are common after mosquito bites. You may have itching and raised, red 
swelling at the sites of the bites. These reactions usually develop quickly, go away 1 to 4 days 
after a mosquito bite, and do not need treatment. So far, no severe allergic reactions to mosquito 
bites have been reported in prior CHMI studies. You will be observed for 30 minutes after the 
last mosquito bite. We will check the bite area and watch for any severe allergic signs. We may 
give you a steroid cream to use on the skin reactions.
Possible Risks from Stored Samples
There is a small chance that information from your medical records could be given to someone 
who should not get it without your permission. It is possible for someone to use that information 
to discriminate against you when you apply for insurance or employment. Similar problems may 
occur if you give information about yourself or agree to have your medical records released.
What are the risks related to pregnancy? 
If you are able to become pregnant, we will do a pregnancy test before beginning this study. We 
will also give you a pregnancy test before you get CIS43LS and before CHMI. You must use 
effective birth control methods and try not to become pregnant while taking part in this study. If 
you become pregnant, there may be unknown risks to the fetus or unborn child, or risks that we 
did not anticipate. There may be long-term effects of CIS43LS that could increase the risk of 
harm to a fetus. You must tell the study doctor if your birth control method fails while you are in 
the study. If you think or know you have become pregnant while taking part in this research 
study, please contact the research team member identified at the top of this document as soon as 
possible. You should not plan to become pregnant until you have completed participation in this 
study.
Safety Measures You Should Use as a Participant in the Study
You should not expect CIS43LS to protect you from malaria in the future. You should assume 
that you are not protected from malaria. After leaving the study, you should follow your 
physician’s instructions to prevent malaria infection. We also ask that you follow our instructions 
below:

Travel: Do not travel outside the local area from the CHMI through 28 days after. Before
or after this point, please let the study staff know about planned travels so we can 
schedule your visits and have contact information before you travel. We ask that you not 
IRB NUMBER: 20I0017
IRB APPROVAL DATE: 10/27/2021


Consent to Participate in a Clinical Research Study
Version Date: 10/26/2021 UMB V8.0
Page 11 of 19
travel to any areas with malaria during the entire period of the study. Country-specific 
information can be provided.

Use of Antibiotics: Avoid taking antibiotics 4 weeks before the CHMI unless prescribed 
by a physician. Please notify the study team immediately if an antibiotic is prescribed for 
you or if you consider taking an antibiotic during the course of the study.

Blood Donation: You will not be permitted to donate blood for transfusion purposes 
while in the study, for 1 year after the CIS43LS administration and for 3 years after the 
CHMI. To make sure that blood is safe for donation, blood banks will not accept blood 
donations for 3 years from anyone who is infected with or treated for malaria and for 1 
year after exposure to an investigational product (CIS43LS).
WHAT ARE THE BENEFITS OF BEING IN THE STUDY?
You will not benefit from being in this study.
Are there any potential benefits to others that might result from the study?
In the future, other people might benefit from this study because the information may help us 
learn more about preventing and treating malaria infection. Results from this study may also be 
used to help develop new products that target malaria or other infectious diseases in the future.
WHAT OTHER OPTIONS ARE THERE FOR YOU?
Instead of being in this study, you could choose not to take part. You may be eligible for other 
studies taking place at UMB or at the NIH.
DISCUSSION OF FINDINGS
New information about the study
If we find out any new information that may affect your choice to participate in this study, we 
will get in touch with you to explain what we have learned. This may be information we have 
learned while doing this study at the NIH and UMB, or information we have learned from other 
scientists doing similar research in other places.
Return of research results
At each visit you will be checked for any health changes or problems. Blood will be drawn at 
almost every study visit to check on your health. You will be told right away by phone call, text, 
or in person in the clinic if any of your test results show a health problem.
After the CHMI, we will draw your blood to test for malaria parasites. You will be told right 
away by phone call, text, or in person in the clinic if we find that you have malaria infection.
We will use some of the blood samples to study how long CIS43LS remains in your body and if 
your body develops an immune response to CIS43LS and to the CHMI. We will also study the 
malaria parasites that we may find in your bloodstream after a CHMI if you get malaria 
infection. These tests are for research purposes only and are not for checking on your health. We 
will not give you these results.
IRB NUMBER: 20I0017
IRB APPROVAL DATE: 10/27/2021


Consent to Participate in a Clinical Research Study
Version Date: 10/26/2021 UMB V8.0
Page 12 of 19
The results of this study may be reported in medical journals, on the internet or at scientific 
meetings. We will give you information about how to find the study results once they are 
available.
EARLY WITHDRAWAL FROM THE STUDY 
You may be removed from the research study by the researcher for any of the following reasons:

You don't keep appointments or follow study procedures;

You get a serious illness that needs ongoing medical care; 

You enroll in another research study at the same time you are in this study;

You become pregnant;

The study is stopped or cancelled;

If the researcher believes that it is in your best interest to remove you from the study.

The study is stopped by regulatory agencies, the study sponsor or study investigators. If
this happens, we will tell you why.
You can stop taking part in the study at any time. However, if you decide to stop taking part in 
this study, you will be asked to keep follow up visits so we can check your health, especially if 
you got a dose of CIS43LS or take part in the CHMI. We may stop collecting samples that are 
for research purposes only.
We don’t know if you will get malaria after the CHMI. If you choose to stop the study after the 
CHMI and before we finish checking you for malaria infection, you will need to be treated for 
malaria by the study doctor regardless of whether you develop symptoms of malaria or parasites 
in your blood.
STORAGE, SHARING AND FUTURE RESEARCH USING YOUR SPECIMENS AND 
DATA
Will your specimens or data be saved for use in other research studies?
As part of this study, we are obtaining specimens and data from you. We will remove all the 
identifiers, such as your name, date of birth, address, or medical record number and label your 
specimens and data with a code so that you cannot easily be identified. However, the code will 
be linked through a key to information that can identify you. We plan to store and use these 
specimens and data for studies other than the ones described in this consent form that are going 
on right now, as well as studies that may be conducted in the future. These studies may provide 
additional information that will be helpful in understanding malaria, or other diseases or 
conditions. This could include studies to develop other research tests, treatments, drugs, devices, 
or that may lead to the development of a commercial product by the NIH and/or its research or 
commercial partners. There are no plans to provide financial compensation to you if this 
happens. Also, it is unlikely that we will learn anything from these studies that may directly 
benefit you.
By agreeing to participate in this study, you are agreeing to have your specimens and data stored 
indefinitely and be used for future research. We will label them with a special code or number. 
Only the study team can link this number to you. Any identifying information about you (like 
name or date of birth) will be kept as confidential as allowed by the law. 
IRB NUMBER: 20I0017
IRB APPROVAL DATE: 10/27/2021


Consent to Participate in a Clinical Research Study
Version Date: 10/26/2021 UMB V8.0
Page 13 of 19
Will your specimens or data be shared for use in other research studies?
We may share your coded specimens and data with other researchers.  If we do, while we will 
maintain the code key, we will not share it, so the other researchers will not be able to identify 
you.  They may be doing research in areas similar to this research or in other unrelated areas. 
These researchers may be at NIH, other research centers and institutions, or commercial entities.
If you change your mind and do not want us to store and use your specimens and data for future 
research, you should contact the research team member identified at the top of this document. 
We will do our best to comply with your request but cannot guarantee that we will always be 
able to destroy your specimens and data. For example, if some research with your specimens and 
data has already been completed, the information from that research may still be used. Also, for 
example, if the specimens and data have been shared already with other researchers, it might not 
be possible to withdraw them. 
In addition to the planned use and sharing described above, we might remove all identifiers and 
codes from your specimens and data and use or share them with other researchers for future 
research at the NIH or other places.  When we or the other researchers access your anonymized 
data, there will be no way to link the specimens or data back to you.  We will not contact you to 
ask your permission or otherwise inform you before we do this.  We might do this even if you 
answered "no" to the above questions.  If we do this, we would not be able to remove your 
specimens or data to prevent their use in future research studies, even if you asked, because we 
will not be able to tell which are your specimens or data.
How Long Will Your Specimens and Data be Stored by the NIH or UMB?
Your specimens and data may be stored by UMB and the NIH indefinitely.
Risks of Storage and Sharing of Specimens and Data
When we store your specimens and data, we take precautions to protect your information from 
others that should not have access to it. When we share your specimens and data, we will do 
everything we can to protect your identity, for example, when appropriate, we remove 
information that can identify you. Even with the safeguards we put in place, we cannot guarantee 
that your identity will never become known or someone may gain unauthorized access to your 
information. New methods may be created in the future that could make it possible to re-identify 
your specimens and data.
PAYMENT
Will you receive any type of payment for taking part in this study?
Some studies, including when taking part at a non-NIH site, offer compensation for participation 
in research. The amount of compensation, if any, is guided by both NIH and UMB policies and 
guidelines.
You will be compensated for your time and inconvenience. It is possible that you may have some 
expenses that are not covered by the compensation provided.
The compensation for specific study visits is as follows:
IRB NUMBER: 20I0017
IRB APPROVAL DATE: 10/27/2021


Consent to Participate in a Clinical Research Study
Version Date: 10/26/2021 UMB V8.0
Page 14 of 19

$400 for a study visit that includes IV administration of CIS43LS with blood draws on 
the same day

$175 for a study visit that includes SC administration of CIS43LS with no blood draw

$325 for the malaria challenge visit with blood draws the day before

$70 total for the timely completion of all 7 days of the daily diary

$75 for a scheduled follow-up visit that includes a research blood draw

$75 for all other clinic visits that do not include research blood draws
Total compensation for completion of all study visits is about $1,445 if you get CIS43LS by IV, 
$1,295 if you get CIS43LS by SC, and between about $720 and $1,630 if you take part in the 
CHMI. The total compensation you get is based on the number and type of study visits you 
complete. 
If you are unable to finish the study, you will receive compensation only for the parts you 
completed.  
With few exceptions, study compensation is considered taxable income that is reportable to the 
Internal Revenue Service (IRS). A “Form 1099-Other Income” will be sent to you if your total 
payments for research participation are $600 or more in a calendar year. 
If you have unpaid debt to the federal government, please be aware that some or all of your 
compensation may be automatically reduced to repay that debt on your behalf.
Will you receive reimbursement or direct payment by UMB as part of your participation?
Some UMB clinical studies offer reimbursement or payment for travel, lodging or meals while 
participating in the research. The amount, if any, is guided by UMB policies and guidelines.
This study does not offer reimbursement for, or payment of, travel, lodging or meals.
COSTS
Will taking part in this research study cost you anything? 
UMB does not bill health insurance companies or participants for any research or related clinical 
care that you receive at UMB.
CONFLICT OF INTEREST 
The UMB has a Financial Conflict of Interest Policy to make sure that studies funded under U.S. 
Public Health Service (PHS) grants are conducted fairly without influence from investigator 
Conflicts of Interest. UMB seeks to provide an environment where  the design, conduct, and 
reporting of such PHS-Funded Research are free from financial bias and ensure fair and impartial 
results. 
CLINICAL TRIAL REGISTRATION AND RESULTS REPORTING 
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required 
by U.S. Law. This Web site will not include information that can identify you. At most, the Web 
site will include a summary of the results. You can search this Web site at any time.
IRB NUMBER: 20I0017
IRB APPROVAL DATE: 10/27/2021


Consent to Participate in a Clinical Research Study
Version Date: 10/26/2021 UMB V8.0
Page 15 of 19
CONFIDENTIALITY PROTECTIONS PROVIDED IN THIS STUDY  
The study doctor will take the following measures to protect the confidentiality of your research 
and/or medical records, such as coding your study record by study subject number, limiting 
access to the study records, and avoiding any individual identifiers (e.g. name, initials, exact date 
of birth) in publication or reports resulting from this study. Also, there will be a limited number 
of people who have access to your study records.
All study files are labeled with a code identifying you only by study subject number, and do not 
contain your name, initials, exact date of birth, or other items that could identify you personally. 
Specimens (e.g. blood samples) will not be labeled with your name or initials.
The monitors, auditors, the IRB, the Food and Drug Administration (FDA), representatives of 
the University of Maryland School of Medicine, the National Institutes of Health and the 
Department of Defense (DOD) will be granted direct access to your medical records for 
verification of the research procedures and date. By signing this document, you are authorizing 
this access.
The FDA may choose to inspect your records since you are a participant in this research study. 
When a study is submitted to FDA, the study doctor agrees to allow FDA access to the study 
records. The FDA will treat the information as confidential, but on rare occasions disclosure to 
third parties may be required by law. Therefore, absolute protection of confidentiality cannot be 
promised.
The data from the study may be published. However, you will not be identified by name. People 
designated from the institutions where the study is being conducted and people from the sponsor 
will be allowed to inspect sections of your medical and research records related to the study. 
Everyone using study information will work to keep your personal information confidential. 
Your personal information will not be given out unless required by law.
The authority to collect this information is under 42 USC 285f.
You may be registered in the University of Maryland School of Medicine computer system as a 
research subject, which may be informative for future clinical care.
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required 
by U.S. Law. This Web site will not include information that can identify you. At most, the Web 
site will include a summary of the results. You can search this Web site at any time.
Will your medical information be kept private? 
We will do our best to make sure that the personal information in your medical record will be 
kept private.  However, we cannot guarantee total privacy.  Organizations that may look at 
and/or copy your medical records for research, quality assurance, and data analysis include:

The NIH and other government agencies, like the Food and Drug Administration (FDA), 
which are involved in keeping research safe for people.

National Institutes of Health Intramural Institutional Review Board

The study Sponsor, VRC or their agent(s)

University of Maryland, Baltimore

Department of Defense (DOD)
IRB NUMBER: 20I0017
IRB APPROVAL DATE: 10/27/2021


Consent to Participate in a Clinical Research Study
Version Date: 10/26/2021 UMB V8.0
Page 16 of 19
The researchers conducting this study and the NIH follow applicable laws and policies to keep 
your identifying information private to the extent possible.  However, there is always a chance 
that, despite our best efforts, your identity and/or information about your participation in this 
research may be inadvertently released or improperly accessed by unauthorized persons.
In most cases, the UMB and NIH will not release any identifiable information collected about 
you without your written permission.  However, your information may be shared as described in 
the section of this document on sharing of specimens and data, and as further outlined in the 
following sections. 
When results of an UMB and NIH research study are reported in medical journals or at scientific 
meetings, the people who take part are not named and identified. In most cases, the NIH will not 
release any information about your research involvement without your written permission. 
However, if you sign a release of information form, for example, for an insurance company, the 
UMB and NIH will give the insurance company information from your medical record. This 
information might affect (either favorably or unfavorably) the willingness of the insurance 
company to sell you insurance.
If we share your specimens or data with other researchers, in most circumstances we will remove 
your identifiers before sharing your specimens or data. You should be aware that there is a slight 
possibility that someone could figure out the information is about you. 
Further, the information collected for this study is protected by NIH under a Certificate of 
Confidentiality. 
Certificate of Confidentiality
To help us protect your privacy, the NIH Intramural Program has received a Certificate of 
Confidentiality (Certificate). With this certificate, researchers may not release or use data or 
information about you except in certain circumstances.  
NIH and UMB researchers must not share information that may identify you in any federal, state, 
or local civil, criminal, administrative, legislative, or other proceedings, for example, if requested 
by a court.  
The Certificate does not protect your information when it:  
1. is disclosed to people connected with the research, for example, information may be used 
for auditing or program evaluation internally by the NIH; or 
2. is required to be disclosed by Federal, State, or local laws, for example, when information 
must be disclosed to meet the legal requirements of the federal Food and Drug 
Administration (FDA); 
3. is for other research;
4. is disclosed with your consent. 
The Certificate does not prevent you from voluntarily releasing information about yourself or your 
involvement in this research. 
The Certificate will not be used to prevent disclosure to state or local authorities of harm to self 
or others including, for example, child abuse and neglect, and by signing below you consent to 
IRB NUMBER: 20I0017
IRB APPROVAL DATE: 10/27/2021




Consent to Participate in a Clinical Research Study
Version Date: 10/26/2021 UMB V8.0
Page 18 of 19
about your rights while in this study, call the National Institutes of Health Intramural 
Institutional Review Board at 
.
CONSENT DOCUMENT 
Please keep a copy of this document in case you want to read it again.
IRB NUMBER: 20I0017
IRB APPROVAL DATE: 10/27/2021


Consent to Participate in a Clinical Research Study
Version Date: 10/26/2021 UMB V8.0
Page 19 of 19
Study Title:  VRC 612: A Phase 1, Dose Escalation, Open-Label Clinical Trial with 
Experimental Controlled Human Malaria Infections (CHMI) to Evaluate Safety and Protective 
Efficacy of an Anti-Malaria Human Monoclonal Antibody, VRC-MALMAB0100-00-AB 
(CIS43LS), in Healthy, Malaria-Naive Adults
Signing this consent form indicates that you have read this consent form (or have had it read to 
you), that your questions have been answered to your satisfaction, and that you voluntarily agree 
to participate in this research study. You will receive a copy of this signed consent form.
If you agree to participate in this study, please sign your name below.
Printed Name of Participant
Signature of Participant
Date
Signature of Investigator or Designee Obtaining Consent
Date/Time
IRB NUMBER: 20I0017
IRB APPROVAL DATE: 10/27/2021